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Abstract 
 
Biomolecular circuit engineering is critical for implementing complex functions in vivo, 
and is a baseline method in the synthetic biology space. However, current methods for 
conducting biomolecular circuit engineering are time-consuming and tedious. A complete 
design-build-test cycle typically takes weeks’ to months’ time due to the lack of an intermediary 
between design ex vivo and testing in vivo. In this work, we explore the development and 
application of a “biomolecular breadboard” composed of an in-vitro transcription-translation 
(TX-TL) lysate to rapidly speed up the engineering design-build-test cycle. We first developed 
protocols for creating and using lysates for conducting biological circuit design. By doing so we 
simplified the existing technology to an affordable ($0.03/uL) and easy to use three-tube reagent 
system. We then developed tools to accelerate circuit design by allowing for linear DNA use in 
lieu of plasmid DNA, and by utilizing principles of modular assembly. This allowed the design-
build-test cycle to be reduced to under a business day. We then characterized protein degradation 
dynamics in the breadboard to aid to implementing complex circuits. Finally, we demonstrated 
that the breadboard could be applied to engineer complex synthetic circuits in vitro and in vivo. 
Specifically, we utilized our understanding of linear DNA prototyping, modular assembly, and 
protein degradation dynamics to characterize the repressilator oscillator and to prototype novel 
three- and five-node negative feedback oscillators both in vitro and in vivo. We therefore believe 
the biomolecular breadboard has wide application for acting as an intermediary for biological 
circuit engineering. 
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Chapter 1: Introduction to biomolecular circuit engineering and to 
cell-free systems 
 
Overview of thesis 
 
This thesis explores the development and application of an intermediary for engineering 
biomolecular circuits. Biomolecular circuit engineering typically involves designing a circuit and 
immediately implementing the circuit in vivo to test its functionality, with minor (if any) 
simulation and testing outside the end chassis. This differs from other engineering-oriented 
disciplines. For example, architecture utilizes software (AutoCAD) and simulations to 
characterize a structure, while aeronautics uses “wind tunnels” to test prototypes of planes. In 
this thesis, we seek to bridge this gap by using transcription-translation (TX-TL) cell-free lysates 
as an intermediary for going from design to completion for biomolecular circuit engineering. We 
term this intermediary a “biomolecular breadboard” to emphasize its ability to conduct 
prototyping. 
 Chapter 1 presents an introduction to synthetic biology and biomolecular circuit 
engineering, framing the problem in the context of the field. We also delve into the rich history 
of the base technology, cell-free lysates, to understand previous work conducted in the field and 
the current cutting-edge.  
In Chapter 2 we outline our protocol for creating and using TX-TL. This protocol allows 
for accessibility of TX-TL to labs with basic biological infrastructure, and drastically simplifies 
the execution of a TX-TL reaction from the previous standard. We find that TX-TL creation 
costs $0.03/uL, with a typical reaction size of 10 uL.  
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Chapter 3 seeks to further accelerate the design-build-test cycle by removing the 
limitation to use plasmid DNA. Plasmid DNA requires cloning to be created in high yields and 
generally requires a cellular host to replicate. In contrast, linear DNA can be created from purely 
in vitro methods and can reduce design-build-test cycles to under a day. However, exonucleases 
present in TX-TL readily digest linear DNA, and it is unclear if circuits made of linear DNA 
look like those of plasmid DNA. We protect linear DNA using gamS, a lambda phase protein, 
and characterize its activity. We then create a modular and rapid assembly system to build DNA 
ex vivo rapidly. 
Chapter 4 characterizes an important cellular process, protein degradation dynamics, in 
the breadboard. In vivo, synthetic circuit dynamics are maintained by cellular division and 
protein degradation. This allows circuit components to reach steady state. However, in a batch 
mode TX-TL reaction there is no cellular dilution and minimal protein degradation from existing 
AAA+ proteases. We show that ClpXP AAA protease can be supplemented in the breadboard to 
selectively degrade proteins. This is done without significant resource utilization. While it does 
not compensate for cellular dilution, protein degradation can aid in implementing circuit 
dynamics. 
Chapter 5 applies the breadboard to build novel synthetic circuits going from design to 
completion in vitro and in vivo, utilizing the technology developed in Chapters 2-4. A critical 
unresolved question is the ability to transition in vitro circuit prototyping to the in vivo 
environment. We partially address this question in Chapter 5 by demonstrating the prototyping of 
synthetic 3-node and 5-node negative feedback oscillators in vitro and implementing the designs 
successfully in vivo. We compare our results in vitro and in vivo and find that many circuit 
characteristics, such as the dependence of oscillation period on dilution time, circuit architecture, 
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and protein degradation, are conserved in both systems. We end up with a framework to use for 
prototyping.  
We conclude in Chapter 6 with a discussion of the biomolecular breadboard findings. We 
also discuss other work that has demonstrated the utility of the biomolecular breadboard, and 
future planned work. In particular, we focus on the necessity to completely characterize the in 
vitro to in vivo transition, introduce work on a high-throughput method associating in vitro and in 
vivo metrics, and evaluate the breadboard for commercialization potential. 
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Overview of synthetic biology and biomolecular circuit engineering 
 
While no consensus exists on what synthetic biology “is,” there is general acceptance that 
it relies heavily on engineering complexity (Heinemann & Panke 2006; Endy 2005). Engineering 
can be conducted towards understanding natural phenomena like cell signaling (Sprinzak et al. 
2010), or to build completely novel functions such as artificial logic gates (Moon et al. 2012) or 
pathogen sensors (Saeidi et al. 2011; Kotula et al. 2014). To facilitate engineering, the field has 
developed a myriad of tools, from rapid methods of conducting genomic engineering (Wang et 
al. 2009; Le Cong et al. 2013) to databases of standardized parts (Y.-J. Chen et al. 2013; Stanton 
et al. 2014; Mutalik et al. 2013) to cheap DNA synthesis and sequencing (Kosuri et al. 2010; Eid 
et al. 2009). At its extreme, there are automated “foundries” to merge all of these technologies 
into a parallelized synthetic circuit build-and-test platform (Smanski et al. 2014; Temme et al. 
2012).  
 To conduct engineering, all of these tools accept in one way or another a fundamental 
restriction – the need for conducting final testing in a cell. This brings many limitations. The 
time spent exponentially increases with circuit size (Moon et al. 2012) or with organism 
complexity (C.-H. Chen et al. 2007). While there are some attempts to get around final testing in 
a cell with predictive modeling (Ellis et al. 2009), these methods are not in wide use likely due to 
the inability of models to capture cellular complexity.  It is enlightening to go over the current 
cloning and testing process to see what parts are most time-consuming and demanding. 
The current cloning and testing process 
 The main restriction of the cloning and testing process is the need to have all plasmids in 
a compatible expression mode with the cell. For prokaryotes, this involves ensuring that origins 
of replications responsible for replicating the plasmids are compatible among general families 
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(Couturier et al. 1988). To do so, larger circuits need to have multiple pieces built on one 
plasmid, which requires utilizing methods of DNA assembly. 
 For example, assume three coding sequences A, B, and C compose a circuit to be 
expressed in E. coli. The initial step requires assembling each coding sequence into an 
expressible unit composed of a promoter and/or regulatory region, terminator, and a compatible 
vector. Many methods can be used to assemble the DNA, including BioBricks Assembly (Lee et 
al. 2011), Golden Gate Assembly (Engler et al. 2009; Sarrion-Perdigones et al. 2011), Ligation-
based methods (de Kok et al. 2014), and Isothermal Assembly (Gibson et al. 2009). While the 
assembly is typically 1-3 hours, assembly is not 100% efficient and can have multiple error 
modes, from non-ideal assembly conditions (salt, non-pure DNA) to excessive secondary 
structure (Casini et al. 2014). Many of these conditions are not predictable until after the 
multiple-day to a week process of transformation, screening, and sequencing. In addition, if the 
coding sequences are toxic or over-expressed, the host cell may either mutate the plasmid or 
carry a load precluding its growth (Miroux & J. E. Walker 1996; Baneyx 1999).  Therefore, each 
cycle may require multiple iterations of testing and debugging to be successful, which can take 
significant time. 
 Assuming the initial cloning is successful, each of the expression cassettes for A, B, and 
C must then be cloned into one plasmid using the same procedure as before. Larger segments 
typically lead to less efficient ligation reactions (Gibson et al. 2009). Additionally, repeat regions 
introduced from redundant vectors can lead to deletions and plasmid instability (Lilley 1981). 
Finally, plasmids may hit a size barrier for replication, which can further decrease efficiency and 
require alternative cloning strategies (Cheah et al. 1987). 
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 After cloning is complete, the circuit is ready for testing in the final chassis, the cell. This 
involves a final transformation of the circuit plasmids into the host. For well-characterized 
bacteria such as E. coli this process is relatively straightforward. However, other bacteria may be 
resistant to transformation, resulting in additional time of diagnosis and testing. A classic 
example is Wolbachia, a bacteria that is clinically important for reducing malaria load (T. 
Walker et al. 2011) but only transformable by selected bacteriophage (Fujii et al. 2004). Finally, 
with successful transformation the circuit may introduce too high of a metabolic load to be 
characterized (Ceroni et al. 2015). However, assuming everything goes correctly the circuit may 
simply not work for many heterologous reasons, from design constraints to strain dependence 
(Kelly et al. 2009). Failure modes require additional design build test cycles, which add to 
engineering time. Given these limitations, it is not surprising that one of the success stories of 
synthetic biology – the engineering of artemisinin production by E. coli and by yeast – required 
an estimated 150 person-years of labor to complete (Keasling 2014). 
 To elucidate the gains of a possible in vitro intermediate, we will review a core 
application area in synthetic biology, that of metabolic engineering, and note the requirements in 
the metabolic engineering process. 
Core application area: Metabolic engineering 
 Metabolic engineering is the process of optimizing production of a metabolite within a 
cellular environment by manipulation of the genetic pathways needed to create the metabolite. 
The metabolic engineering market size is large for synthetic biology, with an estimate of $50 
billion (2011) for all bio-catalyzed processes (Murphy 2011). In addition, metabolic engineering 
typically requires large-scale engineering of large pathways, and epitomizes the need for a faster 
in vitro intermediate. 
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 A primary success story in synthetic biology has been the production of artemisinin from 
microbial sources to treat malaria. Artemisinin is a potent anti-malarial naturally formed in the 
Artemisia annua plant. Isolation from plant sources yields 5 kg of drug per 1000 kg of plants, 
requiring 2.5 acres to grow and costing $900-1600/kg (Hale et al. 2007). To increase yields and 
reduce costs, attempts to produce artemisinin in E. coli begun in 2003 (Martin et al. 2003), 
culminating in optimization in 2006 (Ro et al. 2006) and 2009 (Tsuruta et al. 2009) and 
production in yeast in 2013 (Paddon et al. 2013) at 5 kg/200 L of culture, replacing the previous 
2.5 acre requirement. 
 The final pathway used to create artemisinic acid, a precursor to artemisinin, is shown in 
Figure 1 (Paddon et al. 2013). This pathway contains at least 16 enzymes up-regulated to convert 
acetyl-CoA into artemisinic acid. The complexity of the pathway can be seen in the branch-off 
from FPP to amorphadiene; in order to maximize amorphadiene yield, it is necessary to repress 
ergosterol-related production to shift metabolic flux to amorphadiene. While this pathway is very 
complex for implementation in E. coli, previous work was conducted strictly in E. coli using 
enzymes from yeast (Martin et al. 2003). Many basic pathway properties, such as enzyme 
conversion efficiencies and binding affinities, were addressed by utilizing protein variants in 
vivo. With 16 enzymes or more, however, the optimization space is vast; modifying individual 
components in vivo requires extensive cloning and characterization work. An in vitro system can 
speed up the optimization cycle by allowing for high-throughput and modular testing. 
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Figure 1. Artemisinic acid production in yeast. Production of artemisinin in yeast, showing 
pathway going from acetyl-CoA to artemisinic acid. In blue boxes is a zoom-in of amorphadiene 
conversation to artemisinic acid. Figure courtesy {Paddon:2013ik}. 
  
 Another example of metabolic engineering of large pathways involves the production of 
useful commodity chemicals. These can include 1,3-Propanediol (Nakamura & Whited 2003),  
1-Butanol (Atsumi et al. 2008), and 1-Propanol (Shen & Liao 2008), among others whose 
processes are commercially proprietary. We focus on 1,4-Butanedol (BDO), a commodity 
chemical for producing plastics (Yim et al. 2011). This pathway to produce 1,4-BDO in E. coli 
from succinate or alpha-ketoglutarate consists of seven enzymes, of which two are naturally 
expressed in E. coli and five are heterologous. These enzymes are expressed from genomic 
integrations or from compatible plasmids, and are optimized for 1,4-BDO production. Unlike the 
artemisinin pathway, the 1,4-BDO pathway also heavily relies on metabolic flux analysis to 
9 
 
determine limiting steps and to provide insights on optimizing endpoint production (Wiechert 
2001). 
 Since implementing the pathway in vivo, new work has commenced to try to collect data 
in vitro, both to determine stoichiometry of enzymes necessary for optimal production and to 
conduct purely experimental flux analyses (Wu et al. 2015). In vitro, it was found that the 
enzyme pathway can also express 1,4-BDO in a batch mode reaction Additionally, the 
conversion of 4-Hydroxybutyrate to downstream metabolites was found as a limiting step. These 
results lend promise to using an in vitro system as an intermediate to learn more about the 
pathway to be engineered and to limit in vivo manipulations. 
 
 
Figure 2. 1,4-Butanediol(BDO) production in E. coli. Production of 1,4 BDO in E. coli. 
Numbered in black are steps catalyzed with naturally occurring enzymes, and in red are steps 
with heterologous genes. Figure courtesy {Yim:2011ee}. 
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Overview of cell-free systems 
 In this thesis we propose utilizing a cell-free transcription and translation system as the 
basis for the biomolecular breadboard intermediary from design to implementation in vivo. Cell-
free systems have a rich history as one of the original platforms in which biological experiments 
were conducted. In this section, we explore the history of cell-free systems as well as the latest 
work in utilizing cell-free systems for circuit prototyping. 
Historical use and development of cell-free systems 
 
Cell-free systems have been in use since the 1950’s to explore basic biological 
phenomena (Hoagland et al. 1958; Wood & Berg 1962). This was partially out of necessity, as E. 
coli was not transformable before 1970 (Mandel & Higa 1970) and there were no tools for 
conducting DNA manipulation (and little understanding of DNA, as the double helix structure 
had just been identified in 1953 (Watson & Crick 1953)). Research into enabling longevity of 
cell-free systems (J Heinrich Matthaei 1961) revealed as well the basis for discovering the amino 
acid code (Nirenberg & Matthaei 1961), which ultimately won the Nobel Prize in Medicine in 
1968.  
Zubay’s 1973 review of cell-free systems (Zubay 1973), itself a modification of 
Nirenberg’s protocols, is widely cited as the source of the original cell-free “S30” protocol in use 
today. As summarized in (Holland & Bundy 2012), extract preparation can be divided up into 
discrete segments: growth, lysis, clarification, “run-off” reaction (temperature incubation for set 
periods of time), dialysis, and final clarification. Zubay’s 1973 protocol relies on clarification 
spins at 30,000 x g, resulting in the “S30” moniker. This protocol was generally used as-is until 
the 1990’s, and significant work was done in utilizing the protocol for characterizing DNA 
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replication (Diaz et al. 1981), enterotoxins (Lathe et al. 1980), and high-yield protein synthesis 
using continuous flow (Spirin et al. 1988).  
Improvements have been made on the original cell-free protocol, namely in process 
optimization, lysis methods, and energy systems. In the former area, specific modifications of 
interest include the exclusion of a dialysis step (T. W. Kim et al. 2006), optimization of runoff 
time (Kwon & Jewett 2015), and reduction of spin speeds to 12,000 x g (T.-W. Kim et al. 2008). 
A variety of lysis methods have also been employed, from the original French press method 
(Zubay 1973) to sonication (Kwon & Jewett 2015; Holland & Bundy 2012), to homogenization 
(Liu et al. 2005; Yang et al. 2012) and physical lysis (bead-beating) (Kigawa et al. 2004; Shin & 
Noireaux 2010a). Finally, a variety of energy sources exist to power cell-free systems, such as 
pyruvate (Jewett & Swartz 2004), phosphoenolpyruvate (D.-M. Kim & Swartz 2001), 3-
phosphoglyceric acid (Shin & Noireaux 2012), glucose (T.-W. Kim et al. 2007), and maltose 
(Caschera & Noireaux 2013). All of these improvements generally seek to improve overall yield 
from cell-free reactions, as the field shifted to emphasizing yields from pure in vitro expression 
of specialized proteins. While these improvements allowed for increased protein production, the 
utility of cell-free systems shifted away from being used as a tool for understanding natural 
phenomena and more towards pure protein production. 
Cell-free systems for circuit prototyping 
 
In parallel with S30 extract development, work was conducted on a novel cell-free 
system from individual components (Shimizu et al. 2001). Marketed as PUREexpress©, this 
system has been useful in conducting controlled cell-free reactions, as the environment does not 
have degradation of mRNA and DNA. This property allowed for PURExpress to be used in 
specialized protein production applications (Sawasaki et al. 2002) despite its low yield compared 
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to traditional S30 systems. In addition, it found a niche use as an environment for building 
biochemical circuits. Examples of circuits built include switches (J. Kim et al. 2006) and 
oscillators (J. Kim & Winfree 2011). 
The first real foray into building circuits in lysates, however, was done in 2003 when 
wheat germ extract was supplemented with components to demonstrate activation and repression 
cascades (Noireaux et al. 2003). This effort was expanded to E. coli in 2005 (Noireaux et al. 
2005) and further in 2010, when native non-T7 regulatory systems were utilized to express genes 
(Shin & Noireaux 2010a; Shin & Noireaux 2010b) and later switches, cascades, and logic gates 
(Shin & Noireaux 2012). The latter implementation, which is the application of the TX-TL 
protocol developed in Chapter 2, was unique, as it used regulatory regions that were from native 
E. coli versus those from T7 phage. The most complex circuit example to date was then 
implemented in TX-TL with an assembly of active, virulent T7 bacteriophage from 40 kbp and 
60 genes (Shin et al. 2012). These experiments indicated that complexity could be prototyped in 
vitro. Recent work has also demonstrated circuits with real-world applicability, namely using 
RNA aptamers to build Ebola sensors on lyophilized TX-TL on paper (Pardee et al. 2014) and in 
vitro oscillators in cell-like microfluidic arrays (Karzbrun et al. 2014).  
Before the work done in this thesis, it was unclear if cell-free systems could not only 
prototype circuits in vitro but also act as an intermediate between the in vitro and the in vivo 
environment. For this to be true, there must be a predictive capacity of in vitro systems for the in 
vivo environment. Only the combination of S30-based lysates and native-regulation circuits can 
produce this trait. During the duration of thesis work, initial work was conducted characterizing 
in vitro to in vivo predictive capability for basic transcriptional and translational units (Chappell 
et al. 2013), as well as implementation of RNA-based cascades in vitro and in vivo (Takahashi et 
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al. 2014). We hope that the work presented in Chapters 2-5 and planned future work 
demonstrates predictability between the in vitro and in vivo environment and establishes that 
cell-free systems can be used as a “biomolecular breadboard” to enable rapid biological systems 
engineering. 
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Short Abstract 
 
This five-day protocol outlines all steps, equipment, and supplemental software necessary 
for creating and running an efficient endogenous Escherichia coli based TX-TL cell-free 
expression system from scratch. With reagents, the protocol takes 8 hours or less to setup a 
reaction and collect and process data. 
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Long Abstract 
Ideal cell-free expression systems can theoretically emulate an in vivo cellular 
environment in a controlled in vitro platform.1 This is useful for expressing proteins and genetic 
circuits in a controlled manner as well as for providing a prototyping environment for synthetic 
biology.2,3 To achieve the latter goal, cell-free expression systems that preserve endogenous 
Escherichia coli transcription-translation mechanisms are able to more accurately reflect in vivo 
cellular dynamics than those based on T7 RNA polymerase transcription. We describe the 
preparation and execution of an efficient endogenous E. coli based transcription-translation (TX-
TL) cell-free expression system that can produce equivalent amounts of protein as T7-based 
systems at a 98% cost reduction to similar commercial systems.4,5 The preparation of buffers and 
crude cell extract are described, as well as the execution of a three tube TX-TL reaction. The 
entire protocol takes five days to prepare and yields enough material for up to 3000 single 
reactions in one preparation. Once prepared, each reaction takes under 8 hours from setup to data 
collection and analysis. Mechanisms of regulation and transcription exogenous to E. coli, such as 
lac/tet repressors and T7 RNA polymerase, can be supplemented.6 Endogenous properties, such 
as mRNA and DNA degradation rates, can also be adjusted.7 The TX-TL cell-free expression 
system has been demonstrated for large-scale circuit assembly, exploring biological phenomena, 
and expression of proteins under both T7- and endogenous promoters.6,8 Accompanying 
mathematical models are available.9,10 The resulting system has unique applications in synthetic 
biology as a prototyping environment, or “TX-TL biomolecular breadboard.”  
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Introduction 
 
Cell-free expression technology began in the 1950’s as purely translational, advancing 
years later to encompass coupled transcription-translation mechanisms using T7 bacteriophage 
DNA.11,12 Since then, numerous efforts have been made to optimize the creation of crude cell 
extract (or E. coli S30 extract).13,14 These optimizations include prolonging cell-free protein 
synthesis through ATP regeneration or strain modifications, and reducing protocol time and 
cost.15-17 Alternative cell-free expression systems exist that use reconstituted components in lieu 
of crude cell extract for expression.5 Both crude cell extract and reconstitution methods have 
been developed for commercial use. 
With the advent of synthetic biology, there is an increased need for a well-characterized 
platform to test and express engineered biological modules and circuits.18,19 This platform must 
be versatile, well-characterized, simple to manipulate, and focused on user-supplied components. 
Despite being developed half a century earlier, cell-free systems based on E. coli intrinsically 
share these requirements, as they are a simplified in vitro representation of cellular processes 
without the complexity of growth and metabolism. Additionally, all of the foundational 
knowledge from in vivo work on E. coli applies readily to E. coli cell-free systems. 
Although cell-free expression systems can have applications in synthetic biology, to date 
the goal of most cell-free expression systems has been the maximization of protein and 
metabolite yield. This is accomplished by using T7 bacteriophage transcription of sequences 
driven by T7 promoters.20 Although expression is efficient and robust, these systems serve a 
highly specialized purpose. Cell regulation methods are limited, target DNA templates must be 
reengineered to include T7 promoters, and certain sequences such as ribosomal complexes 
cannot be transcribed and assembled.21,22 Existing cell-free expression systems are unable to 
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maintain high yields while preserving endogenous regulatory mechanisms, a versatility 
necessary for synthetic biology. 
We have developed an endogenous E. coli cell-free expression system that preserves the 
efficiency of protein expression demonstrated by previous systems but adds additional versatility 
by allowing expression and regulation based on both endogenous and exogenous (T7 or other) 
mechanisms. The protocol described here is originally based on Kigawa et al. (2004) and Liu et 
al. (2005), but has significant modifications. It utilizes Mg- and K- glutamate over Mg- and K- 
acetate for increased efficiency, removes 2-mercaptoethanol, and lyses cells using a bead-
beater.17,23,24 Bead-beating is chosen over homogenization, pressure-based methods, or 
sonication due to its lower cost and comparable yields to competing systems.23 3-
phosphoglyceric acid (3-PGA) is used as the energy source, as it was found to give superior 
protein yields when compared to creatine phosphate and phosphoenolpyruvate.4,25 Our system 
can produce up to 0.75 mg/mL of reporter protein using either a sigma70-based promoter with 
lambda-phage operators or a T7-driven promoter, similar to yields from other commercial 
systems.4,6 Five days are required to produce all necessary reagents (Figure 1). Furthermore,  it 
provides a 98% cost reduction compared to comparable commercial cell-free systems – material 
costs are $0.11 per 10 µL reaction, which rises to $0.26 with labor included (Figure 2). 
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Procedure 
Crude Extract Cell Preparation 
 
Preparing crude cell extract over three days requires two people to conduct efficiently.  
The protocol functionally consists of three parts: culture growth (step 1.1 to step 1.11), cell lysis 
(step 1.12 to step 1.37), and extract clarification (step 1.38 to step 1.52). It is presented divided 
into days for convenience. Ideal extract can produce 0.75 mg/mL of deGFP from plasmid 
pBEST-OR2-OR1-Pr-UTR1-deGFP-T500 (addgene #40019), and has a crude cell extract 
concentration between 27-30 mg/mL of protein.4 However, extract characteristics vary from 
batch to batch. The following recipe supplies enough for approximately 3000 single reactions (6 
mL crude cell extract). If scaling down, it is recommended to use no less than 1/6 of values given 
here. Due to time constraints, scaling up is not recommended. 
 
Day 1: 
1.1)   Prepare bacterial culture media, culture plate, and media supplements as described in 
Table 1. See Supplemental Material 1 for recipes. 
1.2)   Streak BL21-Rosetta2 strain from -80°C onto a 2xYT+P+Cm agar plate and incubate for 
at least 15 hours at 37°C or until colonies are readily visible. Note: Chloramphenicol 
(Cm) is used to select for a plasmid encoding rare tRNAs in the BL21-Rosetta2 strain. 
 
Day 2: 
1.3)   Prepare buffers and supplements as described in Table 2. See Supplemental Material 1 
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for recipes.   
1.4)   Prepare and sterilize materials required for day 3, including: 6 x 4 L Erlenmeyer flasks 
with aluminum foil cover (autoclaved), 4 x 1 L sterile centrifuge bottles, funnel 
(autoclaved), 100 g of 0.1 mm glass beads (autoclaved), 2 stir-bars (autoclaved), 1 L and 
500 mL graduated cylinder (autoclaved), 2 x 1 L beakers (autoclaved), 3 mL syringe with 
18-gauge needles (sterile), 2-3 float buoys, 2-3 10k MWCO dialysis cassettes (sterile), 
cuvettes. 
1.5)   Prepare mini-culture 1. Add 4 mL of 2xYT+P media and 4 µL of Cm to a 12 mL sterile 
culture tube and pre-warm to 37°C for 30 minutes. 
1.6)   Inoculate mini-culture 1 with a colony from the 2xYT+P+Cm agar plate. Incubate at 220 
rpm, 37°C for 8 hours. 
1.7)   7 hours and 30 minutes later, prepare mini-culture 2. Add 50 mL of 2xYT+P media and 
50 µL of Cm to a sterile 250 mL Erlenmeyer flask and pre-warm to 37°C for 30 minutes. 
1.8)   Inoculate mini-culture 2 with 100 µL of mini-culture 1 and incubate at 220 rpm, 37°C for 
8 hours. 
 
Day 3: 
1.9)   Weigh four empty sterile 50 mL Falcon tubes and record mass in Table 3. Chill Falcon 
tubes on ice; these will be subsequently used in step 1.18. 
1.10)   7 hours and 30 minutes after step 1.8, prepare final bacterial culture media. Using a 
sterile 1 L graduated cylinder, transfer 660 mL of 2xYT+P media into each of six 4 L 
Erlenmeyer flasks and pre-warm to 37°C for 30 minutes. Note: 4 L or larger Erlenmeyer 
flasks are recommended for proper aeration. 
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1.11)   Add 6.6 mL of mini-culture 2 into each 4 L Erlenmeyer flask. Incubate at 220 rpm, 37°C 
until the culture reaches an OD of 1.5-2.0 at 600 nm (corresponding to mid-log growth 
phase). Check OD periodically with a 1:10 culture dilution for accuracy. This step 
should take no more than 3h – 3h45min; rapid growth and collection during mid-log 
phase is critical for extract quality. 
1.12)   Immediately after growth, transfer all cultures evenly into four 1 L centrifuge bottles and 
centrifuge at 5000 g for 12 minutes at 4°C to pellet bacterial cells.  
1.13)   While centrifuging, complete S30A buffer preparation by adding 4 mL of 1 M DTT to 2 
L of previously prepared S30A. Mix and maintain buffer on ice. 
1.14)   When centrifuging is finished, completely remove supernatant from step 1.12 by 
decanting and blotting the centrifuge bottles on a sterile paper towel. 
1.15)   Add 200 mL of S30A buffer at 4°C to each of the four centrifuge bottles, and shake the 
bottles vigorously until pellet is completely solubilized with no remaining clumps. 
Centrifuge the four bottles at 5000 g for 12 minutes at 4°C.  
1.16)   Completely remove supernatant from previous step by decanting and blotting the 
centrifuge bottles on a sterile paper towel. 
1.17)   Repeat steps 1.15 and 1.16. 
1.18)   Add 40 mL S30A buffer at 4°C to each centrifuge bottle. Transfer each pellet and S30A 
combination into a chilled Falcon tube from 1.9). Note: This step is to transfer the pellets 
into a smaller container. 
1.19)   Centrifuge the Falcon tubes at 2000 g for 8 minutes at 4°C. Remove supernatant by 
decanting. 
1.20)   Re-centrifuge the Falcon tubes at 2000 g for 2 minutes at 4°C. Completely remove 
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residual supernatant by pipet. Keep on ice. 
1.21)   Weigh the four Falcon tubes with pellet and record mass in Table 3. Calculate pellet 
mass, S30A buffer volume needed, and mass of beads needed based on the specific 
formulas in Table 3. 
1.22)   Correct loading and bead beating of the pellet is critical to making quality extract, 
and is the most challenging step. It is recommended to review the video before 
attempting. Failure to avoid air bubbles and distribute beads evenly will result in 
inefficient extract. 
1.23)   Add the amount of S30A buffer calculated in Table 3 to each Falcon tube, vortex until 
homogenous, and return to ice. 
1.24)   While keeping the other Falcon tubes on ice, add beads intermittently to a single Falcon 
tube in three aliquots, each using 1/3 of the total beads. After addition of each aliquot 
of beads, vortex for 30 seconds. Place Falcon tube on ice between vortex steps and after 
final vortex. After last aliquot is added, ensure beads are uniformly distributed. A 
thick paste should be formed. 
1.25)   Prepare a 5 mL (volume) pipet tip by cutting off the end using a sterile razor blade to 
create a 3-4 mm opening. Dial pipet to 2 mL. Note: Different pipet sets and tips provide 
different amounts of suction that may not be sufficient to pull and release thick bead-cell 
solution; a 1mL pipet tip with end removed can be used in lieu.  
1.26)   Place 20 bead-beating tubes on ice. 
1.27)   Verify high viscosity of cell-bead solution using modified pipet. It should be viscous to 
the point of barely exiting the pipet tip during ejection. If too viscous, re-adjust pipet tip 
according to step 1.25. If not viscous enough, beads can be added in increments of (pellet 
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mass * 0.05), to a maximum mass of (pellet mass * 5.1). After each addition of beads, 
vortex for 30 seconds and return to ice. See Figure 3a for a demonstration of viscosity. 
1.28)   Remove bead-cell solution from Falcon tube using modified pipet, and transfer into a 
sterile bead-beating tube, filling it three-quarters full with bead-cell solution. Spin 
extremely briefly (1s) on a counter mini-centrifuge to remove air bubbles without 
redistributing beads. See Figure 3b-d for still images of bead-beating tube loading. 
1.29)   Finish adding bead-cell solution to form a concave meniscus.  
1.30)   Add a very small drop of bead-cell solution onto the inside of a bead-beating tube cap, 
being careful to not impede the outside lip of the cap; otherwise, the bead-beating 
tube will not close sufficiently. Tap the cap on a flat surface and verify that there are 
no air bubbles on the bottom of the cap. 
1.31)   Cap the bead-beating tube with the bead-beating cap from the previous step. Hand to 
assistant for bead beating. If done correctly, the cap should be tightly sealed, no air 
bubbles should be visible, and little (if any) bead-cell solution should overflow. Redo 
the loading process if air bubbles are visible or the cap does not fully close.  
1.32)   Vortex Falcon tube from step 1.24 with the remaining bead-cell solution to ensure even 
distribution of beads. Repeat steps 1.28 to 1.31 until Falcon tube is empty; then repeat 
steps 1.24 to 1.31 for each additional Falcon tube. 
1.33)   Conduct steps 1.33 to 1.38 simultaneously. Have assistant take filled bead-beating 
tubes from 1.31 and place on ice. Once two filled bead-beating tubes have been collected 
and have been on ice for at least one minute, begin bead beating.  
1.34)   Beat one tube for 30 seconds at 46 rpm. Place upside down on ice for 30 seconds while 
beating the other tube. 
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1.35)   Repeat previous step such that each filled bead-beating tube has been beat for 1 minute 
total. 
1.36)   Repeat steps 1.33 to 1.35 until 8 filled bead-beating tubes (or the maximum amount the 
centrifuge can hold) have been processed. Then, construct filter apparatus from 15 mL 
Falcon (Figure 3e). Add a new bead-beating cap, flat-part face up, to the bottom of a 15 
mL Falcon. Then, remove cap from processed bead-beating tube and press micro-
chromatography column firmly onto end of processed bead-beating tube until 
completely sealed. Snap off elution end of micro-chromatography column, and place 
micro-chromatography column, elution end down, into empty bead-beading tube. Place 
this complex into 15 mL Falcon. Repeat for all 8 filled bead-beating tubes; keep on ice 
when complete.  
1.37)   Centrifuge 8 filter apparatuses, Falcon tube uncapped, at 6000 g for 5 minutes at 4°C to 
separate extract and pellet from beads. 
1.38)   Verify each bead-beating tube has produced viable extract. Properly beat extract will 
not be turbid, and the pellet will have two distinct layers. Discard all turbid tubes, and 
transfer the supernatant from non-turbid tubes into individual 1.75 mL micro-centrifuge 
tubes, taking as little pellet as possible. Keep on ice until all bead-beating tubes have 
been processed.  See Figure 3f comparing a correctly vs. incorrectly processed bead-
beating tube. 
1.39)   Centrifuge micro-centrifuge tubes from previous step at 12000 g for 10 minutes at 4°C. 
1.40)   Transfer pellet-free supernatant into empty bead-beating tubes using a pipet, 
consolidating 500 µL into a new bead-beating tube. 
1.41)   Incubate previous step, with bead-beating caps removed, at 220 rpm, 37°C for 80 
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minutes. This step digests remaining nucleic acids using endogenous exonucleases 
released during the bead-beading process, and can be done by standing the bead-beating 
tube up in a tissue culture tube.  
1.42)   Prepare dialysis materials. Complete S30B buffer preparation by adding 2 mL of 1 M 
DTT to 2 L of previously prepared S30B. Mix and add 900 mL into each of two sterile 1 
L beakers. Add sterile magnetic stirrer into each beaker; keep at 4°C. 
1.43)   After step 1.41,  extract should look turbid. Consolidate extract into 1.5 mL aliquots in 
1.75 mL micro-centrifuge tubes, and centrifuge at 12000 g for 10 minutes at 4°C. 
1.44)   Using a pipet, consolidate pellet-free supernatant into 15 mL Falcon tubes on ice, and 
mix well by capping the tube and inverting. Save 10 µL of supernatant on ice for step 
1.47. 
1.45)   Determine total amount of extract produced, and hydrate the necessary number of 10k 
MWCO dialysis cassettes by submersing in S30B for 2 minutes, assuming 2.5 mL of 
extract per cassette.  
1.46)   Load cassettes with 2.5 mL of extract. Each beaker can take up to 2 cassettes; dialyze, 
stirring, at 4°C for 3 hours. Note: partial loading of cassettes is acceptable. Dialyzing 
increases protein production yield. 
1.47)   During the previous step, characterize extract protein concentration with a Bradford 
assay, using extract saved in step 1.44. See Supplemental Material 2 for details. 
1.48)   After dialysis is complete, aliquot extract by 1.5 mL in 1.75 mL micro-centrifuge tubes. 
Centrifuge at 12000 g for 10 minutes at 4°C. A pellet will form at the bottom of the tube. 
1.49)   Consolidate clear supernatant from previous step by pipetting into a 15 mL Falcon tube 
on ice. Homogenize by inverting 5-10 times. 
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1.50)   Based on concentration determined by Bradford in step 1.47, determine amount of extract 
to aliquot into individual 1.75 mL tubes. Each individual tube should have a volume 
with 810-900 mg of total protein. Extract should have a total protein concentration 
greater than 27 mg/mL. This step requires assistance to conduct expediently. Note: 
Aliquot extract below 30 mg/mL into 30 µL aliquots, and scale if concentration is higher; 
for example, aliquot extract at 28 mg/mL by 30 µL, and aliquot extract at 32 mg/mL by 
28.1 µL. 
1.51)   Aliquot extract following step 1.50, taking care to avoid bubbles. Flash-freeze extract in 
liquid nitrogen. Note: Aliquots with bubbles can be removed by centrifuging at 10000 g 
for 30 seconds at 4°C. 
1.52)   Remove tubes from liquid nitrogen using a strainer and immediately store at -80°C. 
Safety: Wear protective eyewear; the caps of extract tubes may come off due to the 
temperature difference between liquid nitrogen and room temperature. 
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Amino Acid Solution Preparation 
 
Amino Acid Solution should be prepared in bulk. The following recipe utilizes one full 
kit of RTS Amino Acid Sampler, supplying enough for approximately 11000 single reactions. If 
scaling down, it is recommended to use no less than half a kit. Each amino acid in the stock is 
supplied at 1.5 mL, 168 mM, except for leucine at 140 mM. The final composition of Amino 
Acid Solution is leucine, 5 mM, all other amino acids, 6 mM. This is 4x working concentration.  
2.1)   Remove all 20 amino acids from -20°C and thaw at room temperature. Once thawed, 
vortex until amino acids dissolve, incubating at 37°C if necessary. After amino acids are 
dissolved, put all amino acids on ice except for Asn, Phe, and Cys, which are kept at 
room temperature. Cys may not fully dissolve. 
2.2)   On ice, add 12 mL of sterile water to a sterile 50mL Falcon tube. 
2.3)   Add 1.5 mL of each amino acid in the following order, taking care to vortex the Falcon 
tube after each addition and to keep the solution on ice: Ala, Arg, Asn, Asp, Gln, Glu, 
Gly, His, Ile, Lys, Met, Phe, Pro, Ser, Thr, Val, Trp, Tyr, Leu, Cys.  Cys can be added as 
a suspension. After addition, vortex until solution is relatively clear, incubating at 
37°C if necessary. Cys may not fully dissolve. 
2.4)   Aliquot Amino Acid Solution into 50 tubes at 26 µL each on ice. Aliquot the rest at 500 
µL per tube on ice. The 26 µL aliquots will be used for calibrating extract, while the 500 
µL aliquots will be used for preparing buffer. While aliquoting, vortex the main stock 
frequently to avoid unequal distribution of suspension. 
 
2.5)   Flash freeze aliquots in liquid nitrogen and store at -80°C. Safety: Wear protective 
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eyewear; the caps of extract tubes may come off due to the temperature difference 
between liquid nitrogen and room temperature. 
2.6)   Optional: Conduct an activity assay of newly-made Amino Acid Solution against 
previously made Amino Acid Solutions. 
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Energy Solution Preparation 
 
Energy Solution is used both for calibrating crude cell extract and for creating buffer, and 
should be prepared in bulk. The following recipe supplies enough for approximately 10000 
single reactions. If scaling down, it is recommended to use no less than 1/24 of values given 
here. As the Energy Solution is a significant monetary cost, first time users may want to prepare 
at 1/24 scale. The final composition of Energy Solution is HEPES pH 8 700 mM, ATP 21 mM, 
GTP 21 mM, CTP 12.6 mM, UTP 12.6 mM, tRNA 2.8 mg/mL, CoA 3.64 mM, NAD 4.62 mM, 
cAMP 10.5 mM, Folinic Acid 0.95 mM, Spermidine 14 mM, and 3-PGA 420 mM. This is 14x 
working concentration. If desired, each individual item in Table 4 can be stored at -80°C for 
later use. 
3.1)   Remove all chemicals in Table 4 from -80°C, -20°C, or 4°C to room temperature for 30 
minutes. 
3.2)   Prepare stock solutions as described in Table 4. See Supplemental Material 1 for 
recipes. Place all solutions on ice after preparation. 
3.3)   In a 15 mL Falcon tube, add in the following order, taking care to vortex the Falcon tube 
after each addition and to keep the solutions on ice: 3.6 mL 2 M HEPES, 144 µL water, 
1.39 mL nucleotide mix, 576 µL 50 mg/mL tRNA, 576 µL 65 mM CoA, 276 µL 175 mM 
NAD, 170 µL 650 mM cAMP, 288 µL 33.9 mM Folinic acid, 144 µL 1 M spermidine, 
and 3.09 mL 1.4 M 3-PGA. 
3.4)   Aliquot Energy Solution into 50 tubes at 7 µL each on ice. Aliquot the rest at 150 µL per 
tube on ice. The 7 µL aliquots will be used for calibrating extract, while the 150 µL 
aliquots will be used for preparing buffer. While aliquoting, vortex the main stock 
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frequently. 
3.5)   Flash freeze aliquots in liquid nitrogen and store at -80°C. Safety: Wear protective 
eyewear; the caps of extract tubes may come off due to the temperature difference 
between liquid nitrogen and room temperature. 
3.6)   Optional: Conduct an activity assay of newly made Energy Solution against previously 
made Energy Solutions. 
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Buffer Preparation 
Buffer Preparation requires the completion of Crude Cell Extract Preparation, Amino 
Acid Solution Preparation, and Energy Solution Preparation. Each buffer is unique to a batch 
of crude cell extract. Mg-glutamate, K-glutamate, and DTT (in that order) are optimized in this 
section to produce reactions with maximum levels of expression. The following protocol utilizes 
a pre-written template, TXTL_e(template)_calibration_JoVE.xlsx (Supplemental Material 3), 
to calibrate pre-prepared crude cell extract and prepare buffer. However, one can also calibrate 
crude cell extract and prepare buffer without the template by optimizing Mg-glutamate, K-
glutamate, and DTT manually and setting up buffer such that along with extract, it is 75% of a 
total reaction volume. If calibrating manually, final reaction conditions can be found in step 5. 
 
4.1)   Complete the “General Data” form. 
4.2)   Thaw on ice 100 mM Mg-glutamate (4°C), 3 M K-glutamate (4°C), 6 mM Amino Acid 
Solution (26 µL, -80°C), Energy Solution (7 µL, -80°C), 100 mM DTT (-20°C), positive 
control DNA (-20°C), 40% PEG-8000 (4°C), crude cell extract (-80°C), and water (4°C). 
Note: Use 1 nM working concentration pBEST-OR2-OR1-Pr-UTR1-deGFP-T500 
(Addgene plasmid 40019) for the positive control (excitation 485 nm, emission 525 nm), 
or another reference which produces high signal intensity.4 
4.3)   Prepare seven 10.5 µL reactions, testing a range of 4-10 mM additional Mg-glutamate, by 
aliquoting set amounts of stock Mg-glutamate into individual micro-centrifuge tubes. 
Note: Although 10.5 µL reactions are initially prepared, the final reaction is 10 µL. 
 
4.4)   Prepare master mix as indicated in the template under “Mg-glutamate calibration,” 
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adding an extra 80 mM of K-glutamate. Keep on ice and vortex after the addition of 
each item. Note: The values given here and in the template are in addition to the 
amounts of Mg-glutamate, K-glutamate, and DTT present in the S30B buffer used to 
make crude cell extract. 
4.5)   Add master mix to samples containing Mg-glutamate and prepare reactions. See steps 
5.10 to 5.13 for detailed instructions. 
4.6)   Run reaction at 29°C, either in an incubator or a plate reader. 
4.7)   Determine optimum Mg-glutamate concentration by end-expression level and maximal 
rate of protein expression (Figure 4a). Note: Runtimes vary depending on experiment but 
typically last under 8 hours.  
4.8)   Repeat steps 4.2 to 4.7 for K-glutamate under “K-glutamate calibration,” setting Mg-
glutamate levels to those found in step 4.7. 
4.9)   Repeat steps 4.2 to 4.7 for DTT under “DTT calibration,” setting Mg-glutamate levels to 
those found in step 4.7 and K-glutamate levels to those found in step 4.8. Note: We have 
found that added DTT does not significantly affect end-expression levels. 
4.10)   Use values found in calibration under “Buffer composition” to determine the composition 
of buffer to be prepared. Based on the amount of crude cell extract produced, a master 
mix recipe is produced for a set amount of buffers.  
4.11)   Thaw aliquots as listed in master mix recipe on ice. Once thawed, prepare master mix, 
keeping on ice and vortexing after the addition of each item.  
4.12)   Aliquot by amount stated under “Buffer composition.” Flash-freeze buffer tubes in liquid 
nitrogen. While aliquoting, vortex the main stock frequently. 
4.13)   Remove tubes from liquid nitrogen using a strainer and immediately store at -80°C. 
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Safety: Wear protective eyewear; the caps of extract tubes may come off due to the 
temperature difference between liquid nitrogen and room temperature. 
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Experimental Execution of a TX-TL Reaction 
Final reaction conditions are: 8.9-9.9 mg/mL protein (from crude extract), 4.5 mM-10.5 mM 
Mg-glutamate, 40-160 mM K-glutamate, 0.33-3.33 mM DTT, 1.5 mM each amino acid except 
leucine, 1.25 mM leucine, 50 mM HEPES, 1.5 mM ATP and GTP, 0.9 mM CTP and UTP, 0.2  
mg/mL tRNA, 0.26 mM CoA, 0.33 mM NAD, 0.75 mM cAMP, 0.068 mM folinic acid, 1 mM 
spermidine, 30 mM 3-PGA, and 2% PEG-8000. A basic TX-TL reaction has 3 parts (tubes): 
crude cell extract, buffer, and DNA. The ratio is: 75% buffer and extract, 25% DNA. 
Reactions can vary in volume, and we use 10 µL by convention to minimize reaction volume 
and enable running in a 384-well plate. Larger volumes require agitation for proper oxygenation. 
The following protocol utilizes a pre-written template, TXTL_JoVE.xlsx (Supplemental 
Material 4), to conduct a 10 µL reaction. Items in purple indicate user-input values, and 
items in blue indicate additional reagents to add to the reaction. However, one can also 
conduct a reaction without the template by following reaction conditions outlined above. 
 
5.1)   Complete the “General Data” form.  
5.2)   Under “Master Mix Preparation,” insert the extract percentage value from step 4.1 into 
the purple box. 
5.3)   Design your experiment in silico using the “Master Mix Preparation” (rows 10-17) and 
“DNA Preparation” (rows 19-50) sections. Generally, constants can be put into the 
“Master Mix Preparation” section, while variables can be put into the “DNA Preparation” 
section. Minimize samples per experiment to avoid sample evaporation and 
experimental start time bias. See Figure 6 for a sample setup.  
5.4)   Under “Master Mix Preparation,” add reagents such as inducers or proteins, which will 
go in all samples at a constant concentration. Starting with row 14, fill out the blue 
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shaded areas, keeping one reagent to each line. Units are relative ratios.  
5.5)   Under “DNA Preparation,” add DNA which will be sample specific. Sample IDs #1 and 
#2 correspond to positive and negative controls, respectively. Sample IDs #3 and above 
are user-modifiable for DNA, stock concentration in ng/µL, length in base pairs, desired 
final concentration in nM, and repeats (of 10 µL reactions). The amount of stock DNA to 
reach desired final concentration is automatically calculated. The total across the row 
sums to 10.5*n, where n is the number of repeats. Note: Although the final reaction 
volume is 10 µL, the calculations assume a total volume of 10.5 µL per reaction, to 
account for volume lost during pipetting. 
5.6)   Under “DNA Preparation,” add reagents or additional DNA which will be sample 
specific to blue columns. Stock DNA concentrations in nM can be calculated under 
“DNA Preparation,” while sample specific reagents require manual calculation based on 
a total reaction volume of 10.5*n. The entered volumes are subtracted out of the water 
volume of the same row.  
5.7)   Remove needed number of tubes of buffer, crude cell extract, and positive control under 
“Tubes to thaw,” from -20°C or -80°C and thaw on ice. 
5.8)   Prepare DNA samples. For each sample ID, aliquot out the indicated DNA, water, and 
user-supplied items per the “DNA Preparation” section into a micro-centrifuge tube, at 
room temperature. Note: to avoid sample loss, recently calibrated pipets and low-stick 
pipet tips and micro-centrifuge tubes are recommended.  
5.9)   When tubes from step 5.7 are thawed, prepare the master mix consisting of buffer, 
extract, and any global user-supplied items based on the orange-shaded boxes, keeping on 
ice and vortexing after the addition of each item. Note: Extract is extremely viscous. 
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Aliquots with bubbles can be removed by centrifuging at 10000 g for 30 seconds at 4°C. 
5.10)   Add the amount of master mix indicated in the orange cells under “DNA Preparation” 
(column O) to each DNA sample, and keep at room temperature. Treat this as the 
reaction start time. 
5.11)   Vortex each sample, and centrifuge at 10000 g for 30 seconds at room temperature to 
bring down any residual sample and to reduce bubbles. 
5.12)   If conducting reaction in micro-centrifuge tubes, incubate directly at 29°C. Otherwise, 
pipet 10 µL of sample into a 384-well plate. Note: Reactions in volumes greater than 10 
µL may require agitation for oxygenation.  
5.13)   Centrifuge plate at 4000 g for 30 seconds at room temperature to bring down any residual 
sample and to reduce bubbles. Seal plate afterwards to prevent evaporation. 
5.14)   Run reaction at 29°C. Note: Runtimes vary depending on experiment but typically last 
under 8 hours. 
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Representative Results 
 
We have presented a five day protocol for the preparation of an endogenous Escherichia 
coli based TX-TL cell-free expression system. A sample timeline for creating the reagents – 
crude cell extract and buffer – can be found in Figure 1. Once created, these reagents can be 
stored at -80°C for up to one year. After reagents are created, experimental setup and execution 
can be done in less than 8 hours. 
We optimized the expression conditions of the TX-TL cell-free expression system. Other 
user-supplied additions, such as buffers or DNA solutions, should be calibrated for toxicity 
beforehand. For example, different methods of processing plasmids result in different expression 
due to salt content. We also tested the effect of Tris-Cl elution buffer on reaction efficiency 
(Figure 5). 
An example of crude cell extract calibration, referring step 4.1 to 4.9, is shown in Figure 
4a. In general, our experiments show that the crude cell extract is most sensitive to Mg-
glutamate levels, followed by K-glutamate levels. To demonstrate the cell-free expression 
system, we constructed and tested a negative feedback loop based on tet repression.26 (Figure 6). 
In the cell-free expression system, the same circuit run with and without aTc shows a 7-fold end-
point expression change of deGFP reporter after eight hours of expression. Although this 
experiment does not require global inducers or repressors, if necessary they can be added under 
“Master Mix Preparation.” 
45 
	  
Discussion 
 
The endogenous Escherichia coli based TX-TL cell-free expression system described 
here is an easy-to-run three tube reaction that can take less than eight hours from set up to data 
collection. The process of creating all reagents requires five days’ time total (with significant 
labor requirements on only one day), but produces crude extract for 3000 reactions and buffer-
making reagents for 10000 reactions (Figure 1). Furthermore, crude extract and buffer-making 
reagents are stable for at least 1 year at -80°C, allowing for multiple uses of one preparation.4 At 
$0.11 per 10 µL reaction ($0.26 including labor), costs are 98% lower than comparable 
commercial systems (Figure 2).  
There are some unresolved limitations, however, to the system. The end efficiency of 
each crude cell extract preparation can vary based on user proficiency and on environmental 
conditions, although typical yield variation is between 5-10% (Figure 4b). As a result, batch-to-
batch variability in both end-point expression and in expression dynamics are to be expected. 
These variations will likely remain until extract is fully characterized or until extract creation is 
fully automated. If the cell-free expression system is used to conduct sensitive quantitative 
experiments, it is advisable to run all experiments with the same batch of crude cell extract. The 
yield from a single crude cell extract batch, about 3000 reactions, should be sufficient for typical 
experimental courses.  Although we suspect variation can be removed by scaling up and 
automating the procedure, such attempts would involve a substantial resource investment.  
Additionally, although end-point expression levels are reasonably easy to determine, 
more work needs to be done in understanding dynamics intrinsic to the cell-free system. It is 
known that both resource competition and resource limitation can affect expression dynamics. 
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For example, limited endogenous sigma 70 can result in a saturating regime with increased DNA 
template producing an expression profile analogous to that of nucleotide or amino acid 
depletion.9,27 However, dynamics do not have to be fully understood to utilize the system. For 
pure increases of yield, optimization can be done by machine-learning approaches.28 Questions 
of resource competition and limitation can be addressed by mathematical models verified using 
experimental data. 
The protocol presented here is optimized for a BL21-Rosetta2 strain, but is generalizable 
to other E. coli strains. Modifications in BL21-Rosetta2, such as the removal of the gene 
encoding lon protease and the addition of genes encoding rare tRNAs, allow for maximal protein 
production. We have attempted the protocol with two other extract strains – BL21 only and a 
BL21 trxA knockout –and found 50% less protein yield. We hypothesize that yields similarly 
decrease when using other strains. Other changes in parameters, such as switching 2xYT growth 
medium for LB and other rich broths, have resulted in decreased protein yield.   
Cell-free expression systems utilizing both endogenous and exogenous transcription-
translation machinery and regulation mechanisms have wide applications in both protein and 
metabolite expression and in synthetic biology.3,29 Instead of being limited to T7-regulated 
circuits, one can envision producing complex biomolecules in a user-controllable setting using a 
mix of native E. coli promoters and exogenously supplied transcription and regulation 
mechanisms. Without limitations of cell division and metabolism, variability in synthetic circuits 
such as the repressilator or in metabolic engineered pathways such as those producing 
artemisinin can be reduced or better understood.30,31 We have used these advantages to 
implement genetic switches, as well as to understand sigma factor sequestration.9,32 Such 
technology can also form the backbone of “minimal” or “artificial” cells – small, well-
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characterized, and self-sufficient embodied units of extract.33,34  
Ultimately, we anticipate immediate uses of this endogenous cell-free expression system 
as a prototyping environment for synthetic biology. Nicknamed the “TX-TL biomolecular 
breadboard,” the cell-free expression system provides a controllable environment where 
synthetic circuits ultimately destined for in vivo expression can undergo rounds of prototyping – 
cycles of testing on basic plasmid, linear, or chemically synthetized DNA, followed by analysis 
and rapid modification. Prototyping rounds can be aided by predictive mathematical models 
currently being developed. By removing cloning and in vivo manipulation for non-final circuits, 
we anticipate engineering cycle times to be reduced to 1-3 days instead of the current weeks’ 
standard. 
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Figure 1 
 
 
Figure 1. Timeline for crude cell extract, amino acid solution, and energy solution 
preparation. A five-day timeline for a typical execution of the protocol is given above, 
optimized for overnight incubations and daytime working steps. 
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Figure 2 
 
 
Figure 2. Cost and expression analysis of competing crude cell extracts. a) Breakdown of the 
costs of labor and materials of the TX-TL cell-free expression system. Based on costs of 
reagents as of December 2012, and labor costs of $14 per hour. b) Comparison of TX-TL 
cell-free expression system costs vs. other commercial systems. Costs are broken down per 
µL, although reaction volumes may vary per kit.  c) Comparison of TX-TL cell-free 
expression system yield vs. other commercial systems. Protein expression yield determined by 
manufacturer standards. 
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Figure 3 
 
 
 
Figure 3. Loading and processing of a bead-beating tube. a) Demonstration of correct 
viscosity of cell-bead solution. Cell-bead solution will have a viscosity dependent on many 
factors, including amount of S30A buffer added, amount of beads added, and time spent on ice. 
b) Loading of bead-beating tube before quick tabletop centrifugation. The centrifugation 
removes bubbles accumulated during loading. c) Bubbles surfacing after tabletop 
centrifugation. The size of the bubbles will vary; they can be popped or removed using a pipet 
tip. d) Completely filled bead-beating tube before capping. A meniscus is formed in the bead-
beating tube, and the cap has enough to cover and cause small amounts to overfill. e) Correctly 
loaded filter apparatus. These can be reused. f) Comparison of correctly vs. incorrectly 
processed bead-beating tube. The tube on the left is a well-beat tube – it features a small and 
well-delineated top layer, and very clear supernatant. The tube on the right is suboptimal, based 
on the larger, hazy second layer and the hazy supernatant. Tubes that are suboptimal should not 
undergo additional processing. 
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Figure 4 
 
 
 
 
Figure 4. Properties of crude extract preparations. a) Typical calibration plots for crude 
cell extract. Crude extract is calibrated for additional Mg-glutamate, K-glutamate, and DTT 
levels, in that order. Shown is endpoint fluorescence after 8 hours, as well as maximal rate of 
protein production based on a 12-minute moving average. Based on these plots, an acceptable 
range of additional Mg-glutamate is 4 mM, K-glutamate is 60-80 mM, and DTT is 0-3 mM. Note 
that every crude extract needs to be calibrated independently for these three variables. b) 
Variation from extract preparations. Endpoint fluorescence of two crude extracts prepared on 
different dates is shown; error bars are 1 standard deviation from three independent runs on 
different days. 
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Figure 5 
 
 
 
 
Figure 5. Effects of DNA solution on expression efficiency. a) Comparison of two different 
purification methods for processing plasmids. 1 nM of pBEST-OR2-OR1-Pr-UTR1-deGFP-
T500 is prepared using only a QiaPrep Spin Miniprep Kit (Purification method 1) or post-
processed with a QiaQuick PCR purification kit (Purification method 2). Shown is endpoint 
fluorescence after 8 hours, as well as maximal rate of protein production based on a 12-minute 
moving average. Error bars are 1 standard deviation from four independent runs on different 
days. b) Effect of elution buffer (Tris-Cl). Different concentrations of Tris-Cl are compared in 
a cell-free expression reaction based on the expression of 1 nM of pBEST-OR2-OR1-Pr-UTR1-
deGFP-T500.  Concentrations given are final concentrations of Tris-Cl in the reaction; elution 
buffer used is 10 mM Tris-Cl. Error bars are 1 standard deviation from three independent runs on 
different days. 
 
  
55 
	  
Figure 6 
 
 
 
Figure 6. Sample TX-TL run of a negative feedback loop. a) Sample setup of a cell-free 
execution reaction. Tests “on” vs. “off” state of the negative feedback loop, with positive and 
negative controls. b) Plasmid map of negative feedback loop. c) Representative results. Data 
reflects experiment in a) and b), with negative control subtracted from signal. Genetic circuit 
shown in insert. Error bars are 1 standard deviation from three independent runs on different 
days.
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Table 1  
Reagents for day 1 of Crude Cell Extract protocol. 
 
Name Concentration Amoun
t 
Sterilizati
on 
Notes 
Chlora
mpheni
col 
(Cm) 
34 mg/mL in 
ethanol 
1 mL Filter 
sterilize 
(0.22 µM) 
Can be made in larger volumes 
stored at -20°C for later use. 
2xYT+
P+Cm 
agar 
plate 
31 g/L 2xYT, 40 
mM potassium 
phosphate dibasic, 
22 mM potassium 
phosphate 
monobasic, 34 
µg/ml 
chloramphenicol 
1 plate Autoclave  
2xYT+
P media 
31 g/L 2xYT, 40 
mM potassium 
phosphate dibasic, 
22 mM potassium 
phosphate 
monobasic  
4 L Autoclave  
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Table 2  
Reagents for day 2 of Crude Cell Extract protocol. 
 
Name Concentration Amoun
t 
Sterilizati
on 
Notes 
Tris 
base 
2 M 250 mL Filter 
sterilize 
(0.22 µM) 
or 
autoclave 
Can be stored at room 
temperature. 
DTT 1 M 6 mL Filter 
sterilize 
(0.22 µM) 
Can be made in larger volumes 
and stored at -20°C for later use. 
S30A 
buffer 
14 mM Mg-
glutamate, 60 mM 
K-glutamate, 50 
mM Tris, pH 7.7 
2 L Autoclave To reach pH 7.7, titrate with 
acetic acid. Add DTT to 2 mM 
final concentration just before 
use. Store at 4°C. 
S30B 
buffer 
14 mM Mg-
glutamate, 60 mM 
K-glutamate, ~5 
mM Tris, pH 8.2 
2 L Autoclave To reach pH 8.2, titrate with 2M 
Tris. Add DTT to 1 mM final 
concentration just before use. 
Store at 4°C. 
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Table 3  
S30A buffer and bead mass calculator, for day 3 of Crude Cell Extract protocol. 
 
 Falcon 
1 2 3 4 
Empty 50 mL Falcon (g)     
50 mL Falcon with pellet (g)     
Pellet mass (50 mL Falcon with pellet – empty 50 mL 
Falcon) (g) 
    
S30A buffer volume to add (pellet mass* 0.9) (mL)     
Total mass of beads to add (pellet mass * 5.0) (g)     
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Table 4  
Reagents to prepare for Energy Solution protocol. 
 
Name Concentration Amoun
t 
Sterilizati
on 
Notes 
HEPES 2 M, pH 8 4 mL None To reach pH 8, titrate with 
KOH. 
Nucleot
ide Mix 
156 mM ATP and 
GTP, 94 mM CTP 
and UTP, pH 7.5 
1.5 mL None To reach pH 7.5, titrate with 
KOH.  
tRNA 50 mg/mL 600 µL None  
CoA 65 mM 600 µL 
 
None  
NAD 175 mM, pH 7.5-8 300 µL None To reach pH 7.5-8, titrate with 
Tris at 2 M. 
cAMP 650 mM, pH 8 200 µL None To reach pH 8, titrate with Tris 
at 2 M. 
Folinic 
Acid 
33.9 mM 300 µL None Although only 300 µL is 
needed, recipe in supplemental 
is for 1.15 mL. 
Spermi
dine 
1 M 150 µL None Store at 4°C, heat to 37°C to 
melt. 
3-PGA 1.4 M, pH 7.5 3.2 mL None To reach pH 7.5, titrate with 
Tris at 2 M. 
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Table 5 
Material list. 
 
Name of Reagent/Material Company Catalog 
Number 
Comments 
2xYT  MP 
biomedicals 
3012-032  
3-PGA Sigma-Aldrich P8877  
ATP Sigma-Aldrich A8937  
Bacto-agar BD 
Diagnostics 
214010  
Bead-beating tubes 
(polypropylene microvials) 
BioSpec 522S  
Beads, 0.1 mm dia. BioSpec 11079101  
BL21 Rosetta 2 E. coli strain Novagen 71402  
Bradford BSA Protein Assay Kit Bio-rad 500-0201  
cAMP Sigma-Aldrich A9501  
Chloramphenicol  Sigma-Aldrich C1919  
CoA Sigma-Aldrich C4282  
CTP USB 14121  
Cuvettes, 1.5 mL Fisher 14-955-127  
DTT Sigma-Aldrich D0632  
Folinic acid Sigma-Aldrich F7878  
GTP USB 16800  
HEPES Sigma-Aldrich H6147  
K-glutamate  Sigma-Aldrich G1149  
Mg-glutamate Sigma-Aldrich 49605  
Micro Bio-Spin Chromatography 
Columns  
Bio-Rad 732-6204  
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NAD Sigma-Aldrich N6522  
Nunc 384-well optical bottom 
plates 
Thermo-
Scientific 
142761  
Nunc sealing tape Thermo-
Scientific 
232701  
PEG-8000 Promega V3011  
Potassium phosphate dibasic 
solution 
Sigma-Aldrich P8584  
Potassium phosphate monobasic 
solution  
Sigma-Aldrich P8709  
RTS Amino Acid Sampler 5 Prime 2401530  
Slide-A-Lyzer Dialysis Cassettes, 
10k MWCO (Kit) 
Thermo-
Scientific 
66382  
Spermidine Sigma-Aldrich 85558  
Tris base Fischer BP1521  
tRNA (from E. coli) Roche Applied 
Science 
MRE600  
UTP USB 23160  
1 L Centrifuge Bottle Beckman-
Coulter 
A98813 This is specific for 
Avanti J-series; 
obtain equivalent 
size for centrifuge in 
use. 
4 L Erlenmeyer Flask Kimble Chase 26500-4000  
Avanti J-26XP Centrifuge Beckman-
Coulter 
393127 Or 1L-capable 
centrifuge 
equivalent. 
Forma 480 Orbital Shaker Thermo 
Scientific 
480 Or chest-size 6 x 4 L 
shaker equivalent. 
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JLA-8.1000 Rotor Beckman-
Coulter 
363688 Or 1 L-capable, 
5000 g rotor 
equivalent for 
centrifuge. 
Mini-Beadbeater-1 BioSpec 3110BX  
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Supplemental Material 1  
Recipes for Items. 
 
 
Chloramphenicol, 34 mg/mL: Prepare 0.51 g chloramphenicol and add ethanol to 15 mL. 
Filter sterilize (0.22 µM), aliquot to 1 mL tubes, store at -20°C for later use. 
2xYT+P+Cm agar plate: Prepare 1.24 g 2xYT, 1.6mL potassium phosphate dibasic 
solution @ 1 M, 0.88mL potassium phosphate monobasic solution @ 1 M, 0.6 g agar, 
and water to 40 mL. Autoclave. Let cool to 50°C and add 40 µL Cm. Aliquot 25 mL into 
a 100x15 mm petri dish, and let cool for an hour. 
2xYT+P media: Prepare 124 g 2xYT, 160 mL potassium phosphate dibasic solution @1 
M, 88 mL potassium phosphate monobasic solution @ 1 M, and water to 4 L. Aliquot out 
into 2x1.88 L and 0.24 L. Autoclave. 
Tris base, 2 M: Prepare 60.57 g Tris base and water to 250 mL. Sterilize, store at RT for 
later use. 
DTT, 1 M: Prepare 2.31 g DTT and water to 15 mL. Filter sterilize (0.22 µM), aliquot to 
1 mL tubes, store at -20°C for later use. 
S30A buffer: Prepare 10.88 g Mg-glutamate and 24.39 g K-glutamate, 50 mL Tris at 2M, 
acetic acid (to pH 7.7), and water to 2 L. Autoclave, store at 4°C, add 4 mL 1 M DTT 
before use. 
S30B buffer: Prepare 10.88 g Mg-glutamate and 24.39 g K-glutamate, Tris at 2 M (to pH 
8.2), and water to 2 L. Autoclave, store at 4°C, add 2 mL 1 M DTT before use. 
HEPES: Prepare 1.91 g HEPES (MW 238.21), KOH (to pH 8), and water to 4mL. 
tRNA: Prepare 30 mg of tRNA and water to 600 µL. 
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CoA: Prepare 30 mg of CoA (MW 767.53) and water to 600 µL. 
NAD: Add 34.83 mg of NAD (MW 663.43), Tris at 2 M (to pH 7.5-8), and water to 300 
µL. (Add 27 µL of Tris at 2 M to bring the solution to pH 7.5-8). 
cAMP: Add 42.80 mg of cAMP (MW 329.22), Tris at 2 M (to pH 8), and water to 200 
µL. (Add 73 µL of Tris at 2 M to bring the solution to pH 8). 
Folinic Acid (33.9 mM): To 20 mg of solid folinic acid calcium salt (MW 511.5), add 
1.15 mL water. 
Spermidine: Prepare 23.55 µL of spermidine (MW 145.25) and water to 150 µL. Prepare 
at room temperature after melting briefly at 37°C. 
3-PGA: Add 1.03 g of 3-PGA (MW 230.02), Tris at 2 M (to pH 7.5), and water to 3.2 
mL. (Add 1.73 mL of Tris at 2 M to bring the solution to pH 7.5). 
Nucleotide Mix: Add 145 mg of ATP dipotassium salt dihydrate (MW 619.4), 133 mg of 
GTP disodium salt (MW 567.14), 79.4 mg of CTP disodium salt dihydrate (MW 563.16), 
82.6 mg of UTP trisodium salt dihydrate (MW 586.12), KOH at 15% dilution (to pH 7.5), 
and water to 1.5 mL. (Add 353 µL of KOH at 15% dilution to bring the solution to pH 
7.5). 
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Supplemental Material 2 
Bradford Assay. 
6.1)   Remove Bradford agent from 4°C and set at room temperature. 
6.2)   Prepare 50 µL BSA Standard at 1 mg/mL and at 0.1 mg/mL. 
6.3)   Prepare 40 µL 20x dilution of extract from step 1.47. 
6.4)   Add 800 µL water to 7 cuvettes. 
6.5)   Prepare standard cuvettes for 0 mg/mL, 1 mg/mL (10 µL 0.1 mg/mL BSA), 2 
mg/mL (20 µL 0.1 mg/mL BSA), 4 mg/mL (4 µL 1 mg/mL BSA), 6 mg/mL (6 
µL 1 mg/mL BSA). 
6.6)   Prepare experimental cuvettes for 2 µL of sample and 4 µL of sample. 
6.7)   Add 200 µL of Bradford agent to each cuvette and mix well by pipetting. Incubate 
at room temperature for at least 10 minutes. 
6.8)   Produce standard curve at OD 595nm using cuvettes from step 6.5.  Reject 
standard curve if r^2 < 0.95. 
6.9)   Determine extract concentration at OD 595nm using cuvettes from step 6.6. 
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Supplemental Material 3 
Buffer calibration spreadsheet. 
 
See  TXTL_e(template)_calibration_JoVE.xlsx on www.jove.com 
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Supplemental Material 4 
 Cell-free expression run spreadsheet. 
 
See  TXTL _JoVE.xlsx on www.jove.com 
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Abstract 
Accelerating the pace of synthetic biology experiments requires new approaches 
for rapid prototyping of circuits from individual DNA regulatory elements. However, 
current testing standards require days to weeks due to cloning and in vivo transformation. 
In this work, we first characterized methods to protect linear DNA strands from 
exonuclease degradation in an Escherichia coli based transcription-translation cell-free 
system (TX-TL), as well as mechanisms of degradation. This enabled the use of linear 
DNA PCR products in TX-TL.  We then compared expression levels and binding 
dynamics of different promoters on linear DNA and plasmid DNA. We also demonstrated 
assembly technology to rapidly build circuits entirely in vitro from separate parts. Using 
this strategy, we prototyped a four component genetic switch in under 8 hours entirely in 
vitro. Rapid in vitro assembly has future applications for prototyping multiple component 
circuits if combined with predictive computational models. 
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Introduction 
The current mode of building synthetic circuits relies heavily on in silico design 
followed by in vivo testing and revision. Complete circuits are cloned into a plasmid for 
propagation in vivo, a labor-intensive and serial process that has a 1-week testing cycle, 
which scales poorly for complex circuits (Fig. 1a).1-3 Although large-scale successes have 
been accomplished by this testing method, there is a significant time cost to this 
engineering cycle. For example, the industrial production of artemisinin from synthetic 
circuits in E. coli and S. cerevisiae has taken 150 “person-years,” of which much time 
can be attributed to part testing.4, 5 
This current method ignores a commonly applied process in engineering: testing 
of circuits in a simplified prototyping environment, such as a breadboard, to decrease 
complexity and increase iteration speed. Cell-free protein synthesis systems are a 
simplified alternative to in vitro systems that are known for ease-of-use and well-defined 
features.6-8 Circuits such as oscillators, switches, and translational regulators9-11 have 
been implemented either in reconstituted cell-free systems or in S30 extracts.12, 13 
However, these extracts either lack significant similarity to the in vivo environment or are 
optimized for protein production in lieu of circuit design. The ideal cell-free expression 
system should act as a “biomolecular breadboard” intermediary between circuit testing 
and in vivo implementation. It should mirror the E. coli in vivo state while preserving 
protein production capability and regulatory mechanisms.14 
We propose an S30-based transcription-translation system (TX-TL) that we have 
developed to serve as part of a biomolecular breadboard. This system is currently 
supported with characterizations of transcriptional and translational processes, 
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computational models, and protocols for its creation and use.14-18 We have also 
demonstrated simple logic gates, cascades, and large-scale assembly of bacteriophage.14, 
19 While most circuits implemented in S30 based extracts utilize plasmid DNA to avoid 
exonuclease degradation from endogenous RecBCD, linear DNA can be protected from 
degradation with the RecBCD inhibitor bacteriophage gamS protein both in vivo and in 
other S30 extracts.20, 21 The ability to run circuits off of linear DNA opens up possibilities 
for rapid prototyping, as linear DNA can be created in high yields either synthetically or 
entirely in vitro in just a few hours. Linear DNA could also enable applications not 
possible with plasmid DNA, such as the expression and analysis of toxic proteins by 
bypassing in vivo transformation and selection. 
In this paper, we established using linear DNA with the biological breadboard for 
rapid prototyping (Figure 1b). We first developed protective mechanisms to make linear 
DNA expression comparable to that of plasmid DNA. We also verified recent findings in 
other S30 extracts which suggested that transcriptional processes using linear DNA are 
disparate from those using plasmid DNA.22 To validate linear DNA as a prototyping 
medium, we compared expression of linear DNA to plasmid DNA for a family of 
promoters and demonstrated similar circuit dynamics for a genetic switch. A rapid, 
entirely in vitro assembly technique was then developed to assemble regulatory elements 
and basic circuits from standard or custom pieces in under 4 hours, with complete testing 
in under 8 hours. By maintaining an engineering cycle time of 8 hours or less, our 
technology theoretically enables prototyping of multi-component circuits in a standard 
business day. 
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Results and Discussion 
 
Linear DNA can be protected from degradation in TX-TL 
We initially sought to characterize the stability of linear DNA in TX-TL. Integral 
to this is accurate quantification of both linear and plasmid dsDNA concentration, as 
large errors in quantifying small amounts of dsDNA can introduce significant 
downstream bias.23 This is especially true for TX-TL, as some experiments require less 
than 10 ng/μL of stock dsDNA. Two common methods for dsDNA quantification 
commonly in use include spectrophotometry and fluorometry. We compared both and 
established guidelines for measuring linear and plasmid DNA concentrations 
(Supplemental S1, Figure S1, Table S1). 
Unless otherwise stated, all experiments in the paper were done with a single 
extract batch to avoid extract-to-extract variation14, and DNA sequences used can be 
found in Supplemental Information (Supplemental S2).  
To determine ideal conditions for expression of a linear DNA template, we 
compared the production of fluorescent reporter deGFP from plasmid pBEST-OR2-OR1-
Pr-UTR1-deGFP-T500 to that of the 810 bp linear DNA product with no steric protection 
on the 5’ or 3’ end.  This plasmid was previously optimized for high expression in TX-
TL.16 The deGFP synthesis off of linear DNA was less than 2% that of plasmid DNA 
(Figure 2a). In order to use lower concentrations of DNA templates for prototyping, we 
expanded upon previous work which added purified lambda gam in an S30 extract to 
protect DNA from exonuclease degradation.21 We utilized gamS, a truncated form of 
lambda gam.20 We also developed a non-toxic storage buffer for use in TX-TL by 
conducting a toxicity assay of common protein storage buffer additives in an alternate 
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extract (Figure S2, Figure S3). Notably, glycerol as a cryoprotectant is highly toxic to 
TX-TL and required replacement with DMSO. With gamS protein present in the reaction, 
deGFP synthesis off of the OR2-OR1-Pr-UTR1-deGFP-T500 linear DNA was 37.6% that 
of plasmid DNA (Figure 2a).   
We determined a gamS working concentration of 3.5 μM by comparing the 
protective ability of dilutions of purified protein on 2 nM of linear DNA without steric 
protection (Figure 2b). We used this concentration for subsequent experiments. We 
hypothesize that 3.5 μM is significantly above saturating levels to inactivate RecBCD, as 
at 3.5 μM and above the incubation of gamS with crude extract did not improve 
expression, while below 3.5 μM incubation time improved expression (Figure S4). While 
purified gamS improved linear DNA expression, it showed no toxicity to plasmid DNA 
expression (Figure 2c).  
We also conducted a saturation curve of plasmid and linear DNA by measuring 
endpoint deGFP concentration as a function of DNA concentration. Using this data, we 
defined a linear regime and saturation regime (Figure S5). The linear regime is defined as 
the linear region of DNA concentration and output signal, implying little to no resource 
limitation. In the saturation regime, increased DNA only marginally increases signal. We 
defined resource limitation broadly as any aspect limiting an in vitro reaction, such as 
polymerase and ribosome saturation or resource depletion (NTPs, amino acids). We ran 
circuits in the linear regime of DNA concentration to avoid resource limitation affects. 
While plasmid DNA entered the saturation regime above 4 nM, linear DNA remained in 
the linear regime up to 16 nM (Figure 2c). This established a typical working 
concentration for linear DNA, and suggested the ability to calibrate linear DNA results to 
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plasmid DNA results by concentration. While much of the discrepancy in saturation can 
be attributed to promoter strength differences of plasmid versus linear DNA, there may 
also be contributions from antibiotic resistance cassettes on plasmid DNA diverting 
resources from the production of deGFP that we did not explore. 
With the presence of gamS, we also tested steric protective mechanisms to inhibit 
degradation by RecBCD and other exonucleases.21, 24 We first tested two independent 
non-coding sequences flanking the ends of our linear cassette (Figure 2d). “Sequence 1” 
was derived from the original plasmid, while “Sequence 2” was from the coding 
sequences of two long E. coli genes, gltB and lhr, presumed to have no large internal 
reading frames. Protection was both sequence-specific and length-dependent. 5 bp of 
protective sequences on each end increased signal 2.4-fold over no protective ends. 
Protection reached a maximum around 250 bp-500 bp, with 6-fold larger signal over no 
steric protection. Therefore, unless otherwise specified we used 250 bp of protective 
sequences for subsequent linear constructs. We also tried protecting linear DNA with 1, 
2, or 5 phosphorothioate modifications at the 5’ end added by PCR, and found 
improvement only when 5 bp or less of non-coding DNA protection was present (Figure 
S6a). Interestingly, 5 phosphorothioates on the 0 bp protection construct significantly 
changed the dynamics of expression, suggesting a minimum protective length of 15 bp 
from the -35 promoter region (Figure S6b).  
DNA degradation in TX-TL is incomplete from the 5’ or 3’ end 
 
Little is known about degradation patterns of multiple copies of linear DNA in 
S30 extract-based systems. Knowing whether each copy is selectively degraded at the 5’ 
end or completely removed from the reaction has ramifications for positioning of circuits 
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on linear DNA. To directly measure DNA concentration over the linear regime of a TX-
TL reaction, we labeled a typical non-saturating amount of linear DNA (2 nM, 25 ng) 
with a fluorescent probe, AlexaFluor-594, in a complementary spectrum to the deGFP 
reporter. We first incorporated the probe randomly throughout the linear DNA by PCR 
using an AlexaFluor-594-5-dUTP, which replaced dTTP (Figure 3a). Despite the 
labeling, linear DNA retained expression ability as measured by deGFP signal. Negligible 
DNA was degraded within 1 hour and over 75% remained within 4 hours when templates 
were protected by gamS, suggesting minimal degradation of template over a typical 
period of data collection. We also labeled the same template only at the 5’ end through 
PCR by using primers with AlexaFluor-594 covalently bound (Figure 3b). While 
expression of deGFP was equally conserved, there was significant degradation of 
AlexaFluor-594 signal as compared to samples labeled throughout the entire linear DNA. 
We concluded that when gamS and when multiple copies of linear DNA are present, 
there is incomplete degradation at the 5’ end. This is supported by previous data showing 
only modest expression improvement from increased steric protection lengths (Figure 
2d), as well as evidence suggesting the existence of always-active RecBCD complex 
despite saturating gamS concentration.25 While RecBCD is the primary dsDNA 
exonuclease, we cannot discount the action of other dsDNA exonucleases such as 
ExoVII.26, 27 To our knowledge, this is the first evidence of an exonuclease degradation 
mechanism with multiple copies of linear DNA. 
We also determined that degradation of linear DNA is a saturated process limited 
by the amount of exonuclease. We conducted the same degradation assay, but using 
saturating amounts of DNA (250 ng, 20 nM) and saw no significant degradation at 120 
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minutes in the presence of gamS (Figure S7). Degradation also seemed invariant to 
extract preparation conditions. We also made an extract prepared at 29°C, based on 
previous work where lower preparation temperature decreased exonuclease activity on 
linear DNA.28 However, we saw no decreased degradation. Based on these findings, we 
concluded that linear DNA remained present throughout the TX-TL reaction, and could 
be significantly protected against exonuclease degradation at high concentrations or with 
sufficient steric protection.  
Linear DNA is an alternative to plasmid DNA for circuit prototyping  
Although circuits can be prototyped rapidly using linear DNA, recent studies in 
other S30 extracts demonstrated a discrepancy between relative expression of linear 
templates versus plasmid templates.22 These discrepancies were attributed to structural 
differences between plasmid and linear DNA, as relative activity was recovered by re-
ligation of linear DNA and was independent of translation. We hypothesized that despite 
structural differences between linear and plasmid DNA, prototyping could still be 
accomplished by calibrating promoter strength based on DNA concentration between 
linear and plasmid DNA for constitutive promoters. While a large amount of DNA is 
needed to obtain signal in other kits, TX-TL allows significant expression for small 
template concentrations. By working in a linear regime, circuits can be executed such that 
large amounts of free polymerases and ribosomes exist at all times (Figure S5). 
We tested twelve commonly used sigma-70 based promoters and a negative 
control of random DNA for in vitro plasmid strength, in vitro linear DNA strength, and in 
vivo strength. Linear DNA was protected with gamS protein and 250 bp of non-coding 
DNA on either end. Nine promoters are minimal sigma-70 promoters from the Biobrick 
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parts library (http://parts.igem.org/), while three are inducible and well-characterized.29, 30 
These constructs all identically expressed deGFP downstream of an untranslated region 
containing a strong RBS “UTR1.”16 When each Biobrick promoter was compared in the 
linear regime and normalized to J23101, there was no correlation between results in vivo 
and in TX-TL either on plasmid or on linear DNA. (Figure 4a). However, when data was 
taken at highest concentrations measured there was a correlation, if limited, between 
results in vivo and in TX-TL on plasmid DNA (Figure S8). Figure S8 results are similar 
to a panel done previously in a separate S30 extract, albeit with a different reporter, 
weaker RBS, different plasmid, and different temperature.22 More work needs to be done 
to reconcile both datasets, although these results suggest that circuits tested in saturated 
phase on plasmid DNA most accurately represent the in vivo environment. In the in vivo 
environment, we speculate high copy plasmids on strong promoters may reach saturated 
phase expression. Each inducible promoter was also tested constitutively with the 
repressor inactivated or not present, and limited correlation was found between in vivo 
results and TX-TL results (Figure 4b). Interestingly, inducible promoters seemed to have 
vastly stronger strength relative to the minimal sigma-70 based promoter panel in TX-TL.  
For the Pl-tetO1 and Pl-lacO1 promoters, we also characterized the response in 
TX-TL of linear and plasmid DNA to varying amounts of inducer in the presence of 
repressor (Figure 4c). Data was fit to a Hill function with a Hill coefficient of unity 
(Supplemental S3). Operator binding dynamics were similar, with a Michelis-Menten 
binding coefficient within two standard deviations for Pl-tetO1 and within one standard 
deviation for Pl-lacO1. Data for Pl-tetO1 may be biased, however, as TX-TL showed 
toxicity at values above 10 μM aTc, which seemed to be below saturation phase. We 
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assumed that for Pl-tetO1 and Pl-lacO1, repression binding and unbinding was similar for 
linear and plasmid DNA at individual operator site.  
To calibrate linear DNA to plasmid DNA for constitutive expression, we tested 
each promoter at different concentrations. Based on the results of endpoint expression, a 
saturation curve was produced for both linear and plasmid DNA, where expression was 
plotted as a function of DNA concentration (Figure 4d).  We used a cutoff of r2 > 0.975 to 
determine a linear regime for each promoter (Figure S9). This data was used to develop a 
calibration table for linear and plasmid DNA, where the slope of the linear regression line 
indicated promoter strength in the linear regime (Table 1). A Plasmid:Linear (P:L) ratio 
was also determined. All promoters were stronger on plasmid DNA than linear DNA, 
ranging from 1.40-23.74 fold. The carrying capacity of TX-TL was capped at 15 μM. 
However, independent of promoter strength all constructs approached the saturating 
regime at 32 nM of linear DNA. This suggested a theoretical limit of DNA carrying 
capacity independent of absolute signal strength, but we were unable to test 
concentrations above 32 nM for linear DNA or 16 nM for plasmid DNA. 
To demonstrate the ability to prototype circuits using either plasmid or linear 
DNA, we built a 4-piece genetic switch with two fluorescent outputs, deGFP and deCFP 
(Figure 5).31 Linear DNA constructs were derived from plasmid DNA by PCR, and had 
gamS present as well as 250 bp of steric protection. 2 nM of each reporter and 1 nM of 
each repressor were used. We then examined the dynamics of the genetic switch by 
plotting the endpoint expression values at 36 different combinations of IPTG and aTc 
inducers. When both deGFP and deCFP were scaled for equivalent expression, the 
genetic switch behaved as expected with deGFP expression at high IPTG and deCFP 
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expression at high aTc. As predicted, expression from linear DNA at similar 
concentrations was also lower than for plasmid DNA. Based on this result, we believe 
linear DNA prototyping is a viable alternative to plasmid DNA prototyping. 
Linear DNA can be rapidly assembled for prototyping circuits 
 
After establishing linear DNA circuit prototyping, we sought to create a method 
for rapid assembly of linear pieces that would enable us to go from assembly to testing in 
4-8 hours, and simultaneously allow us to generate plasmid DNA post-transformation 
(Figure 6a). Unlike other in vivo assembly methods, which ultimately require efficiency 
as well as selectivity, we were primarily concerned with selectivity as our templates 
would be end amplified by PCR. We also favored rapid cycle times in linear DNA to 
modularity post-construction, which has been shown to speed up the design cycle in 
vivo.32 We initially tested three methods of in vivo assembly for adoption purely in vitro: 
Isothermal assembly, Chain Reaction Cloning, and Golden Gate assembly.2, 33, 34 Each 
method is based on a different mechanism of action – recombination-based cloning, 
blunt-end cloning, or sticky-end cloning. Of these three, only Isothermal assembly and 
Golden Gate assembly produced enough yield to obtain constructs.   
We first assembled a common network motif, a negatively autoregulated gene35, 
from four linear parts using both Isothermal assembly and Golden Gate assembly (Figure 
S10a). The assembly products were PCR amplified directly afterwards to produce rapid 
assembly products ready for prototyping in TX-TL. The assembly product was also 
transformed, cultured, purified, and amplified by PCR to produce a positive control. All 
constructs were sequenced before testing in TX-TL. When run on an agarose gel, rapid 
assembly products were of the expected size when compared to a post-transformation 
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positive control, with higher than 95% purity (Figure S10b). However, while all 
constructs showed responses to aTc induction some demonstrated significant background 
activity (Figure S10c). We hypothesized that a non-specific product caused by mis-
ligation could significantly bias results. To counteract this, we developed a standard 
assembly procedure based on Golden Gate assembly. By using a standard assembly, any 
mis-ligation would be less likely to lead to mis-assembled products capable of 
expression.  
Our standard Golden Gate assembly procedure also allowed us to recycle 
commonly used parts and to ensure functional activity of the desired product. Our 
standard consisted of five pieces – a promoter, 5’ untranslated region (UTR), coding 
sequence, terminator, and vector (Figure S11). It was designed to be compatible with 
previously used non-coding sequences and primers on the pBEST vector backbone. We 
revised a pre-existing standard for use in TX-TL by creating 4 bp binding overhangs with 
increased specificity.36 Using different overhangs with little overlap was necessary, as we 
found decreased specificity with multiple base pair overlaps. We also designed our PCR 
primers to overlap at the junction sites of vector and promoter and vector and terminator, 
respectively, which further minimized non-specific products. This decreased steric 
protection ends to 31 bp.  
Using our standard with pre-made pieces, we rapidly prototyped a Pl-tetO1-
deGFP construct and demonstrated functional equivalency in less than 5 hours (Figure 
6b-c). A detailed time frame with comparisons to testing using plasmids post-
transformation is in Table S2. While the assembly reaction did not produce significant 
amounts of plasmid, a fragment corresponding to the expected size could be amplified. 
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Cleaner PCR products of the assembly reaction were produced by minimizing template 
concentration and by using overlapping PCR primers (Figure S12). Existing non-specific 
products could also be predicted based on size and gel mobility shifts. We have since 
tested multiple assemblies using our rapid assembly standard, and found that correct 
equimolar ratios of starting products are also essential to isolating a clonal product.  
For more complex circuits, we verified our rapid assembly procedure by repeating 
the construction of the genetic switch in Figure 5a, but from rapid assembly products 
(Figure S13a). Specific bands were formed from PCR off of the rapid assembly product, 
and TX-TL runs demonstrated similar results for the product and the positive control 
when responding to IPTG and aTc (Figure S13b-c). This prototyping took under 7 hours 
of time. 
Linear DNA prototyping theoretically allows for large circuits to be tested in a 
single business day 
Our work is primarily focused on the technology development of a rapid 
prototyping procedure using linear DNA in TX-TL. Therefore, we chose only to 
demonstrate proof-of-concept assemblies using simple circuits. However, the real return 
of linear DNA prototyping is in testing large circuits in TX-TL. Unlike traditional testing 
methods reliant on plasmids, the 4-8 hour benchmark provided by our method is 
theoretically independent of the number of components tested. For example, to initially 
test an n-piece circuit in vivo would require log3(n) rounds of plasmid cloning, assuming 
assemblies of 5 units at the same time (four regulatory units plus a vector backbone) 
(Figure 7a-b). This restriction results from the carrying capacity of the cell to maintain a 
limited number of antibiotic cassettes and origins of replication. However, an initial 
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testing cycle in TX-TL on linear DNA would require only the theoretical 8 hours, as each 
construct can be assembled in parallel on linear DNA and immediately tested (Figure 7c). 
The only restriction would be the resource carrying capacity of the TX-TL reaction. 
However, large-scale circuit prototyping is limited by the current lack of relatively large 
synthetic circuits; to our knowledge, the largest currently published circuit is an 11-piece 
logic gate.37 Once rapid assembly is established, a larger bottleneck may be the difficulty 
of formulating and testing novel synthetic circuits with useful function. 
To reach the theoretical 8-hour limit for large circuits, the rapid assembly 
procedure could be automated using robotics with simple pipetting and thermo-cycling 
capability, as the assemblies rely on standard parts, the final part is PCR amplified, and 
the resulting part is added to a constant-temperature TX-TL reaction. Unlike traditional 
methods of testing circuits, there are no cell growth, plasmid miniprep, or centrifugation 
steps. We have not yet explored automation of the rapid assembly procedure. 
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Conclusion 
 
In this paper, we described a rapid prototyping procedure for genetic circuits 
utilizing linear DNA in an E. coli TX-TL cell-free system. This was done by 
characterizing methods of protecting linear DNA, and differences in gene expression 
between linear and plasmid DNA templates. A rapid assembly procedure entirely in vitro 
was developed, which produced results from standard parts in under 8 hours. For a 
genetic switch, circuits on linear DNA qualitatively matched circuits on plasmid DNA. 
Prototyping with linear DNA in TX-TL can decrease cycle times and increase iteration 
speed. 
We demonstrated that linear DNA results could be mapped to plasmid DNA 
results in the context of individual promoters. However, in the context of circuit design 
the mapping becomes more complex due to multiple interconnecting relationships. While 
we saw expected relative circuit behavior for a genetic switch on both linear DNA and 
plasmid DNA, we did not attempt to map results from one mode of prototyping to the 
other. Such mapping may require computational toolboxes using parameters such as 
promoter strength and binding coefficients derived in this work.38 Additionally, one 
would need increased understanding of experimental variation in TX-TL. For example, 
with plasmid DNA we have noticed expression differences dependent on the strain used 
for amplification, and with linear DNA expression differences between samples that were 
not processed in the same batch. Part of the difference is explained by exogenous steps, 
such as salt content post-miniprep using different columns.14 We hypothesize other 
differences may be intrinsic to the DNA used, either through biochemical modifications 
or through conformational differences which have been shown in vivo to affect gene 
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expression.39 Some variation can be compensated for by controls, such as harvesting all 
plasmid DNA used in a single batch. Such approaches are analogous to those addressing 
ubiquitous variation in in vivo systems.29  
Ultimately, one would like to prototype circuits in TX-TL or a comparable in 
vitro environment for functionality in vivo. This could be challenging in light of the lack 
of correlation of results in vivo to those of TX-TL plasmid DNA data in our dataset. 
While promoter strengths could be calibrated individually between TX-TL and in vivo, it 
is unclear how to (or if it is necessary to) calibrate complex circuits with multiple 
interconnecting relationships. Encouragingly, there are examples of circuits prototyped in 
vitro for in vivo demonstration – namely a negative feedback gene and a logic gate.40, 41 
Future work can focus on important parameters in the transition, and on the transition of 
complex circuits of three or more promoters or those not based on known in vivo motifs.  
In vitro systems in general and TX-TL in specific form a strong basis for the 
testing of novel circuits. For applications using T7 promoters or for simple assays, finely 
controlled T7-based reconstituted systems without linear DNA degradation can be used.12 
However, TX-TL and S30 based systems have the additional ability to strongly express 
sigma-70 and alternate sigma promoters, as well as provide nucleic acid degradation. 
There is also a wealth of data from previous S30 extract studies and from recent studies 
allowing for long-term expression42, small-scale expression43, 44, and novel control 
techniques.45 Rapid prototyping techniques explored in this work, when tied into other 
existing technologies and to characterization research, are a compelling and rapid 
alternative to in vivo systems for circuit design and testing. 
 
88 
	  
Methods 
 
Cell-free expression preparation and execution 
Preparation of the cell-free TX-TL expression system was done according to 
previously described protocols, resulting in extract with conditions: 8.9-9.9 mg/mL 
protein, 4.5 mM-10.5 mM Mg-glutamate, 40-160 mM K-glutamate, 0.33-3.33 mM DTT, 
1.5 mM each amino acid except leucine, 1.25 mM leucine, 50 mM HEPES, 1.5 mM ATP 
and GTP, 0.9 mM CTP and UTP, 0.2  mg/mL tRNA, 0.26 mM CoA, 0.33 mM NAD, 
0.75 mM cAMP, 0.068 mM folinic acid, 1 mM spermidine, 30 mM 3-PGA, and 2% 
PEG-8000.14 Unless otherwise specified, one extract set “eZS1” was used consistently 
throughout the experiments to prevent variation from batch to batch. Extract “e10” was 
similarly prepared for toxicity assays. Extract “e13” was prepared using above 
conditions, but grew only at 29°C with a 12-hour second incubation.  TX-TL reactions 
were conducted in a volume of 10 µL in a 384-well plate (Nunc) at 29°C, using a three 
tube system: extract, buffer, and DNA. When possible, inducers such as IPTG or purified 
proteins such as gamS were added to a mix of extract and buffer to ensure uniform 
distribution. For deGFP, samples were read in a Synergy H1 plate reader (Biotek) using 
settings for excitation/emission: 485 nm/ 525 nm, gain 61. For deCFP, settings were 440 
nm/ 480 nm, gain 61. All samples were read in the same plate reader, and for deGFP rfu 
units were converted to µM of protein using a purified deGFP-His6 standard. Unless 
otherwise stated, endpoint measurements are after 8 hours of expression at 29°C. 
 
GamS protein purification 
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The composition of buffers used was buffer L: 50 mM Tris-Cl pH 8, 500 mM 
NaCl, 5mM imidazole, 0.1% Triton X; buffer W: 50 mM Tris-Cl pH 8, 500 mM NaCl, 25 
mM imidazole; buffer E: 50 mM Tris-Cl pH 8, 500 mM NaCl, 250 mM imidazole; buffer 
S: 50 mM Tris-Cl pH 7.5, 100mM NaCl, 1mM DTT, 1mM EDTA, and 2% DMSO. A 
frozen stock of P_araBAD-gamS in a BL21-DE3 E. coli strain was grown overnight in 
LB-carbenicillin media. 100 mL was used to inoculate 1 L LB-carbenicillin to an OD 600 
nm of 0.4-0.6 at 37°C, 220 rpm. Cells were then incubated to 0.25% arabinose (final 
concentration) and grown for four additional hours at 25 C, 220 rpm, before being 
pelleted and frozen at -80°C. Cells were resuspended in buffer L, mechanically lysed, and 
incubated with Ni-NTA agarose (Qiagen). Ni-NTA agarose was washed twice with 15 
column volumes of buffer W and eluted in buffer E. Fractions with a ~13 kD band were 
concentrated and dialyzed into buffer S overnight, and further purified on a 26/60 
Sephadex 75 column. Protein concentration was verified by Bradford, concentrated to 3 
mg/ml using an Ultra-0.5 3K MWCO Centrifugal Filter (Ambion), and stored in buffer S 
at -80°C. Protein purity was verified by gel. Purification steps were verified by SDS-
PAGE gel electrophoresis. 
 
Plasmid DNA and PCR product preparation 
Plasmids used in this study were constructed using standard cloning procedures 
and maintained in a KL740 strain if using an OR2-OR1 promoter (29°C), a MG1655Z1 
strain if using a Pl-tetO1 or Pl-lacO1 promoter, a BL21-DE3 strain for protein 
purification, a BL21 strain for promoter characterization, or a JM109 strain for all other 
constructs. KL740 upregulates a temperature sensitive lambda cI repressor, and 
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MG1655Z1 upregulates tetR and lacI.  PCR products were amplified using Pfu Phusion 
Polymerase (New England Biolabs) for all constructs except for those labeled with 
AlexaFluor-588-5-dUTP, which used Taq Polymerase (New England Biolabs), and were 
DpnI digested. Plasmids were either miniprepped using a PureYield column (Promega) or 
midiprepped using a NucleoBond Xtra Midi column (Macherey-Nagel). All plasmids 
were processed at stationery phase.  Before use in the cell-free reaction, both plasmids 
and PCR products underwent an additional PCR purification step using a QiaQuick 
column (Qiagen) which removed excess salt detrimental to TX-TL, and were eluted and 
stored in 10 mM Tris-Cl solution, pH 8.5 at 4°C for short term storage and -20°C for long 
term storage. 
 
Sequences used for steric protection 
Three sets of sequences were used for steric protection assays. One set was based 
on the vector backbone of previously published pBEST-OR2-OR1-Pr-UTR1-deGFP-
T500 (Addgene #40019). Another set, used only in Figure 2d and referred to as 
“Sequence 2”, was derived from the coding sequence of gltB and lhr. These sequences 
were found by parsing the NCBI GenBank MG1655 record in BioPython for all known 
coding sequences and sorting by size.  A final set, used in Figure 4, was based on the 
vector backbone of pBEST-p15A-OR2-OR1-Pr-UTR1-deGFP-T500. Sequences were 
analyzed using Geneious 6.0 (Biomatters Ltd). 
 
In vitro linear DNA assembly 
Linear DNA fragments were amplified using Pfu Phusion Polymerase (New 
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England Biolabs), DpnI digested for 5 minutes at 37°C (New England Biolabs) while 
verified with agarose gel electrophoresis, and PCR purified using previously described 
procedures. Fragments were then assembled in vitro using either Isothermal assembly or 
Golden Gate assembly. For Isothermal assembly, Gibson Assembly Master Mix (New 
England Biolabs) was used according to manufacturer instructions with 1:3 molar ratio 
vector:insert, and reacted at 1 hour at 50°C. 2 For Golden Gate assembly, a 15 μL 
reaction was set up consisting of equimolar amounts of vector and insert, 1.5 μL 10x 
NEB T4 Buffer (New England Biolabs), 1.5 μL 10x BSA (New England Biolabs), 1 μL 
BsaI (New England Biolabs), and 1 μL T4 Ligase at 2 million units/mL (New England 
Biolabs) 34. Reactions were run in a thermocycler at 10 cycles of 2min/37°C, 3min/20°C, 
1 cycle 5min/50°C, 5min/80°C. For Golden Gate assembly, constructs with internal BsaI 
cut sites were silently mutated beforehand using a QuikChange Lightning Multi Site-
Directed Mutagenesis Kit (Agilent). For the Lambda Exonuclease / Exonuclease digest 
assay, we followed the assembly procedure up to assembly completion but using twice 
the amount of assembly mix. Then, a 20 μL reaction was prepared with 12 μL assembly 
product, 2 μL 10x ExoI reaction buffer (New England Biolabs), 2 μL 10x BSA (New 
England Biolabs), 0.5 μL Lambda Exonuclease (New England Biolabs), 0.5 μL 
Exonuclease I (New England Biolabs), and 3 μL water. The control was not digested. 
Reaction was run for 1 hour at 37°C and PCR purified using previously described 
procedures. 
 
Rapid assembly product protocol 
The in vitro linear DNA assembly protocol was followed. Overlap primers were 
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then designed to bind over the vector:promoter and vector:terminator junctions such that 
while the Tm of the final primer was above 60°C, the Tm of binding on each junction 
side was below 40°C. Then, 1 μL of the resulting assembly product was PCR amplified 
for 35 cycles in a 50 μL PCR reaction, and verified by agarose gel electrophoresis. If the 
resulting band was 80% or more pure, the DNA was PCR purified using previously 
described procedures and used directly in TX-TL. Simultaneously, 2 μL of the assembly 
product was transformed into cells using standard chemically competent or electrically 
competent procedures. The cells were grown, miniprepped, and sequenced. PCR products 
off of the resulting plasmids were used as a positive control. 
 
Linear DNA degradation assay 
To form linear DNA with AlexaFluor distributed on the dUTP, template DNA 
producing deGFP was amplified using a Taq Polymerase (New England Biolabs) and 
AlexaFluor-594-5-dUTP (Invitrogen) according to manufacturer standards with a 
1:3:4:4:4 ratio of AlexaFluor-5-dUTP:dTTP:dCTP:dATP:dGTP (New England Biolabs), 
DpnI digested, and PCR purified using previously described procedures. Successful 
labeling was verified through comparison of pre-stained and SybrSafe post-stained 
agarose gel electrophoresis (Invitrogen). To form linear DNA with AlexaFluor on the 5’ 
end, AlexaFluor 594 was covalently linked on the 5’ end to both forward and reverse 
synthetic primers (Integrated DNA Technologies) and used for PCR amplificaton. For the 
2 nM assay, DNA was then added to a 105 μL TX-TL reaction in triplicate with or 
without gamS protein, and incubated at 29°C. A negative control with no DNA was done 
in parallel. Aliquots of 10 μL were removed at indicated time points and immediately 
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added to 50 μL of PB buffer (Qiagen) and flash-frozen in liquid nitrogen. In parallel, 2 
μL of sample was read for deGFP fluorescence on a Synergy H1 Take3 Plate (Biotek). 
After all samples were collected, samples were PCR-purified to remove degraded 
components and measured on a 384-well plate (Nunc) using setting excitation/emission: 
590 nm/617 nm, gain 100. Negative control values were subtracted per data point. GFP 
signal was normalized to endpoint fluorescence and AlexaFluor-594 signal was 
normalized to DNA present at time 0. For the 250 ng assay, similar procedures were 
followed except 20 nM of DNA was added to 40 μL TX-TL reactions for teach condition 
in triplicate and aliquots of 5 μL were removed and added to 25 μL of PB buffer 
(Qiagen). 
 
In vivo promoter characterization 
Twelve promoters and a random control sequence of DNA were cloned in front of 
UTR1-deGFP-T500 on a p15A low copy plasmid using standard cloning procedures and 
propagated at 29°C in BL21 E. coli (New England Biolabs). Growth at 37°C or cloning 
on a high-copy colE1 plasmid resulted in a significant mutation rate. Single colonies were 
simultaneously sequenced and mixed with glycerol for storage at -80°C. Specific 
sequences can be found in Supplemental S2. Frozen stocks were used to inoculate 300 
mL of culture in MOPS-glycerol-carbenicillin media (MOPS EZ Rich Defined Medium 
Kit, Teknova, using 0.4% glycerol working concentration in lieu of glucose and adding 
100 μg/ml of carbenicillin) in a 96 DeepWell polypropylene plate (Fisher Scientific). The 
Pl-lacO1 sample was grown with 0.5mM of IPTG in addition. Plate was covered with a 
BreatheEasy gas-permeable membrane (Sigma-Aldrich) and grown overnight at 29°C on 
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a Symphony Incubating Microplate Shaker (VWR), shaking at 900 rpm. Cultures were 
then diluted 1:50 in triplicate, grown for 4 hours at 29°C, and diluted to an OD 600 nm of 
0.1 – 0.2 in triplicate depending on growth rate. Cultures were then grown for 90 minutes 
at 29°C, and transferred to a CulturPlate 96-well plate (PerkinElmer) for OD 600 nm and 
fluorescent measurement at excitation/emission 485 nm/520 nm on a Synergy H1 plate 
reader. Background fluorescence from media was subtracted, and each sample was 
normalized to OD 600 nm. The normalized value for the random control was then 
subtracted. Each sample was then normalized to J23101. 
 
TX-TL promoter characterization on linear and plasmid DNA 
Sequenced cultures from frozen stocks were used to inoculate 20 mL of LB-
carbenicillin media and grown in parallel to stationery phase. For each sample, 4 x 3 mL 
of sample was miniprepped using previously described procedures. The miniprep 
products were PCR purified into one 30 μL sample, and re-sequenced. To generate linear 
DNA for each sample with 250 bp of non-coding DNA at each end, the resulting plasmid 
was PCR amplified in 4 x 50 μL reactions, DpnI digested, and PCR purified into one 30 
μL sample. Plasmid and linear DNA were quantified by spectrophotometry. For each 
promoter, DNA was diluted 1:2 from 4-32 nM for linear DNA or 2–6 nM for plasmid 
DNA in water or 0.5 mM IPTG for Pl-lacO1. To generate relative strength to J23101, 
background fluorescence and random control sequence fluorescence were subtracted per 
promoter sample, and endpoint data was normalized to J23101. To generate saturation 
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curves, background fluorescence was subtracted per promoter sample, and correlation 
and slope for each promoter (including the random control sequence) was determined. 
 
TX-TL promoter induction curves 
DNA was prepared as previously mentioned. For Pl-lacO1, 1 nM of a Pl-tetO1-
lacI plasmid and 2 nM of either linear or plasmid Pl-lacO1-deGFP were combined with 
varying amounts of IPTG in the presence of gamS and endpoint fluorescence was read. 
For Pl-tetO1, the same was done but with 1 nM of a Pl-lacO1-tetR plasmid, 2 nM of 
either linear or plasmid Pl-tetO1-deGFP, and 0.5 mM of IPTG in addition to aTc and 
gamS to inactivate any lacI present in the extract. Data was subtracted from background 
fluorescence for those containing aTc. 
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Figure 1 
 
Figure 1. Overview of rapid prototyping procedure of gene circuits. a) Traditional 
testing of circuits, where parts are cloned onto a single plasmid or sets of complementary 
plasmids, tested in vivo, and cycled back to construction. b) Rapid prototyping procedure, 
where circuits are cycled between construction on linear DNA and testing in TX-TL. 
When a final circuit prototype is completed, only 1 cycle occurs of plasmid DNA 
construction and circuit implementation in vivo. 
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Figure 2 
 
Figure 2. Protection of linear DNA from degradation in TX-TL. a) Comparison of 
deGFP time-series fluorescence for plasmid DNA, linear DNA without gamS protection, 
and linear DNA with gamS protection. Plasmid DNA used is pBEST-OR2-OR1-Pr-
UTR1-deGFP-T500, linear DNA is an 810 bp PCR product with no steric protection 
ends, and each is supplied at 16 nM.  b) Endpoint deGFP expression after 8 hours of 2 
nM of linear DNA plotted against signal for different working concentrations of gamS, 
without prior incubation of the protein with crude extract. c) Endpoint deGFP expression 
from plasmid and linear DNA with or without gamS protein, at increasing DNA 
concentrations. Correlation of 0.98 on plasmid DNA is for 0 nM – 4 nM values only; 
correlation of 0.99 on linear DNA is for 0 nM – 16 nM. d) Protection of 2 nM of linear 
DNA using different amounts of non-coding DNA at template ends. Each length 
corresponds to an amount of non-coding base pairs at each end of the linear DNA, and 
Sequence 1 is independent of Sequence 2. Readout is endpoint deGFP fluorescence after 
8 hours, and experiment is in the presence of gamS protein. Error bars represent one 
standard deviation from three independent experiments. 
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Figure 3 
 
 
 
Figure 3. Time-series of DNA degradation in TX-TL at typical working 
concentrations. a) DNA degradation of 2 nM (25 ng) of DNA with or without 3.5 μM of 
gamS. DNA is labeled throughout by an AlexaFluor-594-5-dUTP incorporated by PCR. 
Percentage of DNA remaining is based on 25 ng present at time 0. b) Same experiment as 
panel a), but with AlexaFluor-594 incorporated at the 5’ end on a PCR primer. Error bars 
represent one standard deviation from three independent experiments. 
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Figure 4 
 
 
Figure 4. Comparison of different promoter strengths in TX-TL and in vivo. a) Nine 
commonly used BioBrick promoters are cloned in front of a strong RBS and expressed in 
either mid-log phase in vivo, on plasmids in TX-TL, or on linear DNA pieces in TX-TL. 
Relative endpoint expression of a 4 nM non-saturating amount of linear and plasmid 
DNA is scaled to the strength of J23101, with signal from a random promoter sequence 
subtracted. b) Three inducible promoters expressed constitutively are similarly analyzed, 
scaled to the strength of J23101. For Pl-lacO1, 0.5 mM of IPTG is added both to the in 
vivo and the TX-TL data to sequester any native lacI repressor. c) Hill functions for Pl-
lacO1 and Pl-tetO1 on linear and on plasmid to varying amounts of IPTG and aTc, 
respectively. 1 nM of a plasmid constitutively producing tetR or lacI is combined with 2 
nM of a linear or plasmid reporter. d) Saturation curve for J23101, plotting endpoint 
fluorescence to concentration of linear or plasmid DNA. Both r2 and linear regression line 
are derived from 0 – 16 nM data points. Linear DNA is protected with 250 bp of steric 
protection and with gamS. Error bars represent one standard deviation from three 
independent experiments. 
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Figure 5 
 
 
Figure 5. Comparison of a genetic switch made from linear vs. plasmid DNA. a) 
Diagram of the genetic switch. b) Endpoint fluorescence of deGFP and deCFP for 
plasmid DNA at various IPTG and aTc inducer concentrations. Four plasmid DNA pieces 
are used at 2 nM reporter and 1nM repressor. Due to the logarithmic scale, 0 μM is 
represented as 0.01 μM for IPTG and 0.001 μM for aTc. c) Endpoint fluorescence for 
four linear DNA pieces at the same concentration. Linear DNA is protected with 31 bp of 
steric protection and with gamS. 
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Figure 6 
 
 
Figure 6. Rapid in vitro assembly and prototyping in TX-TL. a) Overview of the rapid 
assembly and prototyping procedure, where DNA parts are assembled using Golden Gate 
assembly (“GGA”) to create a plasmid, which is then directly used as a PCR template to 
create linear DNA at high concentrations suitable for TX-TL. In parallel, the assembly 
product can also be propagated in vivo to yield more copies of clonal plasmid. Time 
comparisons for both methods can be found in Table S2. b) Agarose gel of a gene 
assembled from 5 standard pieces of 66 bp, 103 bp, 110 bp, 707 bp, and 2376 bp. Shown 
are 50 ng each of starting fragments (except 66 bp), fragments post-assembly before and 
after exonuclease digestion (“exo”), and rapid assembly PCR product (“RAP”) compared 
to post-cloned PCR product (“pos”). Arrow indicates expected size of 892 bp. c) 
Functional testing of 4 nM of rapid assembly or post-cloned products, with or without 0.5 
mM IPTG inducer. Experiment conducted in the presence of 2 nM Pl-tetO1-lacI linear 
DNA. Linear DNA is protected with 31 bp of steric protection and with gamS. Error bars 
represent one standard deviation from three independent experiments. 
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Figure 7 
 
 
Figure 7. Linear DNA prototyping of large synthetic circuits in TX-TL. a) A large 
circuit composed of n components is to be prototyped in vivo or in TX-TL. b) Prototyping 
in vivo requires the reduction of n components to three plasmids, which can then be 
transformed into a cell. c) Prototyping using rapid assembly of linear DNA requires 4-8 
hours, as each component can be assembled and tested in parallel. 
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Table 1 
Calibration data for different promoters in TX-TL. Twelve promoters are tested at 
different concentrations in linear (4-32 nM) and plasmid (2-16 nM) DNA form and a 
linear regime is determined based on a cutoff of r2 > 0.975. The slopes (m) are of the 
resulting linear regression, in units of μM deGFP/nM DNA. P:L ratio is the ratio of the 
slopes. “nd”: signal not detectable, “na”: not applicable. Error represents one standard 
deviation from three independent experiments. 
 
Promoter 
name 
Plasmid DNA (P) Linear DNA (L) 
P:L 
ratio 
linear regime 
DNA [nM] r2 m  
linear regime 
DNA [nM] r2 m 
OR2-OR1-
Pr 0-4 0.998 2.211 ± 0.058 0-8 0.979 
1.582  ± 
0.018 1.40 
Pl-tetO1 0-8 0.980 1.187 ± 0.029 0-16 0.993 0.228 ± 0.029 5.21 
Pl-lacO1 0-4 0.990 2.666 ± 0.111 0-8 0.998 0.722 ± 0.085 3.69 
J23113 nd na na 0-8 0.976 0.003 na 
J23114 0-16 0.985 0.025 ± 0.001 0-16 0.981 0.012 2.08 
J23116  0-16 0.975 0.022 ± 0.001 0-16 0.984 0.004 5.50 
J23150 0-16 0.986 0.187 ± 0.009 0-16 0.982 0.022 ± 0.001 8.50 
J23106 0-8 0.992 0.420 ± 0.007 0-16 0.996 0.018 23.33 
J23151 0-8 0.982 1.091 ± 0.108 0-8 0.995 0.186 ± 0.017 5.87 
J23100 0-8 0.995 0.761 ± 0.049 0-8 0.998 0.041 ± 0.006 18.56 
J23101 0-16 0.989 0.470 ± 0.017 0-16 0.978 0.068 ± 0.005 6.91 
J23102 0-16 0.976 0.398 ± 0.018 0-16 0.986 0.024 ± 0.003 16.58 
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Supplemental Information 
 
Included are Supplemental S1 – S3, Table S1 – S2, Figures S1 – S13, and Supplemental 
References. 
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Supplemental S1 
We required a method to accurately quantify broad ranges of DNA, and tested 
both spectrophotometry and fluorometry. Both have known advantages and 
disadvantages: in particular, spectrophotometry is known to be inaccurate at low DNA 
concentrations, while fluorometry can produce biased plasmid DNA results due to 
conformational changes.1 Comparing spectrophotometry (Nanodrop 2000) to fluorometry 
(Qubit 2.0 dsDNA HS and BR Assay), we found that linear DNA and plasmid DNA were 
most accurate and precise on the Nanodrop when at concentrations above 30 ng/μL, 
incurring at most 5.17% error (Figure S1, Table S1). However, for linear DNA from 2-30 
ng/μL both of the dsDNA HS and BR Assays had superior accuracy and precision, 
incurring at most 12.02% error. For plasmid DNA from 2-30 ng/μL only the dsDNA BR 
Assay using a linear standard was accurate and precise, incurring 5.07% error. Based on 
these results, for subsequent data we quantified all constructs above 30 ng/μL on the 
Nanodrop, end-working concentration linear DNA from 2-30 ng/μL using the Qubit 
dsDNA HS Assay, and end-working concentration plasmid DNA from 2-30 ng/μL either 
from diluted Nanodrop stocks above 30 ng/μL or using the dsDNA BR Assay. 
 
DNA Quantification Materials and Methods 
A Nanodrop 2000 UV-Vis spectrophotometer (Thermo Fisher Scientific) and a 
Qubit 2.0 fluorometer (Invitrogen) were used to measure dsDNA concentration. Per run, 
either 500 ng/μL of 1 kb DNA ladder (New England Biolabs) or 500 ng/μL of 
supercoiled DNA ladder (New England Biolabs) were diluted 1:2 down to 0.98 ng/μL in 
TE buffer and used as experimental samples. For the Nanodrop, 2 μL of sample was used 
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to determine concentration. For the Qubit, 2 μL of sample was combined with 198 μL of 
supplied reagent:buffer to determine concentration. Different standards were tested for 
the Qubit, depending on the assay (dsDNA BR or dsDNA HS) and the type of DNA 
quantified (linear or plasmid). Linear standards were supplied by the manufacturer; 
plasmid standards consisted of pUC19 vector at 1000 ng/μL (New England Biolabs) 
diluted 1:10 in TE for the dsDNA BR assay or 1:100 for the dsDNA HS assay. 
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Supplemental S2 
 
The following plasmids, relevant DNA pieces, and primers were used in the study, along 
with Addgene Plasmid Depository Information and sequence data (if applicable). 
 
Plasmids  
 
Name Short 
ID 
Addgene Notes 
pBEST-p15A-Pl-tetO1-UTR1-lacI-T500 1 45784  
pBEST-p15A-Pl-tetO1-UTR1-deGFP-T500 
 
2 45392  
pBEST-p15A-Pl-lacO1-UTR1-TetR-T500 3  Derived from 2 with replacement of 
“deGFP” with “tetR” coding 
sequence 
pBEST_OR2-OR1-Pr_UTR1_deCFP_T500 18  Derived from 21 with replacement of  
“deGFP” with “deCFP” coding 
sequence 
pBEST_OR2-OR1-Pr_UTR1_deGFP-T500 21 40019  
pBADmod1-linker2-gamS 22 45833  
pBEST_OR2-OR1-Pr-UTR1_ClpX-T500 48  Derived from 21 with “ClpX” coding 
sequence from Genbank U00096.3 
substituted for “deGFP” – used as 
T500 template for 134-137. 
pBEST-colE1-Pl-tetO1-UTR1-deGFP-T500 58  Derived from 21 with replacement of 
“OR2-OR1-Pr” with “Pl-tetO1” 
pBEST-2kblhr2-OR2-OR1-
Pr_UTR1_deGFP_T500-1gltB2kb 
87  Derived from gltB and lhr genes 
from Genbank U00096.3 cloned into 
21 - directly after T500 from 
<3354960 (AAAACTA…):3356959 
(…GTGCTTC)> and directly before 
OR2-OR1-Pr from 
<1731632(ACGGTGG…):1733631(
…GGTCCGG). G->A silent 
mutation in T500 
pBEST_OR2-OR1-Pr_UTR1-deGFP-T500 
BsaI, BbsI-safe 
 
105  Derived from 21 with silent 
mutations to make BsaI, BbsI 
compatible 
pBEST-Pl-tetO1-tetR-linker-deGFP-T500 109  Post cloned 4-piece from 
Isothermal/Golden Gate assembly 
(GGA), using sequences from 2 (Pl-
tetO1-UTR1), 3 (tetR+linker from 
primer extension), 21 (linker from 
primer extension + deGFP), and 105 
(vector backbone). 
pBEST-p15A-Pl-tetO1-UTR1-lacI-T500 
BsaI, BbsI-safe 
113  Derived from 1 with silent mutations 
to make BsaI, BbsI compatible 
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pBEST-p15A-OR2-OR1-Pr-UTR1-deGFP-
T500 
121  Derived from 1 with promoter 
replacement 
pBEST-p15A-Pl-tetO1-deGFP-T500 122  “ 
pBEST-p15A-Pl-lacO1-deGFP-T500 123  “ 
pBEST-p15A-J23113-deGFP-T500 124  “ 
pBEST-p15A-J23114-deGFP-T500 125  “ 
pBEST-p15A-J23116-deGFP-T500 126  “ 
pBEST-p15A-J23150-deGFP-T500 127  “ 
pBEST-p15A-J23106-deGFP-T500 128  “ 
pBEST-p15A-J23151-deGFP-T500 129  “ 
pBEST-p15A-J23100-deGFP-T500 130  “ 
pBEST-p15A-J23101-deGFP-T500 131  “ 
pBEST-p15A-J23102-deGFP-T500 132  “ 
pBEST-p15A-pNull-deGFP-T500 133  “ 
P3U2C7T2-v1-1 (Pl-lacO1-deGFP) 134  Post cloned 5-piece GGA using 
sequences from 105 (backbone), 3 
(Pl-lacO1), 21 (UTR1), 21 (deGFP), 
and 48 (T500). 
P4U2C8T2-v1-1 (Pl-tetO1-deCFP) 135  Post cloned 5-piece GGA using 
sequences from 105 (backbone), 2 
(Pl-tetO1), 21 (UTR1), 18 (deCFP), 
and 48 (T500). 
P3U2C5T2-v1-2 (Pl-lacO1-tetR) 136  Post cloned 5-piece GGA using 
sequences from 105 (backbone), 3 
(Pl-lacO1), 21 (UTR1), 3 (tetR), and 
48 (T500). 
P4U2C6T2-v1-2 (Pl-tetO1-lacI) 137  Post cloned 5-piece GGA using 
sequences from 105 (backbone), 2 
(Pl-tetO1), 21 (UTR1), 113 (lacI), 
and 48 (T500). 
 
Promoters, Regulatory Elements, and Coding Sequences 
 
 
Name Sequence 
OR2-OR1-Pr 
 
TGAGCTAACACCGTGCGTGTTGACAATTTTACCTCTGGCGGTGATAATGGTT
GCA 
Pl-tetO1 TCCCTATCAGTGATAGAGATTGACATCCCTATCAGTGATAGAGATACTGAGC
ACA 
Pl-lacO1 ATAAATGTGAGCGGATAACATTGACATTGTGAGCGGATAACAAGATACTGA
GCACA 
J23113 CTGATGGCTAGCTCAGTCCTAGGGATTATGCTAGC 
J23114 TTTATGGCTAGCTCAGTCCTAGGTACAATGCTAGC 
J23116 TTGACAGCTAGCTCAGTCCTAGGGACTATGCTAGC 
J23150 TTTACGGCTAGCTCAGTCCTAGGTATTATGCTAGC 
J23106 TTTACGGCTAGCTCAGTCCTAGGTATAGTGCTAGC 
J23151 TTGATGGCTAGCTCAGTCCTAGGTACAATGCTAGC 
J23100 TTGACGGCTAGCTCAGTCCTAGGTACAGTGCTAGC 
J23101 TTTACAGCTAGCTCAGTCCTAGGTATTATGCTAGC 
J23102 TTGACAGCTAGCTCAGTCCTAGGTACTGTGCTAGC 
pNull ATTCTGGGATTATACAGTAGTAATCACTAATTTAC 
UTR1 AATAATTTTGTTTAACTTTAAGAAGGAGATATA 
T500 CAAAGCCCGCCGAAAGGCGGGCTTTTCTGT 
deGFP ATGGAGCTTTTCACTGGCGTTGTTCCCATCCTGGTCGAGCTGGACGGCGACG
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TAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCT
ACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGC
CCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCG
CTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGA
AGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAA
GACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGA
GCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCT
GGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAA
GAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAG
CGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCC
CGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAA
AGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGC
CGCCGGGATCTAA 
deCFP ATGGAGCTTTTCACTGGCGTTGTTCCCATCCTGGTCGAGCTGGACGGCGACG
TAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCT
ACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGC
CCTGGCCCACCCTCGTGACCACCCTGACCTGGGGCGTGCAGTGCTTCAGCCG
CTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGA
AGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAA
GACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGA
GCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCT
GGAGTACAACTACATCAGCCACAACGTCTATATCACCGCCGACAAGCAGAA
GAACGGCATCAAGGCCAACTTCAAGATCCGCCACAACATCGAGGACGGCAG
CGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCC
CGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAA
AGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGC
CGCCGGGATCTAA 
lacI_GGA_safe ATGAAACCAGTAACGTTATACGATGTCGCAGAGTATGCCGGTGTCTCTTATC
AGACCGTTTCCCGCGTGGTGAACCAGGCCAGCCACGTTTCTGCGAAAACGC
GGGAAAAAGTGGAAGCGGCGATGGCGGAGCTGAATTACATTCCCAACCGCG
TGGCACAACAACTGGCGGGCAAACAGTCGTTGCTGATTGGCGTTGCCACCT
CCAGTCTGGCCCTGCACGCGCCGTCGCAAATTGTCGCGGCGATTAAATCTCG
CGCCGATCAACTGGGTGCCAGCGTGGTGGTGTCGATGGTAGAACGAAGCGG
CGTCGAAGCCTGTAAAGCGGCGGTGCACAATCTTCTCGCGCAACGCGTCAG
TGGGCTGATCATTAACTATCCGCTGGATGACCAGGATGCCATTGCTGTGGAA
GCTGCCTGCACTAATGTTCCGGCGTTATTTCTTGATGTCTCTGACCAGACAC
CCATCAACAGTATTATTTTCTCCCATGAGGACGGTACGCGACTGGGCGTGGA
GCATCTGGTCGCATTGGGTCACCAGCAAATCGCGCTGTTAGCGGGCCCATTA
AGTTCTGTCTCGGCGCGTCTGCGTCTGGCTGGCTGGCATAAATATCTCACTC
GCAATCAAATTCAGCCGATAGCGGAACGGGAAGGCGACTGGAGTGCCATGT
CCGGTTTTCAACAAACCATGCAAATGCTGAATGAGGGCATCGTTCCCACTGC
GATGCTGGTTGCCAACGATCAGATGGCGCTGGGCGCAATGCGCGCCATTAC
CGAGTCCGGGCTGCGCGTTGGTGCGGATATCTCGGTAGTGGGATACGACGA
TACCGAGGACAGCTCATGTTATATCCCGCCGTTAACCACCATCAAACAGGAT
TTTCGCCTGCTGGGGCAAACCAGCGTGGACCGCTTGCTGCAACTCTCTCAGG
GCCAGGCGGTGAAGGGCAATCAGCTGTTGCCCGTCTCACTGGTGAAAAGAA
AAACCACCCTGGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCG
ATTCATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGT
GA 
tetR ATGTCTAGATTAGATAAAAGTAAAGTGATTAACAGCGCATTAGAGCTGCTT
AATGAGGTCGGAATCGAAGGTTTAACAACCCGTAAACTCGCCCAGAAGCTA
GGTGTAGAGCAGCCTACATTGTATTGGCATGTAAAAAATAAGCGGGCTTTG
CTCGACGCCTTAGCCATTGAGATGTTAGATAGGCACCATACTCACTTTTGCC
CTTTAGAAGGGGAAAGCTGGCAAGATTTTTTACGTAATAACGCTAAAAGTTT
TAGATGTGCTTTACTAAGTCATCGCGATGGAGCAAAAGTACATTTAGGTACA
CGGCCTACAGAAAAACAGTATGAAACTCTCGAAAATCAATTAGCCTTTTTAT
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GCCAACAAGGTTTTTCACTAGAGAATGCATTATATGCACTCAGCGCTGTGGG
GCATTTTACTTTAGGTTGCGTATTGGAAGATCAAGAGCATCAAGTCGCTAAA
GAAGAAAGGGAAACACCTACTACTGATAGTATGCCGCCATTATTACGACAA
GCTATCGAATTATTTGATCACCAAGGTGCAGAGCCAGCCTTCTTATTCGGCC
TTGAATTGATCATATGCGGATTAGAAAAACAACTTAAATGTGAAAGTGGGT
CTTAA 
linker sequence 
for tetR-deGFP 
fusion 
GGTGAAAACCTGTACTTCCAGTCTGGTGGTGCT 
 
 
Primers to make linear sequences and other plasmids 
 
 
CHA-R TTTTATCTAATCTAGACATGTGGTATATCTC
CTTCTTAAAGTTAA 
Isothermal assembly piece 1 to make 
109, 2 w/ ZS30432f 
CHB TTTAAGAAGGAGATATACCACATGTCTAGA
TTAGATAAAAGTAAAGTGAT 
Isothermal assembly piece 2 to make 
109, 3 w/ CHB-R 
CHB-R ACCAGACTGGAAGTACAGGTTTTCACCAGA
CCCACTTTCACATTTAAGT 
Isothermal assembly piece 2 to make 
109, 3 w/ CHB 
CHC AACCTGTACTTCCAGTCTGGTGGTGCTATGG
AGCTTTTCACTGGC 
Isothermal assembly piece 3 to make 
109, 21 w/ CHC-R 
CHC-R CTTTGAGTGAGCTGATACCGCAGTCATAAG
TGCGGCGA 
Isothermal assembly piece 3 to make 
109, 21 w/ CHC 
CHD CGTCGCCGCACTTATGACTGCGGTATCAGCT
CACTCAAAG 
Isothermal assembly piece 4 to make 
109, 105 w/ ZS30432r 
ZS3033f TGAGCTAACACCGTGCGT 0 bp protection, 21 w/ ZS3033rb 
ZS3033rb ACAGAAAAGCCCGCCTTTCGGCGGGCTTTG
CTCGAGTTAGATC 
0 bp protection, 21 w/ ZS3033f 
ZS3034f CATGCTGAGCTAACACCG 5 bp protection, 21 w/ ZS3034ra 
ZS3034ra TCGACACAGAAAAGCCCG 5 bp protection, 21 w/ ZS3034f 
ZS3035f GTGTGTGCTGTTCCGCT 25 bp protection, 21 w/ ZS3035r 
ZS3035r AAGGCTCTCAAGGGCATC 25 bp protection, 21 w/ ZS3035f 
ZS3036f AAAACCGAATTTTGCTGG 100 bp protection, 21 w/ ZS3036r 
ZS3036r ATGATAAAGAAGACAGTCATAAGTGCG 100 bp protection, 21 w/ ZS3036f 
ZS3037f TGGCGAATCCTCTGACC 250 bp protection, 21 w/ ZS3037r or 
121-133 w/ ZS30610r or 58, 134-137 
w/ ZS3037r 
ZS3037r TCTTTCCTGCGTTATCCC 250 bp protection, 21 w/ ZS3037f or 
134-137 w/ ZS3037f 
ZS3038f AAAGGGAATAAGGGCGACA 500 bp protection, 21 w/ ZS3038r 
ZS3038r AGCGCCACGCTTCCC 500 bp protection, 21 w/ ZS3038f 
ZS30412f TCCGGTGAGCTAACACC 0 bp protection, 87 w/ ZS303412r 
ZS30412r GTTTTACAGAAAAGCCCGC 0 bp protection, 87 w/ ZS303412f 
ZS30413f AGAAGTGAATGATCTACCGGTC 5 bp protection, 87 w/ ZS303413r 
ZS30413r AAGAGCATCCCGACAGC 5 bp protection, 87 w/ ZS303413f 
ZS30414f ATTACTCGCCCCAGAGGTT 25 bp protection, 87 w/ ZS303414r 
ZS30414r GACAAGGTTTCGCGTTG 25 bp protection, 87 w/ ZS303414r 
ZS30415f GTGGGGAAATCTTCTGCC 100 bp protection, 87 w/ ZS303415r 
ZS30415r CGGCGGGCGATAAAC 100 bp protection, 87 w/ ZS303415f 
ZS30416f GCTACGGCATCATCAGTC 250 bp protection, 87 w/ ZS303416r 
ZS30416r GGTGATGGTGTTGATTTCAC 250 bp protection, 87 w/ ZS303416f 
ZS30417f ACGGTGGCGAAATTCA 500 bp protection, 87 w/ ZS303417r 
ZS30417r GAAGCACAGGCCCACTAC 500 bp protection, 87 w/ ZS303417f 
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ZS30432f ATGACTATCGCACCATCAGCTAACGATATC
CGCCTGAT 
Isothermal assembly piece 1 to make 
109, 2 w/ CHA-R 
ZS30432r GCATCAGGCGGATATCGTTAGCTGATGGTG
CGATAGTCA 
Isothermal assembly piece 4 to make 
109, 21 w/ CHD 
ZS30433f 
ATCTAGGTCTCTAACGATATCCGCCTGAT 
GGA piece 1 to make 109, 2 w/ 
ZS30433r 
ZS30433r GTTATGGTCTCGACATGTGGTATATCTCCTT
CTTAAAGTTAA 
GGA piece 1 to make 109, 2 w/ 
ZS30433f 
ZS30434f GATACGGTCTCCATGTCTAGATTAGATAAA
AGTAAAGTGAT 
 
GGA piece 2 to make 109, 3 w/ 
ZS3081r 
ZS30435r GTGCCGGTCTCATACCGCAGTCATAAGTGC
GGCGA 
GGA piece 3 to make 109, 21 w/ 
ZS3081f 
ZS30436f 
GGTTTGGTCTCCGGTATCAGCTCACTCAAAG 
GGA piece 4 to make 109, 105 w/ 
ZS30436r 
ZS30436r ACGTTGGTCTCTCGTTAGCTGATGGTGCGAT
AGTC 
GGA piece 4 to make 109, 105 w/ 
ZS30436f 
ZS30512f 
AACAGGGTCTCACATGGAGCTTTTCACTGG 
GGA “C7”, “C8”, 21 w/ ZS30523r or 
18 w/ ZS30523r 
ZS30513r GTCCGGGTCTCACGACTCTCAAGGGCATCG
GT 
GGA “T2”, 21 w/ ZS30524f 
ZS30514f GTCCTGGTCTCTATGCGTGGTTGTCTTCGTA
CGTCCGTCACGTTC 
GGA “v1-1”, 105 w/ ZS30514r 
ZS30514r ATATAGGTCTCTGTCGGGCATTGTCTTCGCT
CCTTCCGGTGG 
GGA “v1-1”, 105 w/ ZS30514f 
ZS30515f TAGCGGGTCTCTGTCGTGCCTTGTCTTCGTT
ACGTCCGTCACGTTC 
GGA “v1-2”, 105 w/ ZS30528r 
ZS30521r CGTAAGGTCTCAGCTTGCTGTGCTCAGTATC
TCT 
GGA “P4”, 2 w/ ZS3057f 
ZS30522f AGCCAGGTCTCAAAGCAATAATTTTGTTTA
ACTT 
GGA “U2”, 21 w/ ZS3059r 
ZS30523r 
TTAGTGGTCTCATTCATTAGATCCCGGCGGC 
GGA “C7”, “C8”, 21 w/ ZS30512f or 
18 w/ ZS30512f 
ZS30524f GGCTCGGTCTCATGAAGCATCTGGTGAATA
ACTCGAG 
GGA “T2”, 21 w/ ZS30513r 
ZS30528r AGGTGGGTCTCTATGCTATGTTGTCTTCGCT
CCTTCCGGTGG 
GGA “v1-2”, 105 w/ ZS30515f 
ZS30534r CGTAAGGTCTCAGCTTGCTGTGCTCAGTATC
TTGT 
GGA “P3”, 3 w/ ZS3057f 
ZS3057f 
AGAACGGTCTCAGCATTGCTGTTCCGCTGG 
GGA “P3”, “P4”, 3 w/ ZS30534r or 
2 w/ ZS30521r 
ZS3059r TCCCCGGTCTCACATGGTATATCTCCTTCTT
A 
GGA “U2”, 21 w/ ZS30522f 
ZS30610r 
GAAGATCATCTTATTAATCAGATAAAATAT 
250 bp protection, 121-133 w/ 
ZS3037f 
ZS30611f ACGAGGCCCTTTCGTCT 250 bp protection, 109 w/ ZS30611r 
ZS30611r ACGAGGCCCTTTCGTCT 250 bp protection, 109 w/ ZS30611f 
ZS3064f T*G*AGCTAACACCGTGCGT 0 bp protection, 2 TS, 21 w/ ZS3064r 
ZS3064r A*C*AGAAAAGCCCGCCTTTCGGCGGGCTTT
GCTCGAGTTAGATC 
0 bp protection, 2 TS, 21 w/ ZS3064f 
ZS3065f T*G*A*G*C*TAACACCGTGCGT 0 bp protection, 5 TS, 21 w/ ZS3065r 
ZS3065r A*C*A*G*A*AAAGCCCGCCTTTCGGCGGGC
TTTGCTCGAGTTAGATC 
0 bp protection, 5 TS, 21 w/ ZS3065f 
ZS3066f C*A*TGCTGAGCTAACACCG 5 bp protection, 2 TS, 21 w/ ZS3066r 
ZS3066r T*C*GACACAGAAAAGCCCGCCTTTCGGCGG 5 bp protection, 2 TS, 21 w/ ZS3066f 
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GCTTTGCTCG 
ZS3067f C*A*T*G*C*TGAGCTAACACCG 5 bp protection, 5 TS, 21 w/ ZS3067r 
ZS3067r T*C*G*A*C*ACAGAAAAGCCCGCCTTTCGG
CGGGCTTTGCTCG 
5 bp protection, 5 TS, 21 w/ ZS3067f 
ZS3068f 
T*G*GCGAATCCTCTGACC 
250 bp protection, 2 TS, 21 w/ 
ZS3068r 
ZS3068r 
T*C*TTTCCTGCGTTATCCC 
250 bp protection, 2 TS, 21 w/ 
ZS3068f 
ZS3069f 
T*G*G*C*G*AATCCTCTGACC 
250 bp protection, 5 TS, 21 w/ 
ZS3069r 
ZS3069r 
T*C*T*T*T*CCTGCGTTATCCC 
250 bp protection, 5 TS, 21 w/ 
ZS3069f 
ZS3071f 
/5Alex594N/TGGCGAATCCTCTGACC 
250 bp protection, 5’ AF594, 21 w/ 
ZS3071r 
ZS3071r 
/5Alex594N/TCTTTCCTGCGTTATCCC 
250 bp protection, 5’ AF594, 21 w/ 
ZS3071f 
ZS30810f CAACCACGCATTGCTGTT 
 
Overlap primers on “v1-1”, 134-135 
w/ ZS30810r 
ZS30810r CAATGCCCGACTCTCAAG 
 
Overlap primers on “v1-1”, 134-135 
w/ ZS30810f 
ZS30811f CAAGGCACGACTCTCAAG 
 
Overlap primers on “v1-2”, 136-137 
w/ ZS30811f 
ZS30811r ACAACATAGCATTGCTGTTC 
 
Overlap primers on “v1-2”, 136-137 
w/ ZS30811r 
ZS3081f TCCTTGGTCTCGCTTCCAGTCTGGTGGTGCT
ATGGAGCTTTTCACTGGC 
 
GGA piece 3 to make 109, 21 w/ 
ZS30435r 
ZS3081r TAACCGGTCTCAGAAGTACAGGTTTTCACC
AGACCCACTTTCACATTTAAGT 
 
GGA piece 2 to make 109, 3 w/ 
ZS30434f 
 
 
 
 
  
119 
	  
Supplemental S3 
 
Inducible promoters Pl-tetO1 and Pl-lacO1 in linear and plasmid DNA were fit to a 
standard Hill function to approximate Michaelis-Menten dynamics using Prism 6.0 
software (GraphPad Software, Inc.), which assumes a hill slope of 1.0: 
 𝒅𝒆𝑮𝑭𝑷 = 	   𝑽𝒎𝒂𝒙[𝒊𝒏𝒅𝒖𝒄𝒆𝒓]𝑲𝒎 + [𝒊𝒏𝒅𝒖𝒄𝒆𝒓] 
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Table S1 
Comparing absorbance and fluorometric quantifications of linear and plasmid 
DNA. (numerical). Data from Figure S1 in numerical form, with percent error from 
expected value included. 
 
 
Linear Nanodrop BR linear standard HS linear standard 
Expecte
d 
(ng/μL) 
Actual 
(ng/μL) % Error 
Actual 
(ng/μL) 
% 
Error 
Actual 
(ng/μL) 
% 
Error 
500 
490.8 +/ 
4.2 1.84% 
471.7 +/- 
41.3 5.67% 
  
250 
251.3 +/- 
2.1 0.53% 
229.7 +/- 
2.5 8.13% 
  
125 
126.7 +/- 
3.6 1.36% 
114.7 +/- 
1.2 8.27% 55 
56.00
% 
62.5 
63.80 +/- 
3.10 2.08% 
53.63 +/-
2.24 
10.99
% 
55.33 +/- 
1.15 
11.47
% 
31.25 
32.87 +/- 
2.61 5.17% 
27.73 +/- 
2.00 
11.25
% 
28.07 +/- 
2.38 
10.19
% 
15.625 
17.33 +/- 
1.99 10.93% 
13.97 +/- 
1.40 
10.61
% 
13.77 +/- 
1.76 
11.89
% 
7.8125 
9.60 +/- 
1.84 22.88% 
6.97 +/- 
0.92 
10.74
% 
7.02 +/- 
1.09 
10.14
% 
3.90625 
5.67 +/- 
1.50 45.07% 
3.51 +/- 
0.82 
10.06
% 
3.44 +/- 
0.69 
12.02
% 
1.95312
5 
3.70 +/- 
0.82 89.44% 
1.77 +/- 
0.54 9.38% 
1.78 +/- 
0.32 8.86% 
0.97656
3 
2.50 +/- 
1.13 
156.00
% 
1.17 +/- 
0.05 
19.30
% 
0.91 +/- 
0.15 6.65% 
 
Plasmid Nanodrop BR linear standard HS linear standard 
BR plasmid 
standard 
HS plasmid 
standard 
Expecte
d 
(ng/µL) 
Actual 
(ng/µL) % Error 
Actual 
(ng/µL) 
% 
Error 
Actual 
(ng/µL) 
% 
Error 
Actual 
(ng/µL) 
% 
Error 
Actual 
(ng/µL) 
% 
Error 
500 
494.2 +/- 
7.1 1.15% 
516.0 +/- 
24.3 3.20% 
  
556.7 +/- 
47.3 
11.33
% 
  
250 
255.7 +/- 
4.6 2.28% 
244.7 +/- 
6.4 2.13% 
  
260.7 +/- 
18.0 4.27% 
  
125 
128.9 +/- 
5.3 3.15% 
122.0 +/- 
7.5 2.40% 
  
124.0 +/- 
3.5 0.80% 
  
62.5 
64.87 +/- 
4.02 3.79% 
59.90 +/- 
4.16 4.16% 
46.43 +/- 
6.93 
25.71
% 
61.10 +/- 
3.47 2.29% 
  
31.25 
32.83 +/- 
3.32 5.07% 
29.43 +/- 
3.40 5.81% 
19.10 +/- 
0.72 
38.88
% 
29.37 +/- 
1.01 6.03% 
27.13 +/- 
1.93 
13.17
% 
15.625 
16.83 +/- 
2.50 7.73% 
14.83 +/- 
2.11 5.07% 
8.57 +/- 
0.85 
45.13
% 
14.53 +/- 
0.74 6.99% 
12.77 +/- 
1.50 
18.29
% 
7.8125 
8.67 +/- 
2.23 10.93% 
7.54 +/- 
1.19 3.49% 
4.02 +/- 
0.28 
48.50
% 
7.32 +/- 
0.31 6.26% 
5.70 +/- 
0.75 
27.04
% 
3.90625 
4.57 +/- 
1.70 16.91% 
3.75 +/- 
0.87 4.00% 
1.99 +/- 
0.20 
49.14
% 
3.52 +/- 
0.26 9.97% 
2.90 +/- 
0.22 
25.76
% 
1.95312
5 
2.80 +/- 
1.73 43.36% 
1.88 +/- 
0.57 3.57% 
0.99 +/- 
0.06 
49.33
% 
1.84 +/- 
0.17 5.96% 
1.44 +/- 
0.07 
26.27
% 
0.97656
3 
1.60 +/- 
1.40 63.84% 
1.17 +/- 
0.11 
19.81
% 
0.50 +/- 
0.04 
48.77
% 1.12 
14.69
% 
0.72 +/- 
0.08 
26.48
% 
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Table S2 
Time Estimates of a Test Cycle in TX-TL.  Time needed for rapid assembly in vitro 
versus traditional cloning, corresponding to Figure 6, is presented.  
 Rapid Assembly1 Conventional 
Techniques (plasmid 
generation) 
PCR of segments na  1 h 15 min 
DpnI digest2, 3 na 5 min 
Assembly reaction4 1 h 1 h 
Transformation and Recovery na 1 h 30 min 
Overnight growth on plates na 16 h 
Colony isolation and liquid media growth na 8 h 
Miniprep na 30 min 
PCR of rapid assembly product 1 h 15 min  
PCR Cleanup3 15 min 15 min 
Setup TX-TL 15 min 15 min 
TOTAL pre-TX-TL 2 h 45 min 1 d + 
TOTAL post-TX-TL 4 h – 8 h 1 d + 
 
1 Rapid Assembly assumes the use of premade, re-usable modular parts – if these are not 
available, add 1 h 20 min to predicted time and follow beginning of “Conventional 
Techniques” protocol. 
2 Assumes the use of a fast-digest enzyme. 
3 During digest, run the previous reaction on an agarose gel to determine purity and 
reaction completion. 
4 Golden Gate Assembly has multiple protocols, from 1h to 3h20min in length. Protocol 
listed here assumes 10 cycles of 2min/37°C, 3min/20°C, 1 cycle 5min/50°C, 5min/80°C. 
Difficult assemblies can be accomplished by increasing cycling steps or by doing a 
constant at 37°C. Isothermal assembly can also be used in lieu. 
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Figure S1 
 
 
 
Figure S1. Comparing spectrophotomeric and fluorometric quantifications of linear 
and plasmid DNA. (graphic). a) 2 μL of 1kb linear ladder DNA at the expected ng/μL is 
either measured in the Nanodrop or the Qubit fluorometer using the dsDNA BR assay or 
dsDNA HS assay. Error bars represent a standard deviation from three independent 
samples, and “na” indicates out of range of the machine. b) Same process as a), but with 
supercoiled plasmid ladder DNA. BR linear standard: supplied with Qubit dsDNA BR 
Assay kit; HS linear standard: supplied with Qubit dsDNA HS Assay kit; BR plasmid 
standard: pUC19 plasmid DNA of known concentration at 0 ng/μL and 100 ng/μL in TE 
buffer; HS plasmid standard: pUC19 at 0 ng/μL and 10 ng/μL in TE buffer. 
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Figure S2 
 
 
Figure S2. Effects of different additives on TX-TL efficiency. A variety of different 
additives commonly used in protein buffers are tested for toxicity. Endpoint fluorescence 
after 8 hours is determined for 1nM of pBEST-OR2-OR1-Pr-UTR1-deGFP-T500 at the 
final working concentrations listed in TX-TL or at 1:5 dilutions. Percent wildtype activity 
is against a control with no additive. Error bars represent one standard deviation from 
three independent experiments. Experiment is done in extract “e10.” 
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Figure S3 
 
 
Figure S3. Purification of gamS protein into gamS storage buffer S. a) GamS protein 
is purified, expressed, and concentrated into 3 mg/ml as described in “Materials and 
Methods.” Shown is the Coomassie Brilliant Blue stain of the purification procedure. b) 
Buffer toxicity of gamS storage buffer in TX-TL at different dilutions. Storage buffer 
composition (“buffer S”) is 50 mM Tris-Cl pH 7.5, 100 mM NaCl, 1 mM DTT, 1 mM 
EDTA, 2% DMSO. Experiment is done in extract “e10.” 
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Figure S4 
 
 
 
Figure S4. Effect of incubation time of gamS protein on linear protection. GamS 
protein to the listed concentration is added either directly to the crude cell extract for 30 
minutes at room temperature (“incubation,” square-x) or directly to the DNA (“no 
incubation,” black-x). In the “incubation” case, crude cell extract incubated with gamS 
protein is then moved to 4°C and added to DNA. In the “no incubation” case, crude cell 
extract at 4°C is added directly to a mix of DNA and gamS protein. Reaction is run with 
2 nM of linear DNA with no protection, and deGFP endpoint signal is measured. Error 
bars represent one standard deviation from three independent experiments.   
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Figure S5 
 
Figure S5. Definition of linear regime and saturation regime in TX-TL. Cartoon 
diagram shows hypothetical reaction with reporter protein, where rate of signal increase 
with DNA is constant up to 4 nM (“linear regime”, green), begins to slow from 4 nM to 7 
nM before becoming 0 above 7 nM (“saturation regime,” red). The linear regime is not 
resource-limited, while the saturation regime is resource limited. Purple semicircle: RNA 
polymerase; green oval: ribosome; grey lines: DNA; red line: mRNA; pink squiggly: 
protein.  
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Figure S6 
 
 
Figure S6. Protection of linear constructs with varying amounts of 
phosphorothioates. a) Endpoint expression of 2 nM linear DNA with 0, 2, or 5 
phosphorothioates (“PT”) on the 5” end on constructs with 0 bp, 5 bp, or 250 bp of non-
coding DNA protection. b) Top, time-series data of expression from 2nM of a linear 
DNA construct with no non-coding sequence protection on either side of promoter OR2-
OR-Pr and of terminator. All data series are scaled to an endpoint expression of 1.0 after 
8 hours. Below, nucleotide sequence of the left side of the construct, with operator, 
promoter -35 and -10, and phosphorothioate sites notated.2 Error bars represent one 
standard deviation from three independent experiments. Linear DNA is protected with 
gamS. 
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Figure S7 
 
 
Figure S7. Degradation of saturating amounts of DNA in extracts prepared at 
different temperatures with and without gamS protein. Degradation rates of 250 ng 
(20 nM) of linear DNA with AlexaFluor-584 labeled dUTPs over time in extract 
produced at 37°C (extract “eZS1”) or 29°C (extract “e13”). Signal is scaled to maximum 
DNA levels at time t=0. Error bars represent one standard deviation from three 
independent experiments.  
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Figure S8 
 
 
 
  
Figure S8. Comparison of strengths of different promoters using maximum 
measured amounts of DNA in TX-TL. a) Figure 4a is repeated for constitutive 
promoters but using maximum measured amounts of plasmid and linear DNA. b) Figure 
4b is repeated for inducible promoters expressed constitutively.  
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Figure S9 
 
 
 
Figure S9. Individual traces of saturation curves. Saturation curves similar to Figure 
4d, plotted for all promoters. r2 and linear regression line are based on a cutoff of 0.975 
and correspond to data from Table 1. Linear DNA is protected with 250bp of steric 
protection and with gamS. Error bars represent one standard deviation from three 
independent experiments. 
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Figure S10 
 
Figure S10. Rapid assembly and testing of a negative feedback gene. a) A four-piece 
negative feedback gene is assembled from standard pieces. b) Comparison by agarose gel 
electrophoresis of rapid assembly product made by Isothermal assembly (“RAP-iso”), 
rapid assembly product made by Golden Gate assembly (“RAP-GGA”), and post-cloned 
PCR product (“pos”). Arrow indicates expected band. Linear DNA is protected with 250 
bp of steric protection and with gamS. c) Functional testing of 6 nM of rapid assembly 
products compared to post-cloned PCR product with or without 10 μM aTc.  
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Figure S11 
 
Figure S11. Overview of standard cloning procedure. a) A five-piece standard adopted 
with specific ligation ends for a promoter, 5’ UTR, coding sequence, terminator, and 
vector based on the previously used pBEST backbone. b) Diagram of sequences for 
ligation at each site. 
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Figure S12 
 
Figure S12. Purity of rapid assembly product as a function of template 
concentration and of overlapping primers. For a standard 5-piece assembly, the rapid 
assembly product (“RAP”) is amplified off 1 μL, 2 μL, or 5 μL of template in a 50 μL 
PCR reaction. A post-cloned PCR product (“pos”) is also produced. Non-overlapping 
primers refer to binding sites that do not cross the assembly junction between the vector 
and promoter and the vector and terminator; overlapping primers cross this junction. 
White arrow: template DNA; Blue arrows: Non-specific products removed by 
overlapping primers; Red arrow: non-specific products retained by overlapping primers. 
Red arrow is presumed to be self-ligated vector based on size. 
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Figure S13 
 
 
Figure S13. Rapid assembly of genetic switch. a) A four-piece genetic switch, identical 
to that in Figure 5a. b) Comparison of rapid assembly product (“RAP”) to post-cloned 
PCR product (“pos”) for four linear pieces formed, using overlap primers. c) Functional 
assay of RAP products versus post-cloned PCR products for “on” or “off” states of 
genetic switch. 2 nM of reporter and 1 nM of repressor is tested, and “+ IPTG” indicates 
the 0.5 mM IPTG, 0 µM aTc state while “- IPTG” indicates the 0 mM IPTG, 10 µM aTc 
state. Linear DNA is protected with 31 bp of steric protection and with gamS.  Error bars 
represent one standard deviation from three independent experiments.   
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Introduction 
An in vitro S30-based Escherichia coli expression system (“Transcription-
Translation”, or “TX-TL”) has been developed as an alternative prototyping environment 
to the cell for synthetic circuits [1-5].  Basic circuit elements, such as switches and 
cascades, have been shown to function in TX-TL, as well as bacteriophage assembly [2, 
6]. Circuits can also be prototyped from basic parts within 8 hours, avoiding cloning and 
transformation steps [7]. However, most published results have been obtained in a “batch 
mode” reaction, where factors that play an important role for in vivo circuit dynamics – 
namely protein degradation and protein dilution – are severely hindered or are not 
present. This limits the complexity of circuits built in TX-TL without steady-state or 
continuous-flow solutions [8-10].  However, alternate methods that enable dilution either 
require extra equipment and expertise or demand lower reaction throughput.  
We explored the possibility of supplementing TX-TL with ClpXP, an AAA+ 
protease pair that selectively degrades tagged proteins [11], to provide finely-tuned 
degradation. The mechanism of ClpXP degradation has been extensively studied both in 
vitro and in vivo [12-15]. However, it has not been characterized for use in synthetic 
circuits – metrics such as toxicity, ATP usage, degradation variation over time, and 
cellular loading need to be determined. In particular, TX-TL in batch mode is known to 
be resource limited [16], and ClpXP is known to require significant amounts of ATP to 
unfold different protein targets [17, 18]. We find that ClpXP’s protein degradation 
dynamics is dependent on protein identity, but can be determined experimentally. 
Degradation follows Michaels-Menten kinetics, and can be fine tuned by ClpX or ClpP 
concentration. Added purified ClpX is also not toxic to TX-TL reactions. Therefore, 
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ClpXP provides a controllable way to introduce protein degradation and dynamics into 
synthetic circuits in TX-TL. 
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Results and Discussion 
There are two methods to supplement ClpXP into TX-TL: by expressing the 
proteins off of plasmid DNA or by adding purified protein. We first attempted to express 
both ClpX and ClpP off of DNA, and found that ClpX when expressed was able to 
degrade fluorescent ssrA-tagged reporters at a rate independent of ClpP concentration 
(data not shown). However, expressing ClpX posed two difficulties: degradation was 
rate-limited and time-delayed based on production rate of ClpX, and the load of ClpX 
expression reduced the expression of other synthetic circuits. To avoid these problems, 
we tried to purify a N-terminal His-tagged version of ClpX using a standard Ni-NTA 
procedure; however, we found that this version of ClpX lost activity after the purification 
procedure when stored in a previously developed glycerol-free buffer compatible with 
TX-TL [7]. We hypothesized that a linked-hexametric form previously developed would 
be more stable in solution [13].  With the His-tagged linked-hexameric N-terminal 
deletion form of ClpX, we were able to retain activity (Fig. 1ab). We refer to this as the 
ClpX form hereafter. To quantify degradation rates, we also purified fluorescent proteins 
with and without –ssrA tags (Fig. 1c). 
We first verified the ability of purified ClpX to selectively degrade ssrA-tagged 
versions of deGFP, mRFP, and Venus over non-tagged versions (Fig. 2). ClpX is 
selective for ssrA-tagged versions over non-ssrA tagged versions, and has a degradation 
rate dependent on protein identity. This is similar to findings in vitro, where ClpX is 
known to have different unfolding rates and ATP hydrolysis rates depending on the target 
difficulty [17, 19]. We also determined the concentration dependence of ClpX to 
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degradation rate and throughput (Fig. 3ab). Initially, we made a simple Michelis-Menten 
model: 𝑑 𝐺𝐹𝑃𝑑𝑡 = 	  −𝑘<=> 𝐶𝑙𝑝𝑋𝑃 𝐺𝐹𝑃𝐺𝐹𝑃 +	  𝐾D  
 𝐶𝑙𝑝𝑋𝑃 = min	  ( 𝐶𝑙𝑝𝑋 , 𝐶𝑙𝑝𝑃 ) 
 
We set Km to 1.1 µM, kcat to 0.9 min-1 based on previously published parameters 
[14], and estimated initial (native) concentrations of 20 nM ClpX and of 250 nM ClpP in 
TX-TL extract. We also ran a TX-TL experiment varying added ClpX concentrations 
from 0 nM to 400 nM. Comparing the modeling data to the experimental data, ClpXP 
degradation closely follows Michaelis-Menten kinetics as described. We also determined 
concentration dependence of ClpX to Venus-ssrA and mRFP-ssrA, and then plotted the 
degradation rate vs. time (Fig. 3c). Since the degradation rate changes over time as the 
concentration of substrate decreases, we plotted degradation rate vs. added ClpX 
concentration at t = 16.5 min, which we took as an initial degradation rate (Fig. 3d). In 
this figure, the dependence of fluorescent reporter to added ClpX concentration can be 
clearly discerned, with a saturation point between 200-400 nM of additional ClpX added 
to the system, suggesting a rate-limiting native ClpP concentration. The decreased 
degradation rate of Venus-ssrA relative to deGFP-ssrA and mRFP-ssrA can also be seen. 
Based on this figure, additional ClpX is able to increase deGFP-ssrA degradation rates by 
5-fold, mRFP-ssrA degradation rates by 4.2-fold, and Venus-ssrA degradation rates by 
1.8-fold. 
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We additionally tried to supplement TX-TL with ATP and Mg, based on the 
known heavy usage of ClpX for protein unfolding (500 ATP per titin I27 subunit, ~100 
aa) [19]. With 200 nM of added ClpX in TX-TL, there was a clear effect on the 
degradation of Venus-ssrA over deGFP-ssrA and mRFP-ssrA, indicating that at working 
concentrations of proteins likely achievable in a typical TX-TL reaction ATP 
concentration was not rate-limiting except on hard-to-degrade proteins (Fig. 4).  
In order for supplemented ClpX to be a useful tool for controlled protein 
degradation, either the addition of ClpX or the ClpX storage buffer must not be toxic to 
expression of proteins off of DNA in TX-TL. We diagnosed this by diluting purified 
ClpX into a TX-TL reaction driving the production of deGFP off of a strong promoter, 
and saw no effect at saturating ClpX levels to DNA expression (Fig. 5). We also verified 
that ATP was not rate-limiting to ClpXP degradation and DNA expression by treating the 
degradation of mRFP-ssrA as a “background process” running during a TX-TL reaction 
producing deGFP (Fig. 6). As 10 µM of mRFP-ssrA is approaching the maximum protein 
concentration producible by TX-TL, this result suggests that ATP is at a saturating level 
in a typical TX-TL reaction. However, we did not test the combination of a difficult-to-
degrade protein such as Venus-ssrA combined with the expression of saturating amounts 
of mRFP, which would support this conclusion. 
We also explored increasing the amount of ClpP in a saturated ClpX TX-TL 
reaction to verify that ClpP was a limiting reagent. For simplicity, we expressed ClpP off 
of a strong promoter instead of adding purified amounts of ClpP. In the main extract 
used, “eZS6” derived from an ExpressIQ strain (New England Biolabs), ClpP was able to 
marginally increase degradation of deGFP-ssrA in the presence of 200 nM of ClpX (Fig. 
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7a). However, the ability to increase degradation was more pronounced in an alternate 
extract, “e8”, made from a BL21 Rosetta2 strain (Novagen) (Fig. 7b). This indicates that 
ClpXP degradation dynamics can be different depending on strain and on preparation, 
which could vary the amount of native ClpX or ClpP already present.  
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Conclusion 
We explored the use of supplementing the ClpXP system inherent in TX-TL with 
purified ClpX protease to provide fine-tunable degradation to run synthetic dynamic 
circuits. ClpXP degradation closely follows Michaelis-Menten kinetics, but has varying 
degradation rates depending on substrate. Degradation can also be controlled by ClpX 
concentration, allowing for up to 5-fold increased degradation rates over non-tagged 
variants. Degradation does not limit the running of synthetic circuits when purified ClpX 
is added, and rates can be further increased by adding ClpP when ClpX reaches saturated 
conditions between 200-400 nM. 
While ClpXP provides tunable degradation, it may not be an ideal substitute for 
protein dilution, as degradation is neither linear nor stepwise. However, due to the fact 
that degradation closely follows Michaelis-Menten kinetics, degradation can be included 
in a “biological breadboard”-type model [20] to predict amounts needed to implement 
circuit dynamics. This can be easily done for fluorescent proteins, but may require 
indirect assays for other commonly used circuit components such as activators or 
repressors. However, once substrate degradation rates are characterized supplementing 
ClpX is easy to accomplish and fairly predictable when adjusting for concentration. 
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Materials and Methods 
Cell-free extract preparation and execution 
Preparation and execution of TX-TL was according to previously described 
protocols [1], with a modification in strain to ExpressIQ (New England Biolabs) and lysis 
according to work by Jewett et al. (personal communication).  This resulted in extract 
“eZS6” with conditions: 9.9 mg/mL protein, 9.5 mM Mg-glutamate, 95 mM K-glutamate, 
0.33 mM DTT, 1.5 mM each amino acid except leucine, 1.25 mM leucine, 50 mM 
HEPES, 1.5 mM ATP and GTP, 0.9 mM CTP and UTP, 0.2  mg/mL tRNA, 0.26 mM 
CoA, 0.33 mM NAD, 0.75 mM cAMP, 0.068 mM folinic acid, 1 mM spermidine, 30 mM 
3-PGA, 2% PEG-8000. Only “eZS6” is used to prevent extract-to-extract variation, 
except in the final figure where “e8” prepared from BL21 Rosetta2 (Novagen) using 
previously described protocols [1] was used.  Reactions were conducted in 15 µL in a 
384-well plate (Nunc) at 29°C, and read in a Synergy H1/MF or H4 plate reader (Biotek). 
Settings used were: deGFP, 485 nm/515 nm gain 61; Venus, 505 nm/ 535 nm, gain 61; 
mRFP, 580 nm/ 610 nm, gain 100.  
 
Protein purification 
For fluorescent proteins eGFP, mRFP, and Venus and variants eGFP-ssrA, 
mRFP-ssrA, and Venus-ssrA, coding sequences were cloned into a T7-lacO inducible 
vector containing a N-terminus His6 tag using standard techniques and propagated in a 
BL21-DE3 strain (New England Biolabs). Proteins were purified following a similar 
protocol as in [7], but were grown in TB broth in lieu of LB broth, induced with 1 mM 
IPTG (final concentration), and selected for a band between 25 kDa – 35 kDa 
146 
	  
corresponding to the fluorescent protein in question. Fluorescent proteins were further 
processed in a Supradex 20 10/300 column to select for pure, active proportions, and 
flash-frozen at -80°C in a storage buffer consisting of: 50 mM Tris-Cl pH 7.5, 100 mM 
NaCl, 1 mM DTT, 1 mM EDTA, 2% DMSO shown previously to be amenable to usage 
in TX-TL [7]. Final concentrations were: deGFP-ssrA, 164.8 µM; deGFP, 184.8 µM; 
mRFP-ssrA, 185.6 µM; mRFP, 170.6 µM; Venus-ssrA, 87.9 µM; Venus, 147.5 µM. 
For ClpX, a monomeric N-terminal deletion variant Flag-
clpXdeltaNLinkedHexamer-His6 was used [13] (Addgene #22143), as purifying the 
wildtype with a N-terminal His-tag using general Ni-NTA purification techniques 
resulted in a loss of activity. We followed a Ni-NTA purification procedure listed in [12], 
followed by Supradex 20 10/300 and functional testing for pure, active proportions above 
250 kDa. Active proportions were flash frozen in the same buffer used for fluorescent 
proteins. Final concentration of ClpX was 1.95 µM.  
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Figure 1 
 
Figure 1. Purification of clpXdeltaNLinkedHexamer (“ClpX”) and fluorescent 
proteins. a) ClpX with a His6 tag is purified in a Ni-NTA column and run on denaturing 
SDS-PAGE gel. b) Size excluded chromatography of elute product on a Superdex 200 
10/300 column, with a functionality test of active species. B5-B11 are fractions combined 
for forward use. c) Three fluorescent proteins (deGFP, mRFP, Venus), with or without 
ssrA tags, with a His6 tag are purified in a Ni-NTA column and run on denaturing SDS-
PAGE gel. Last column is active, purified fractions combined for forward use. 
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Figure 2 
 
 
 
 
 
Figure 2. Degradation of deGFP, Venus, and mRFP by added ClpX.  400 nM of 
purified ClpX is combined with approximately 5 µM of purified fluorescent proteins with 
and without ssrA degradation tags in TX-TL. 
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Figure 3 
 
 
 
 
Figure 3. Dependence of degradation on ClpX concentration. A) Shown to the left is a 
Michaelis-Menten kinetics model of degradation of fluorescent GFP-ssrA over time, 
using Km 1.1 µM, kcat 0.9 min-1, similar to literature values [14]. Added ClpX is varied 
from 400nM to 0nM.  Showing to the right is experimental data demonstrating similar 
results as modeling data for deGFP-ssrA. B) Degradation rate of deGFP-ssrA, Venus-
ssrA, and mRFP-ssrA over time with varied ClpX concentration. At the arrow is t = 16.5 
min. C) Degradation rate plotted at t = 16.5 min as a function of added ClpX, for both 
ssrA tagged and non-ssrA tagged fluorescent proteins. 
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Figure 4 
 
Figure 4. Dependence of degradation on added ATP and Mg. A) With added ClpX set 
to 200 nM, degradation of fluorescent ssrA tagged proteins is plotted as a function of 
time and additional ATP and Mg added to each reaction. B) Degradation rate at t = 16.5 
min from above data is plotted as a function of additional ATP and Mg. 
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Figure 5 
 
 
Figure 5. Toxicity of added ClpX to TX-TL expression. A plasmid expressing deGFP 
off of a strong promoter-UTR is added to a TX-TL reaction at 1 nM, and endpoint 
expression after 8 hours is plotted as a function of added, purified ClpX protein.  
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Figure 6 
 
Figure 6. Effect of background degradation processes to TX-TL expression. A 
plasmid expressing deGFP off of a strong promoter-UTR is added to a TX-TL reaction at 
1nM. In the same reaction, purified mRFP-ssrA is being degraded by 200 nM of added 
ClpX. No additional ATP or Mg is added to the reaction. Five different concentrations of 
mRFP-ssrA are tested. Both remaining mRFP-ssrA and deGFP expression are measured 
in real time. 
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Figure 7 
  
 
 
Figure 7. Effect of ClpP expression on degradation. A) In eZS6 extract, a plasmid 
expressing ClpP off of a strong promoter-UTR is added to a TX-TL reaction at varying 
concentrations in the presence of 200 nM of added purified ClpX. Degradation of deGFP-
ssrA is plotted versus time. B) The same experiment as A), but in a different extract. 
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Abstract 
While complex dynamic biological networks control gene expression in all living 
organisms, engineering comparable synthetic networks remains time-consuming and 
challenging. Cell-free environments can speed up engineering, but it remains 
questionable whether complex synthetic networks behave similarly in vivo and in vitro. 
We characterized in vitro the “repressilator,” a three-node synthetic oscillator. We then 
used our cell-free framework to engineer novel three, four, and five-node synthetic 
architectures from characterization of circuit components to rapid analysis of complete 
networks. We validated our cell-free approach by transferring these novel three-node and 
five-node oscillators to Escherichia coli, resulting in robust oscillations reflecting the in 
vitro results. A cell-free framework can thus drastically speed up design-build-test cycles 
in biological engineering and enable the quantitative characterization of synthetic and 
natural networks. 
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Main Text 
 
A central tenet of engineering involves characterizing and verifying prototypes by 
conducting rapid design-build-test cycles in a simplified environment (1). Electronic 
circuits are tested on a breadboard to verify circuit design and aircraft prototypes are 
tested in a wind tunnel to characterize their aerodynamics. A simplified environment does 
not exist for engineering biological systems, nor is accurate software based design 
possible, requiring design-build-test cycles to be conducted in vivo (2). Conducting 
extensive, quantitative and rapid characterization in vivo is severely limited due to 
cumbersome molecular cloning and the difficulties associated with measuring parts, 
components, and systems in cellular hosts.  
In vitro systems promise to be efficient and effective tools to rapidly develop 
novel biological systems and understand their operating regimes (3-5) but whether they 
reflect the cellular environment sufficiently well to be of significance to biological 
engineering has remained questionable. We devised a cell-free framework consisting of 
E. coli lysate (“TX-TL”) (3, 6) and a microfluidic device capable of emulating cellular 
growth and division (4) (Fig. 1). Almost all prototyping can be done on linear DNA, 
which requires less than 8 hours to assemble and test. Here, we demonstrate that a cell-
free environment can fill the gap between theoretical network design and in vivo 
implementation of biological systems and thus provide a simplified and controlled 
environment that drastically reduces the design-build-test cycle (7).  
We first asked whether our cell-free framework could be used to run and 
characterize an existing synthetic in vivo circuit and chose to test the repressilator (8) as a 
model circuit. We successfully implemented the original repressilator network in our cell-
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free framework and observed long-term sustained oscillations with periods matching the 
in vivo study  (Fig 2, Movie S1). We compared the original repressilator to a modified 
version containing a point mutation in one of the CI repressor binding sites in the 
promoter regulating LacI (Fig. 2A). This mutation increases the repressor concentration 
necessary for half-maximal repression (KM), and reduces cooperativity (9). At long 
dilution times (td) both circuits oscillated, but with shifted absolute reporter protein 
concentrations (Fig. 2B). At decreasing dilution times amplitudes decreased and periods 
became faster with a linear dependence on td. Faster dilution times, however, did not 
support oscillations for the modified network (Fig. 2B-C). Experimentally, the range of 
dilution times supporting oscillations can serve as a measure for robust oscillator 
function, which generally diminishes with decreasing synthesis rates or when binding of 
one repressor to its promoter is weakened as in the OR2* mutant (Fig. S1). To give 
another example for an experimental characterization that would be challenging to 
perform in a cellular environment we analyzed the repressilator network in phase space 
showing limit cycle oscillations and invariance to initial conditions (Fig. 2D).  
The cell-free framework also allows rapid characterization of individual network 
components. We measured the transfer functions of repressor-promoter pairs in the 
repressilator network (Fig. 3A, Fig. S2A,B, Table S1) and found that the network is 
symmetric in terms of transfer functions. In the CI promoter OR2* mutant we observed 
the expected shift in KM and decreased steepness of the transfer function. We also 
characterized TetR repressor homologs as building blocks for novel negative feedback 
circuits (Fig. 3A) and with the exception of QacR observed similar transfer functions as 
observed in vivo (10) (Fig. S2C).  
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Using three new repressors, BetI, PhlF and SrpR, we constructed a novel 3-node 
(3n) circuit (3n1) and observed high-amplitude oscillations over a broad range of dilution 
times with the same dependence of amplitude and period on td as for the repressilator 
(Fig. 3B). In our characterization of the repressilator network and the 3n1 oscillator we 
found dilution rates to be critical for the existence, period, and amplitude of oscillations. 
Protein degradation is similar to dilution in that it results in removal of repressor proteins. 
In order to study the effect of degradation we constructed a second 3n network (3n2) 
using TetR, PhlF, and SrpR repressors on linear DNA. One version of the circuit used 
strong ssrA ClpXP degradation tags, while the second used untagged repressors. We 
observed oscillations for both circuits (Fig 3C). However, the circuit without ssrA-tag 
mediated protein degradation exhibited slower oscillations, which extended to lower 
dilution times, showing that protein degradation, just like dilution, affects oscillator 
function and period. Effects of ClpXP-mediated protein degradation, which have been 
shown to be important for existence and frequency of oscillations in vivo (11, 12), can 
thus be emulated in a cell-free environment.  
Theory predicts that ring architectures built from an odd number of repressors 
oscillate, while even-numbered architectures have stable steady states (13, 14). We 
experimentally built and tested a 4-node circuit from LacI, TetR, PhlF, and SrpR on 
linear DNA. Initial pulses of LacI inducer IPTG or TetR inducer aTc allowed us to switch 
expression into either one of the two stable steady states (Fig. 3D).  
Encouraged by the robust oscillations observed in the 3n networks, we built two 
5-node ring oscillators (5n) to test our prototyping environment on a novel synthetic 
network architecture (Fig. 3E). Despite their considerable complexity both circuits 
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oscillated over a broad range of dilution times with the expected period lengthening, 
which could be as long as 19h. Comparing all ssrA-tagged 3n and 5n ring architectures, 
we show that the observed periods could be accurately predicted for all four networks by 
computational simulations (Fig. 3F). Our cell-free framework allows testing and 
characterization of complex networks including verifying networks cloned onto a single 
plasmid, which is the closest approximation to in vivo implementation (Fig. S3). 
To validate our cell-free approach in vivo we cloned the 3n1 and 3n2 networks 
onto low-copy plasmids and co-transformed each with a medium-copy reporter plasmid 
into lacI- JS006 E. coli (15). When tested on a microfluidic device (mother machine 
(16)), both 3n oscillators showed regular oscillations with periods of 6 ±1 hours for at 
least 30 hours (Fig. 4A, Movies S2,3). Both oscillators were surprisingly robust as all 
cells undergoing healthy cellular division oscillated (n = 71) (Fig. S4, Movie S4). 
We next tested our 5n oscillators in vivo. Due to loading effects (17), 5n1 was not 
viable when co-transformed with a strong reporter. When tested with a low expression 
strength reporter both 5n oscillators showed robust oscillations that were maintained for 
at least 70 hours, and over 95% of all analyzed traps containing healthy cells oscillated  
(n = 104). In addition, both 5n networks oscillated with similar periods: 8 hours for 5n1, 
and 9 hours for 5n2 (Fig. 4B, Fig. S4, Movies S5-7).  
We also tested both 3n oscillators on a CellASIC system, which allows planar 
single-layer colony formation. In this system we observed a striking population level 
synchronization of daughter cells inheriting the oscillator state from their mother cells 
(Fig. 4C, Fig. S5A, Movies S8,9). Synchronization was also apparent when using three 
different fluorescent reporters simultaneously (Fig. S5B, Movie S10). We did not 
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observe population level synchronization in the original repressilator, the OR2* mutant 
(Fig. S5C) nor the 5n networks. Synchronized oscillations were not reported with the 
original repressilator (8), and have only been observed in oscillators using intercellular 
communication (18, 19). We hypothesize that the 3n1 and 3n2 synchronization is due to 
increased repressor concentrations as compared to the original repressilator network (Fig. 
S5D), which increases the inheritance of the period phenotype and minimizes the rapid 
de-synchronization expected from stochastic cellular protein fluctuations (20). However, 
a quantitative characterization of the synchronization phenotype requires more in-depth 
understanding of stochastic effects in vivo. 
Because cells were synchronized, we were able to analyze the population as a 
whole to make general conclusions of oscillator behavior. We varied dilution time by 
using different media conditions and media flow rates, and found a direct relationship 
between division times and period, consistent with the in vitro data collected. Oscillation 
periods of the 5n oscillators were also consistent with our in vitro results and showed a 
similar dependence on doubling time (Fig. 4D). 
Finally, we compared 3n1 and 5n2 with weak and strong reporters in vivo to 
analyze the effect of protein degradation on the oscillator period. We theorized that given 
a constant concentration of ClpXP, stronger reporters would result in more ClpXP 
loading, thereby slowing the period of oscillation. ClpXP is thought to influence 
oscillation dynamics in vivo in this manner (11). We found that in the mother machine, 
both the period distributions of 3n1 and 5n2 showed this characteristic (Fig. 4E), which 
reflects our in vitro findings of differential –ssrA tag dependent period length (Fig. 3C). 
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We showed that synthetic dynamic networks can be readily implemented, 
characterized, and engineered in a cell-free framework and consequently transferred to 
cellular hosts and demonstrated the utility of our approach for biological systems 
engineering and component characterization. We observed some differences between the 
in vitro and cellular environment, particularly in the difficulty of predicting cellular 
toxicity and loading effects of the 5n oscillators in vivo. While more work is necessary 
describing and explaining differences between in vitro and in vivo environments (7, 21), 
the observed behavior of complex networks in our cell-free environment reflected 
network behavior in vivo well. The cell-free framework is thus a powerful emulator of the 
cellular environment allowing precise control over experimental conditions and enabling 
studies that are difficult or time consuming to perform in cells. With further 
developments in cell-free lysate systems and supporting technologies, the in vitro 
approach is posed to play an increasing role in biological systems engineering and 
provides a unique opportunity to design, build, and analyze biological systems. 
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Materials and Methods 
 
DNA and strain construction 
DNA was constructed using either Golden Gate Assembly or Isothermal 
Assembly. For linear DNA, all DNA was constructed using previously published Rapid 
Assembly protocols on a “v1-1” vector (7). Linear DNA constructs are summarized in 
Table S2. The original repressilator plasmid, pZS1 (8) was used as a template for initial 
characterization and for construction of the OR2* mutant. Transfer function plasmids 
were constructed by Transcriptic, Inc. For other plasmids, partial sequences were either 
obtained from Addgene (10) or synthesized on gBlocks or ssDNA annealed 
oligonucleotides (Integrated DNA Technologies). Specific plasmids required secondary-
structure free segments, which were designed by R2oDNA (22). JS006 (15) was co-
transformed with origin-of-replication compatible plasmids to create engineered strains. 
Specifically, negative-feedback oscillator units were cloned onto pSC101* low copy 
plasmids (ampR or kanR), while reporters were cloned onto colE1 medium copy 
plasmids (kanR or cmR) (Tables S3 and S4). To modulate the reporter copy number, all 
experiments were conducted below 37°C (23). Strain passage was minimized to avoid 
plasmid deletions due to the recA+ nature of JS006 and the high complexity of oscillator 
plasmids or triple-reporter plasmid. Based on the in vitro and in silico results, we used 
strong transcriptional and translational (24) units to maximize gain. 
 
TX-TL reactions 
Preparation of TX-TL was conducted as described previously (6), but using strain 
“JS006” co-transformed with Rosetta2 plasmid and performing a 1:2:1 
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extract:DNA:buffer ratio.  This resulted in extract “eZS4” with 8.7 mg/mL protein, 10.5 
mM Mg-glutamate, 100 mM K-glutamate, 0.25 mM DTT, 0.75 mM each amino acid 
except leucine, 0.63 mM leucine, 50 mM HEPES, 1.5 mM ATP and GTP, 0.9 mM CTP 
and UTP, 0.2  mg/mL tRNA, 0.26 mM CoA, 0.33 mM NAD, 0.75 mM cAMP, 0.068 mM 
folinic acid, 1 mM spermidine, 30 mM 3-PGA, and 2% PEG-8000. For experiments 
utilizing linear DNA GamS was added to a final concentration of 3.5 µM (7). 
 
Steady-state reactions 
Experiments were performed in a microfluidic nano-reactor device as described 
previousely (4, 6) with some modifications to optimize the conditions for the lysate-based 
TX-TL mix. Reaction temperature was 33°C. Lysate was diluted to 2x of the final 
concentration in 5 mM HEPES 5 mM NaCl buffer (pH 7.2). The reaction buffer mix was 
combined with template DNA and brought to a final concentration of 2x. For a 24 h 
experiment 30 µl of these stocks were prepared. During the experiment, lysate and 
buffer/DNA solutions were kept in separate tubing feeding onto the chip, cooled to 
approximately 6ºC, and combined on-chip. We ran experiments with dilution rates (µ) 
between approximately 2.8 and 0.5 h-1, which corresponds to dilution times, td = ln(2) µ-1, 
between 15 and 85 min. These were achieved with dilution steps exchanging between 7 
and 25% of the reactor volume with time intervals of 7 to 10 min, which alternately 
added fresh lysate stock or fresh buffer/DNA solution into the reactors. Dilution rates 
were calibrated before each experiment. Initial conditions for the limit cycle analysis of 
the repressilator network were set by adding pre-synthesized repressor protein at the 
beginning of each experiment. For this, CI repressor (together with Citrine reporter) and 
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TetR repressor (together with Cerulean reporter) were expressed for 2.5h in batch. On 
chip the initial reaction was mixed to be composed of 25% pre-synthesis reaction and 
75% fresh TX-TL mix and repressilator template DNA. Then, the experiment was 
performed at a td of 19.2 ± 0.3 min.  Initial conditions for the 4-node experiment were 
2.5µM aTc or 250µM IPTG, and the experiment was performed at a td of 44.5 ± 0.9 min. 
DNA template concentrations used in steady-state reactions are listed in Table S5. 
Arbitrary fluorescence values were converted to absolute concentrations from a 
calibration using purified Citrine, Cerulean, and mCherry, which were prepared using 
previously published protocols utilizing a His6 purification method followed by size-
exclusion chromatography and a Bradford assay to determine protein concentration (7). 
 
Transfer function measurement 
Transfer functions of the repressor – promoter pairs were determined in the nano-
reactor device at a minimum of two different dilution times (Fig. S2). All tested 
promoters were cloned into a plasmid in front of a BCD7 ribosomal binding site and the 
Citrine open reading frame. A non-saturating concentration of 1nM plasmid was used in 
the experiment. The repressors were expressed from linear templates carrying the J23151 
promoter and the BCD7 ribosomal binding site with time-varying concentrations, which 
were increased from 0 to 2.5nM and decreased back to 0 during the course of the 
experiment (4). Simultaneously we expressed Cerulean as a reporter for the repressor 
concentration from a linear template at an identical concentration as the repressor 
template. From the concentration of the Citrine reporter we calculated the synthesis rate 
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of the fluorescent protein over time using a model of steady state protein synthesis in the 
nano-reactor device (4),  
(1)  
(2) 	    
where Pd and Pf are dark and fluorescent reporter concentration respectively, t is time, Δt 
is the time interval between dilution steps, dil is the volume fraction replaced per dilution 
step, which was determined during the calibration of the device, and mat is maturation 
rate of the fluorescent protein. Maturation times of Citrine and Cerulean were determined 
as described previously(4) and were 15 ±4 min for Cerulean and 29 ±3 min for Citrine. 
Dark fluorescent protein was calculated from equation (2): 
(3) 	    
and the synthesis rate was calculated from equation (1): 
(4) . 
We used the sum of measured fluorescent Cerulean concentration and equation (3) for 
dark Cerulean as a measure of the total repressor protein present at any time during the 
experiment. The synthesis rates were normalized to their respective maximal values 
(vmax) and plotted against the concentration of the repressor reporter using only repressor 
concentrations higher than 1nM. The transfer curves were then fit to a Hill function 
(5)    
where y is the synthesis rate, ymin is the minimum synthesis rate, n is the Hill coefficient 
and KM is the Michaelis Menten constant for half maximal promoter activity. The fitting 
Pd (t + Δt) = Pd (t)+ syn(t) ⋅Δt −mat ⋅Pd (t) ⋅Δt − dil ⋅Pd (t)
Pf (t + Δt) = Pf (t) + mat ⋅Pd (t) ⋅ Δt − dil ⋅Pf (t)
Pd (t) =
Pf (t + Δt) − Pf (t) + dil ⋅Pf (t)
mat ⋅ Δt
syn(t) = Pd (t + Δt)− Pd (t)+mat ⋅Pd (t) ⋅Δt + dil ⋅Pd (t)
y = f (x) = ymin + (1− ymin )
n
KMn
KM + x
n
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was performed in Igor Pro using orthogonal distance regression with ODRPACK95 
assuming a 9% error in the measurements of Citrine and Cerulean fluorescence. 
 
Vmax measurements 
Relative promoter strengths (vmax values) were determined using the transfer 
function promoter plasmids. In vitro strengths were determined in 5 µl TX-TL reactions 
at a DNA template concentration of 1nM. Reactions were assembled in 384-well plates, 
overlaid with 35 µl Chill-Out Liquid wax (BioRad) and analyzed using a Biotek 
SynergyMx plate reader set to 33ºC reaction temperature, and reading Citrine 
fluorescence with Exc:510±9nm and Em:540±9nm. For comparison, Citrine fluorescence 
at 6h was normalized to the value of pLacI. In vivo strengths were determined using E. 
coli JS006 transformed with the same plasmids. Cells were grown at 29ºC in MOPS 
medium supplemented with 0.4% glycerol and 0.2% casaminoacids. For each strain, three 
independent overnight cultures were diluted 1:50 and grown to mid-log phase. They were 
then diluted to a starting OD600 of 0.15 into 100 µl growth medium in a 96-well plate and 
grown in the plate reader at 29ºC with periodic shaking measuring Citrine fluorescence. 
Fluorescence values were normalized to OD resulting in steady state values after 2 h. 
Average steady state values were normalized to pLacI for comparison with the in vitro 
measurement. 
 
In vivo experiments 
Mother machine (16) experiments were conducted with custom-made 
microfluidic chips (mold courtesy of M. Delincé and J. McKinney, EPFL). E. coli cells 
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were trapped in channels of 30 µm length, 2 µm width and 1.2 µm height. Before loading 
onto the device, cells were grown from a frozen stock to stationery phase. Cells were then 
concentrated 10-fold and loaded onto the chip. Experiments were performed using LB 
medium supplemented with 0.075% Tween-20 at a flow rate of 400 µl/h. Oscillation 
traces were collected from single mother machine traps using the background subtracted 
average fluorescence intensity of the entire trap.  
CellASIC experiments were conducted using B04A plates (Merck Millipore, 
Darmstadt Germany). Flow rates were varied between 0.25 psi – 2 psi. Cells were grown 
from frozen stock in media at running temperature to stationery phase. Cells were then 
diluted 1:100 for 2 hours, and loaded on a equilibrated plate at 1:1000 or less to achieve 
single-cell loading efficiencies per chamber. To vary cellular doubling times, different 
growth media were used: LB (BD Biosciences), M9CA (Sigma Aldrich) with 0.2% 
glucose, 2xYT (MP Bio), and MOPS EZ Rich (Teknova). 
Cells were imaged in time series every 10-20 min using a 100x phase objective 
minimizing both lamp intensity (12% Xcite 120, Excelitas Inc. Waltam MA or 1-2% 
CoolLED pE-2, Custom interconnected Ltd., UK) and exposure times (<500ms) to limit 
photo-toxicity. 
 
Analysis of in vivo data 
Images were processed and stitched (25), if necessary, using Fiji/ImageJ (26). 
Fluorescence traces of cell populations with synchronized oscillations were extracted 
from CellASIC movies using background corrected mean fluorescence intensity from the 
entire field of view. For cells that were not synchronized over the complete field of view, 
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we tracked regions of oscillating sister cells at the edge of the microcolony. We used 
ImageJ to define polygonal regions around those cells and manually shifted the polygonal 
region to track the front of growing cells. Periods were determined from fluorescence 
traces derived from mother machine and CellASIC movies by measuring the time from 
one oscillation peak to the next peak. Doubling times were estimated by averaging over 
the doubling times of at least ten individual cells. 
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Figure 1 
 
 
 
Fig. 1. The cell-free framework allows rapid and extensive characterization of 
biological systems. Schematic representation of the design-build-test cycle using the cell-
free framework. A design is first modeled to obtain intuition about the architecture. Parts 
are then assembled on linear DNA without cloning, and tested in vitro. With functional 
parts, circuit variants can then be tested and working circuits can be extensively 
characterized. Final circuits are cloned onto plasmids and implemented in vivo. Center 
shows the microfluidics device used. Input is a circuit encoded by linear or plasmid DNA 
and TX-TL in vitro reagent, which is then translated and transcribed into protein. For a 
specific example of the cell-free framework applied to engineering a 5-node oscillator 
network see Fig. S3. 
2. Model: 
in silico
4a. Test parts: 
in vitro
1. Design: 
circuit concept
5. Characterize: 
working circuits
3. Build: 
parts on linear DNA
6. Clone and Implement:
in vivo
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multiple variants
(input)
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Figure 2 
 
 
 
Fig. 2. Cell-free repressilator characterization. (A) Application of the cell-free 
framework to characterize the original repressilator (8) and a modified version with a 
point mutation in the CI promoter (OR2*) located in one of the binding sites of the CI 
repressor. (B) Expression from the three promoters of the repressilator and the OR2* 
version at different dilution times. (C) Oscillation periods of the repressilator as a 
function of dilution time. In the OR2* version sustained oscillations were supported in a 
narrower range of dilution times as compared to the original repressilator network. (D) 
Phase portrait of repressilator oscillations starting from different initial TetR and CI 
repressor concentrations. 
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Figure 3 
 
 
 
Fig. 3. Cell-free prototyping and characterization of novel negative feedback 
circuits. (A) Transfer functions of the repressilator repressor-promoter pairs (top) and 
TetR homologs (bottom). The TetR repressor was tested against two different promoters: 
the promoter used in the repressilator (top panel) and the J23119-TetR promoter (10) 
(bottom panel). Lines are Hill function fits. (B) Oscillations of a novel 3-node ring 
oscillator (3n1) constructed on plasmid DNA. (C) Two versions of a second 3-node ring 
oscillator (3n2) on linear DNA were used to study the effect of ClpXP degradation on 
oscillator function. One version was ssrA-tagged on all repressor genes while the other 
version did not carry degradation tags on the repressors. The same reporter with a 
medium-strength degradation tag was used in both versions. (D) A 4-node cyclic negative 
feedback network on linear DNA has two stable steady states that depend on the initial 
conditions. IPTG switched the network into the state where pPhlF was on and pTetR off. 
An initial pulse of aTc resulted in the opposite stable steady state. (E) Two 5-node 
negative feedback architectures oscillated with longer periods than our 3-node networks 
as predicted by simulations (Supplemental Model Information) (F).  
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Figure 4 
 
 
 
Fig. 4. Novel 3-node and 5-node ring oscillators in vivo. (A) Time series traces of 3-
node ring oscillators running in E. coli (mother machine). Single trap traces of 3n1 and 
3n2 observed for 36 h in vivo using a strong pPhlF sfGFP-ssrA reporter and a 
representative image from an “on” and “off” state of oscillation. Scale bar: 5 µm. (B) 
Time series traces of 5-node ring oscillators running in E. coli (mother machine). Single 
trap traces of 5n1 and 5n2 observed for 72 h in vivo using a weak pPhlF sfGFP-ssrA 
reporter. (C) 3n1 displays phase synchrony in vivo (CellASIC). Time series micrographs 
of 3n1 under a strong pPhlF sfGFP-ssrA reporter every 160 min; inset shows individual 
cells of the initial microcolony. Scale bar: 10 µm and 5 µm (inset). (D) Relationship 
between period and division time in vivo. Left, 3n1 in vivo under a strong pPhlF sfGFP-
ssrA reporter. The in vitro data is shown for comparison. Each point in the in vivo data 
corresponds to the period and division time from a CellASIC experiment run under 
different media type and flow rates. Right, 5n2 in vivo under a weak pPhlF sfGFP-ssrA 
reporter. In vivo periods determined at 29ºC and 21ºC growth temperature in mother 
machine experiments. Boxes represent the inner quartile range with the median. (E) 
Influence of reporter concentration on oscillation periods by competing for ClpXP 
degradation. Left, with constant amounts of ClpXP the reporter concentration affects 
repressor degradation and thus oscillation period. Histograms of the periods observed 
with a weak and a strong pPhlF sfGFP-ssrA reporter for both 3n1 and 5n2 run in the 
mother machine. Dashed lines indicate the medians. 
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Figure S1 
 
 
 
Fig. S1. Oscillation parameter regime for a 3-node repressilator network in terms of 
dilution time. (A) Transcription (TX) and translation (TL) rates supporting oscillations at 
different dilution times for a 3-node repressilator network. (B) We experimentally studied 
the effect of varying transcription rates on the WT repressilator by measuring the range of 
dilution times that supported sustained oscillations. Transcription rates could be rapidly 
adjusted by varying DNA template concentrations of the repressilator plasmid. For 
different DNA template concentrations, oscillations occurred in different ranges of 
dilution times. Markers at a period of 0 h indicate a stable steady state, and shaded 
regions highlight dilution times that did not support oscillations for a specific DNA 
template concentration. A simulation of the repressilator network produced similar results 
but did not capture loading effects on the biosynthetic machinery for high DNA template 
concentrations. (C) Increasing the KM value of one repressor, as for CI repressor in the 
OR2* repressilator version, reduces the range of dilution rates that support oscillations as 
indicated by our experimental results (Fig. 2C). 
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Figure S2 
 
 
 
Fig. S2. Repressor characterization. (A) Transfer functions of the repressor – promoter 
pairs were determined using the cell-free framework as described in the Methods. Shown 
are experimental results and analysis using LacI - pLacI(r) as an example. Synthesis rates 
from the promoter of interest could be followed by Citrine fluorescence. Varying 
repressor template DNA concentration over time allowed us to determine synthesis rates 
at different repressor concentrations. Cerulean was co-expressed with the repressor and 
served as reporter for repressor concentration. Transfer functions were obtained by 
plotting Citrine synthesis rates from highest to lowest repressor concentration (grey 
shaded area) against total Cerulean concentration and were identical for different dilution 
times set in the nano-reactor device. (B) Comparison of relative promoter strengths 
(vmax), determined in vitro and in vivo. pCI(r), pTetR(r), and pLacI(r) are from (8); pTetR 
is from (10) and pLacI from (28). Error bars indicate standard deviations of three 
replicates. (C) Comparison of KM values measured in vitro in this study with KM values 
determined in vivo by Stanton et al. (10). KM values were normalized to the KM of TetR.  
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Figure S3 
 
 
 
Fig. S3. Engineering a 5-node negative feedback oscillator using the cell-free 
framework. A novel network architecture, which shows the intended behavior in silico is 
first assembled on linear DNA using in vitro characterized parts. Initial circuit testing on 
linear DNA is advantageous because: i) linear DNA can be synthesized in a few hours, ii) 
it allows rapid testing of multiple circuit variants, iii) and allows expression strengths of 
network components to be easily tuned by varying their relative concentrations. A 
functional circuit can then be further characterized to identify parameter ranges that 
support the desired behavior and to experimentally test hypotheses. If an in vivo 
implementation is intended, the cloned plasmids are verified for correct function in vitro 
before in vivo implementation. 
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Figure S4 
 
 
 
Fig. S4. Robust oscillations of 3-node and 5-node oscillators in vivo. 3-node (top) and 
5-node networks (bottom) oscillate with periods that depend on the network size in vivo. 
Shown are the distributions of observed period lengths with medians indicated by dashed 
lines. Both 3-node and 5-node networks exhibited robust oscillation with all growing 
cells oscillating for the 3-node networks and more than 95% of growing cells oscillating 
for the 5-node networks (defined as at least two distinct oscillation peaks per trace). 
Shown are four example traces for all oscillators in addition to the ones shown in Fig. 
4A-B. Both 3-node networks were analyzed using a strong pPhlF sfGFP-ssrA reporter 
and the two 5-node networks were analyzed using a weak pPhlF sfGFP-ssrA reporter. 
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Figure S5 
 
 
 
Fig. S5. Population level synchronization of 3-node oscillators in vivo. (A) 3n2 
oscillator displays phase synchrony in vivo. 3n2 is run under a strong pPhlF sfGFP-ssrA 
reporter in the CellASIC microfluidic device. (B) 3n2 displays phase synchrony 
observing 3 reporters simultaneously. Reporters are a strong pPhlF Citrine-ssrA, pTetR 
mCherry-ssrA, and pSrpR Cerulean-ssrA. Shown is one oscillation cycle. (C) Original 
repressilator and OR2* repressilator do not show phase synchrony. These are run under 
pTetR(r)-eGFP(ASV) in M9 minimal media; oscillations were not supported in LB. All 
scale bars: 10 µm.  
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Table S1 
Transfer function parameters. Parameter values of repressor – promoter pairs were 
determined by fitting to the Hill equation as described in the Methods. 
Name KM n ymin 
CI – pCI (8) 5.9 1.9 0.04 
CI – pCI(OR2*) (9) 103 1.2 0 
LacI – pLacI(r) (8) 4.1 1.9 0.01 
TetR – pTetR(r) (8) 2.3 1.2 0.02 
LacI – pLacI (28) 3.6 1.7 0.01 
SrpR – pSrpR (10) 86 3.6 0 
PhlF – pPhlF (10) 79 2 0 
TetR – pTetR (10) 7.6 0.8 0 
BetI – pBetI (10) 75.4 1.7 0 
QacR – pQacR (10) 2.0 1.6 0.02 
185 
	  
 
Table S2 
Linear DNAs used in this study. 
Name Description Notes 
pJ23119-tetO-BCD2-phlF-
ssrA(LAA) # 3n2, 5n1, 4n  
 pLacI-BCD2-tetR-
ssrA(LAA) & 5n1, 4n  
 pLambdaCI-BCD2-lacI-
ssrA(LAA) % 5n1  
 pPhlF-BCD2-srpR-
ssrA(LAA) # 3n2, 5n1, 4n  
 pSprR-BCD2-lambdaCI-
ssrA(LAA) # 5n1  
 pSrpR-BCD2-tetR-
ssrA(LAA) # 3n2  
 pPhlF-BCD2-srpR # 3n2/no-ssrA 
 pSrpR-BCD2-tetR # 3n2/no-ssrA 
 pTetR-BCD2-phlF # 3n2/no-ssrA 
 pSrpR-BCD2-lacI-
ssrA(LAA) # 4n 
 pBetI-BCD7-QacR-
ssrA(LAA) # 5n2  
 pPhlF-BCD7-srpR-
ssrA(LAA) # 5n2  
 pQacR-BCD7-tetR-
ssrA(LAA) # 5n2  
 PSrpR-BCD7-BetI-
ssrA(LAA) # 5n2  
 pTetR-BCD7-phlF-
ssrA(LAA) # 5n2  
 pJ23151-BCD7-betI $ transfer fxns 
 pJ23151-BCD7-lacI $ transfer fxns 
 pJ23151-BCD7-lambdaCI $ transfer fxns 
 pJ23151-BCD7-phlF $ transfer fxns 
 pJ23151-BCD7-qacR $ transfer fxns 
 pJ23151-BCD7-srpR $ transfer fxns 
 pJ23151-BCD7-tetR $ transfer fxns 
 pLacI-BCD2-sfGFP-
ssrA(LAA) & test reporter 
 pLambdaCI-BCD2-sfGFP-
ssrA(LAA) % test reporter 
 pPhlF-BCD2-sfGFP- # test reporter 
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ssrA(LAA) 
pSrpR-BCD2-sfGFP-
ssrA(LAA) # test reporter 
 pTetR-BCD2-sfGFP-
ssrA(LAA) # test reporter 
  
# Promoter from Stanton et al. (2014)(10) 
$ Promoter from Anderson promoter panel 
% Promoter from Elowitz and Leibler (2000)(8) 
& Promoter from Lutz and Bujard (1997)(28) 
 
  
187 
	  
Table S3 
Plasmids used in this study. 
Name Description 
Resistan
ce 
Copy 
numbe
r Notes 
pZS1 
% Original 
repressilator 
plasmid ampR pSC101 
 
pZS1 w/ OR2* mutation % ampR pSC101 
minimize 
passages 
pZE21-GFP(AAV) 
% Original 
repressilator 
reporter (pTetO1) kanR colE1 
 
pZE21-eGFP(ASV) 
% pZE21-
GFPAAV with 
eGFP replacement kanR colE1 
 
pET21a(+)-Histag-Cerulean 
Expression vector 
for Cerulean 
purification ampR colE1 
c. Transcriptic 
Inc. 
pET21a(+)-Histag-Citrine 
Expression vector 
for Citrine 
purification ampR colE1 
c. Transcriptic 
Inc. 
pET21a(+)-Histag-mCherry 
Expression vector 
for mCherry 
purification ampR colE1 
c. Transcriptic 
Inc. 
pTetR(r)-BCD7-Citrine % transfer fxns kanR 
pSC101
* 
 
pTetR-BCD7-Citrine # transfer fxns kanR 
pSC101
* 
c. Transcriptic 
Inc. 
pSrpR-BCD7-Citrine # transfer fxns kanR 
pSC101
* 
c. Transcriptic 
Inc. 
pQacR-BCD7-Citrine 
# transfer fxns, in 
vitro reporter kanR 
pSC101
* 
c. Transcriptic 
Inc. 
pPhlF-BCD7-Citrine  
# transfer fxns, in 
vitro reporter kanR 
pSC101
* 
c. Transcriptic 
Inc. 
pLacI-BCD7-Citrine & transfer fxns kanR 
pSC101
* 
c. Transcriptic 
Inc. 
pLacI(r)-BCD7-Citrine % transfer fxns kanR 
pSC101
* 
 
pCI(OR2*)-BCD7-Citrine * transfer fxns kanR 
pSC101
* 
 
pCI-BCD7-Citrine % transfer fxns kanR 
pSC101
* 
 
pBetI-BCD7-Citrine # transfer fxns kanR 
pSC101
* 
c. Transcriptic 
Inc. 
3n1 oscillator plasmid kanR pSC101 minimize 
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* passages 
3n2 oscillator plasmid kanR 
pSC101
* 
minimize 
passages 
5n1 oscillator plasmid kanR 
pSC101
* 
minimize 
passages 
5n2 oscillator plasmid kanR 
pSC101
* 
minimize 
passages 
pBetI-BCD7-phlF-ssrA(LAA) # for building 3n1 ampR 
pSC101
* 
 
pBetI-BCD7-qacR-ssrA(LAA) # for building 5n2 ampR 
pSC101
* 
 
pLacO1-BCD7-tetR-ssrA(LAA) & for building 5n1 ampR colE1 
amplify in lacI 
repressor strain 
pLambdaCI-BCD7-lacI-
ssrA(LAA) % for building 5n1 ampR colE1 
amplify in 
lambdaCI 
repressor strain 
pPhlF-BCD7-srpR-ssrA(LAA) 
# for building 3n1, 
3n2, 5n1, 5n2 ampR 
pSC101
* 
 
pQacR-BCD7-tetR-ssrA(LAA) # for building 5n2 ampR 
pSC101
* 
 
pSrpR-BCD7-betI-ssrA(LAA) 
# for building 3n1, 
5n2 ampR 
pSC101
* 
 pSrpR-BCD7-lambdaCI-
ssrA(LAA) # for building 5n1 ampR 
pSC101
* 
 
pSrpR-BCD7-tetR-ssrA(LAA) # for building 3n2 ampR 
pSC101
* 
 
pTetR-BCD7-phlF-ssrA(LAA) 
# for building 3n2, 
5n1, 5n2 ampR colE1 
amplify in tetR 
repressor strain 
pPhlF-BCD20-sfGFP-
ssrA(LAA) 
# 1 color strong 
reporter used in 
study ampR colE1 
 
pPhlF-BCD22-sfGFP-
ssrA(LAA) 
# 1 color weak 
reporter used in 
study ampR colE1 
 
pPhlF-BCD20-Citrine-
ssrA(LAA) 
# for building 3-
color reporter 
plasmid ampR colE1 
 
pSrpR-BCD20-Cerulean-
ssrA(LAA) 
# for building 3-
color reporter 
plasmid ampR colE1 
 
pTetR-BCD20-mCherry-
ssrA(LAA) 
# for building 3-
color reporter 
plasmid ampR colE1 
 3-color BCD20 reporter, 
pPhlF/pSrpR/pJ23119-tetO 
3 color reporter 
plasmid cmR colE1 
minimize 
passages 
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pTetR(r)-Citrine(ASV) % in vitro reporter kanR colE1 
 pTetR(r)-Cerulean(ASV) % in vitro reporter kanR colE1 
 pLacI(r)-mCherry(ASV) % in vitro reporter kanR colE1 
 pLacI(r)-Cerulean(ASV) % in vitro reporter kanR colE1 
 pCI-Citrine-(ASV) % in vitro reporter kanR colE1 
 
pLacI(r)TetR(ASV) 
% for initial 
conditions 
experiment kanR colE1 
 
pTetR(r)-CI(ASV) 
% for initial 
conditions 
experiment kanR colE1 
  
# Promoter from Stanton et al. (2014)(10) 
$ Promoter from Anderson promoter panel 
% Promoter from Elowitz and Leibler (2000)(8) 
& Promoter from Lutz and Bujard (1997)(28) 
* Promoter from Rosenfeld et al. (2005)(9) 
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Table S4 
Strains used in this study. 
Name E. coli type Resistance Notes 
Rosetta2 JS006 cmR 
 pZS1 + pZE21-GFP(AAV) JS006 kanR ampR 
 pET21a(+)-Histag-Citrine BL21-DE3 ampR 
 pET21a(+)-Histag-
Cerulean BL21-DE3 ampR 
 pET21a(+)-Histag-
mCherry BL21-DE3 ampR 
 3n1 + pPhlF-BCD20-
sfGFP-ssrA(LAA) JS006 kanR ampR minimize passages 
3n1 + pPhlF-BCD22-
sfGFP-ssrA(LAA) JS006 kanR ampR minimize passages 
3n2 + pPhlF-BCD20-
sfGFP-ssrA(LAA) JS006 kanR ampR minimize passages 
3n2 + pPhlF-BCD22-
sfGFP-ssrA(LAA) JS006 kanR ampR minimize passages 
5n1 + pPhlF-BCD20-
sfGFP-ssrA(LAA) JS006 kanR ampR 
cells unhealthy, 
minimize passages 
5n1 + pPhlF-BCD22-
sfGFP-ssrA(LAA) JS006 kanR ampR minimize passages 
5n2 + pPhlF-BCD20-
sfGFP-ssrA(LAA) JS006 kanR ampR minimize passages 
5n2 + pPhlF-BCD22-
sfGFP-ssrA(LAA) JS006 kanR ampR minimize passages 
3n2 + 3-color BCD20 
reporter, 
pPhlF/pSrpR/pJ23119-tetO JS006 kanR cmR minimize passages 
pZS1 + pZE21-
eGFP(ASV) JS006 kanR ampR 
 pZS1 w/ OR2* mutation +  
pZS21-eGFP(ASV) JS006 kanR ampR 
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Table S5 
DNA concentrations used in experiments. 
Experiment DNA and concentration Type of DNA 
   
Repressilator 
orig./OR2*, 3color 
Repressilator pZS1 or pZS1 w/ OR2* 
mutation, 0.5 nM (if not otherwise indicated) Plasmid 
 pTetR(r)-Cerulean(ASV), 5 nM Plasmid 
 pLacI(r)-mCherry(ASV), 5 nM Plasmid 
 pCI-Citrine(ASV), 5 nM Plasmid 
  
 Repressilator, initial 
conditions Reaction in nano-reactor:  
 Repressilator pZS1, 5 nM Plasmid 
 pLacI(r)-Cerulean(ASV), 5 nM Plasmid 
 pTetR(r)-Citrine-(ASV), 5 nM Plasmid 
 Pre-synthesis reaction (CI): 
  pTetR(r)-Citrine(ASV), 5 nM Plasmid 
 pTetR(r)-CI(ASV), 5 nM Plasmid 
 Pre-synthesis reaction (TetR):  
 pLacI(r)-Cerulean(ASV), 5 nM Plasmid 
 pLacI(r)TetR(ASV), 5 nM Plasmid 
   
Response curve 
measurements 
Promoter plasmid: pXXX-BCD7-Citrine, 1 
nM Plasmid 
 
Repressor template: pJ23151-BCD7-XXX, 0-
2.5 nM Linear 
 
Repressor reporter: pJ23151-BCD7-Cerulean, 
0-2.5 nM Linear 
   
3n1 3n1 oscillator plasmid, 5 nM Plasmid 
 pPhlF-BCD7-Citrine, 2.5 nM Plasmid 
   
3n2 
pJ23119-tetO-BCD2-phlF-ssrA(LAA), 1.5 
nM Linear 
 pPhlF-BCD2-srpR-ssrA(LAA), 12 nM Linear 
 pSrpR-BCD2-tetR-ssrA(LAA), 24 nM Linear 
 pTetR(r)-Cerulean(ASV), 5 nM Plasmid 
   
3n2/no-ssrA pJ23119-tetO-BCD2-phlF, 1.5 nM Linear 
 pPhlF-BCD2-srpR, 12 nM Linear 
 pSrpR-BCD2-tetR, 24 nM Linear 
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 pTetR(r)-Cerulean(ASV), 5 nM Plasmid 
   
4n 
pJ23119-tetO-BCD2-phlF-ssrA(LAA), 0.75 
nM  Linear 
 pLacI-BCD2-tetR-ssrA(LAA), 6 nM Linear 
 pPhlF-BCD2-srpR-ssrA(LAA), 6 nM Linear 
 pSrpR-BCD2-lacI-ssrA(LAA), 12 nM Linear 
 pTetR(r)-Cerulean(ASV), 2.5 nM Plasmid 
 pLacI(r)-mCherry(ASV), 2.5 nM Plasmid 
 pPhlF-BCD7-Citrine, 2.5 nM Plasmid 
   
5n1 
pJ23119-tetO-BCD2-phlF-ssrA(LAA), 1.1 
nM Linear 
 pLacI-BCD2-tetR-ssrA(LAA), 16.8 nM Linear 
 pLambdaCI-BCD2-lacI-ssrA(LAA), 1.4 nM Linear 
 pPhlF-BCD2-srpR-ssrA(LAA), 5.6 nM Linear 
 pSprR-BCD2-lambdaCI-ssrA(LAA), 11.2 nM Linear 
 pCI-Citrine(ASV), 3 nM Plasmid 
 pTetR(r)-Cerulean(ASV), 2.5 nM Plasmid 
   
5n1, plasmid DNA 5n1 oscillator plasmid, 5 nM Plasmid 
 pTetR(r)-Cerulean(ASV), 5 nM Plasmid 
 pLacI(r)-mCherry(ASV), 5 nM Plasmid 
 pCI-Citrine(ASV), 5 nM Plasmid 
   
5n2 pBetI-BCD7-QacR-ssrA(LAA), 1 nM Linear 
 pPhlF-BCD7-srpR-ssrA(LAA), 12 nM Linear 
 pQacR-BCD7-tetR-ssrA(LAA), 4 nM Linear 
 pSrpR-BCD7-BetI-ssrA(LAA), 24 nM Linear 
 pTetR-BCD7-phlF-ssrA(LAA), 4 nM Linear 
 pTetR(r)-Cerulean(ASV), 2.5 nM Plasmid 
 pQacR-BCD7-Citrine, 2.5 nM Plasmid 
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Movies 
 
Note: All movies can be found on www.biorxiv.com under listed doi. 
 
Movie S1: 3-color in vitro run of repressilator at td = 47 min. Shown on the right are 
individual channels of pCI-Citrine-ssrA, pTetR-Cerulean-ssrA, and pLacI-mCherry-ssrA. 
These are combined in the composite at the left. 
 
Movie S2: 3n1 in mother machine, single trap. 3n1 using a pPhlF-BCD20-sfGFP-ssrA 
(strong) reporter is run in the mother machine at 29ºC in LB. 
 
Movie S3: 3n2 in mother machine, single trap. 3n2 using a pPhlF-BCD20-sfGFP-ssrA 
(strong) reporter is run in the mother machine at 29ºC in LB. 
 
Movie S4: Run of a panel of 3n2 oscillators in mother machine, using pPhlF-BCD20-
sfGFP-ssrA (strong) reporter. 
 
Movie S5: 5n1 in mother machine.  5n1 using a pPhlF-BCD22-sfGFP-ssrA (weak) 
reporter is run in the mother machine at 29ºC in LB. 
 
Movie S6: 5n2 in mother machine. 5n2 using a pPhlF-BCD22-sfGFP-ssrA (weak) 
reporter is run in the mother machine at 29ºC in LB. 
 
Movie S7: Run of a panel of 5n2 oscillators in mother machine, using pPhlF-BCD22-
sfGFP-ssrA (weak) reporter. 
 
Movie S8: 3n1 in CellASIC. 3n1 using a pPhlF-BCD20-sfGFP-ssrA (strong) reporter is 
run in CellASIC. This video corresponds to Fig. 4C. Conditions: 29ºC, LB media, 12.5% 
lamp intensity, 200 ms exposure, 2 psi flow rate. 
 
Movie S9: 3n2 in CellASIC. 3n2 using a pPhlF-BCD20-sfGFP-ssrA (strong) reporter is 
run in CellASIC. This video corresponds to Fig. S5A. Conditions: 29ºC, LB media, 
12.5% lamp intensity, 200 ms exposure, 2 psi flow rate. 
 
Movie S10: 3n2 with 3-color output run in CellASIC. 3n2 using a pPhlF-BCD20-Citrine-
ssrA, pTetR-BCD20-mCherry-ssrA, pSrpR-Cerulean-ssrA (strong) reporter is run in 
CellASIC. This video corresponds to Fig. S5B. Conditions: 29 C, LB media, 12.5% lamp 
intensity, 200 ms exposure for Citrine and Cerulean (500 ms for mCherry), 2 psi flow 
rate. 
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Chapter 6: Conclusion and Future Directions 
 
 
 In this thesis, we demonstrate that a biomolecular breadboard composed of an in-
vitro lysate, TX-TL, can be used to prototype synthetic circuits cheaply and easily 
(Chapter 2). We furthermore show that circuits can be prototyped in under a business day 
by using linear DNA and modular assembly methods (Chapter 3), and that protein 
dynamics can be implemented in the breadboard through characterization of the AAA+ 
protease ClpXP (Chapter 4). Finally, we demonstrate that the biomolecular breadboard 
combined with a microfluidic device (Niederholtmeyer et al. 2015) can prototype novel 
biomolecular circuits in vitro, and that these circuits can be migrated to the in vivo 
environment (Chapter 5). Therefore, we believe that our biomolecular breadboard can 
serve as an intermediary from design to in vivo implementation. 
 An active area of future work is exhaustively determining the in vitro to in vivo 
connection for cell-free lysates, and implementing predictive in silico modeling to further 
speed up the design-build-test cycle. Basic transcriptional and translational items have 
been tested in vitro and in vivo (Chappell et al. 2013; Sun et al. 2014), transfer functions 
have been shown to be equivalent (Chappell et al. 2013; Sun et al. 2014; Niederholtmeyer 
et al. 2015), and circuits have been migrated from one environment to another 
(Niederholtmeyer et al. 2015; Takahashi et al. 2014). However, the limitations of in vitro 
prototyping to the in vivo environment are unknown. This can be addressed by high-
throughput exploration of circuit variants in vitro, in vivo, and in silico to determine a 
percent association.  
While technology development is an interesting scientific endeavor, its real value 
depends on its widespread adoption. Preliminary results have been promising; from the 
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completion of Chapter 2 to the publication of this thesis, more than fifteen universities 
and commercial organizations have adopted TX-TL use. Additionally, more than 30,000 
reactions have been made using the protocol at Caltech. This has resulted in multiple 
projects which have either been published or have been written up using TX-TL 
technology developed in this thesis, exploring RNA cascades (Takahashi et al. 2014), 
prototyping methodology (Takahashi et al. 2015), novel sensors (de los Santos et al. 
2015), high throughput droplet microfluidics (Ochs & Abate 2015), metabolic 
engineering (Wu et al. 2015), RNA thermometers (Satija et al. 2015), compositional 
context (Yeung et al. 2014), RNA aptamers logic circuits (J. Kim et al. 2014), resource 
limitations (Siegal-Gaskins et al. 2014; Siegal-Gaskins et al. 2013), and temperature 
robustness of circuit architectures (Sen et al. 2013). In one of these projects, a group of 
undergraduate students with limited biological experience were able to go from design to 
completion of a project within two weeks of full-time work and a publication within a 
year (Takahashi et al. 2014). The fast time-frame of these projects indicate a real time-
savings in using the biomolecular breadboard.  
While the breadboard developed in this thesis has found use in the biological 
research community, two communities that can most benefit are those with limited 
biological experience whom see biology as a tool for exploring fundamentally non-
biological questions, and those who are just starting to learn biological procedures. While 
the breadboard is easy to use when reagents in Chapter 2 are pre-made, the protocol 
requires a well-equipped laboratory to execute and requires significant skilled labor and 
initial startup cost. The groups whom most benefit have the least access to this upfront 
capital. In addition, research into improving the breadboard relative to expression 
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strength and ability to match in vivo metrics is mostly based on process improvement, 
which is difficult to pose in an academic fashion. To remove these barriers, one area of 
future work is the commercialization of the biomolecular breadboard technology to allow 
for wider adoption. This commercialization effort would also encourage work into using 
TX-TL and the biomolecular breadboard for high value applications described in Chapter 
1 in metabolic engineering. 
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